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A B S T R A C T
Background
Cystic fibrosis (CF) is the commonest inherited life-shortening illness in people of NorthernEuropean descent and caused by amutation
in the gene that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which functions as a salt transporter.
F508del, the most common CFTR mutation that causes CF, is found in up to 80% to 90% of people with CF. In people with this
mutation, a full length of protein is transcribed, but recognised as misfolded by the cell and degraded before reaching the cell membrane,
where it needs to be positioned to effect transepithelial salt transport. This severe mutation is associated with no meaningful CFTR
function. A corrective therapy for this mutation could positively impact on an important proportion of the CF population.
Objectives
To evaluate the effects of CFTR correctors on clinically important outcomes, both benefits and harms, in children and adults with CF
and class II CFTR mutations (most commonly F508del).
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Cystic Fibrosis Trials Register. We also searched reference lists of
relevant articles and online trials registries. Most recent search: 24 February 2018.
Selection criteria
Randomised controlled trials (RCTs) (parallel design) comparing CFTR correctors to placebo in people with CF with class II mutations.
We also included RCTs comparing CFTR correctors combined with CFTR potentiators to placebo.
Data collection and analysis
Two authors independently extracted data, assessed risk of bias and quality of the evidence using the GRADE criteria. Study authors
were contacted for additional data.
Main results
We included 13 RCTs (2215 participants), lasting between 1 day and 24 weeks. Additional safety data from an extension study of
two lumacaftor-ivacaftor studies were available at 96 weeks (1029 participants). We assessed monotherapy in seven RCTs (317 partic-
ipants) (4PBA (also known as Buphenyl), CPX, lumacaftor or cavosonstat) and combination therapy in six RCTs (1898 participants)
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(lumacaftor-ivacaftor or tezacaftor-ivacaftor) compared to placebo. Twelve RCTs recruited individuals homozygous for F508del, one
RCT recruited participants with one F508del mutation and a second mutation with residual function.
Risk of bias varied in its impact on the confidence we have in our results across different comparisons. Some findings were based on
single RCTs that were too small to show important effects. For five RCTs, results may not be applicable to all individuals with CF
due to age limits of recruited populations (i.e. adults only, children only) or non-standard design of converting from monotherapy to
combination therapy.
Monotherapy versus placebo
No deaths were reported and there were no clinically relevant improvements in quality of life in any RCT. There was insufficient
evidence available from individual studies to determine the effect of any of the correctors examined on lung function outcomes.
No placebo-controlled study of monotherapy demonstrated a difference in mild, moderate or severe adverse effects; however, it is
difficult to assess the clinical relevance of these events with the variety of events and the small number of participants.
Combination therapy versus placebo
No deaths were reported during any RCT (moderate- to high-quality evidence). The quality of life scores (respiratory domain)
favoured combination therapy (both lumacaftor-ivacaftor and tezacaftor-ivacaftor) compared to placebo at all time points. At six
months lumacaftor (600 mg once daily or 400 mg once daily) plus ivacaftor improved Cystic Fibrosis Questionnaire (CFQ) scores
by a small amount compared with placebo (mean difference (MD) 2.62 points (95% confidence interval (CI) 0.64 to 4.59); 1061
participants; high-quality evidence). A similar effect size was observed for twice-daily lumacaftor (200 mg) plus ivacaftor (250 mg)
although the quality of evidence was low (MD 2.50 points (95% CI 0.10 to 5.10)). The mean increase in CFQ scores with twice-
daily tezacaftor (100 mg) and ivacaftor (150 mg) was approximately five points (95% CI 3.20 to 7.00; 504 participants; moderate-
quality evidence). Lung function measured by relative change in forced expiratory volume in one second (FEV1) % predicted improved
with both combination therapies compared to placebo at six months, by 5.21% with once daily lumacaftor-ivacaftor (95% CI 3.61%
to 6.80%; 504 participants; high-quality evidence) and by 2.40% with twice-daily lumacaftor-ivacaftor (95% CI 0.40% to 4.40%;
204 participants; low-quality evidence). One study reported an increase in FEV1 with tezacaftor-ivacaftor of 6.80% (95% CI 5.30 to
8.30%; 520 participants; moderate-quality evidence).
More participants receiving the lumacaftor-ivacaftor combination reported early transient breathlessness, odds ratio 2.05 (99% CI 1.10
to 3.83; 739 participants; high-quality evidence). In addition, participants allocated to the 400 mg twice-daily dose of lumacaftor-
ivacaftor experienced a rise in blood pressure over the 120-week period of the initial studies and the follow-up study of 5.1 mmHg
(systolic blood pressure) and 4.1 mmHg (diastolic blood pressure) (80 participants; high-quality evidence). These adverse effects were
not reported in the tezacaftor-ivacaftor studies.
The rate of pulmonary exacerbations decreased for participants receiving and additional therapies to ivacaftor compared to placebo:
lumacaftor 600 mg hazard ratio (HR) 0.70 (95% CI 0.57 to 0.87; 739 participants); lumacaftor 400 mg, HR 0.61 (95% CI 0.49 to
0.76; 740 participants); and tezacaftor, HR 0.64 (95% CI, 0.46 to 0.89; 506 participants) (moderate-quality evidence).
Authors’ conclusions
There is insufficient evidence that monotherapy with correctors has clinically important effects in people with CF who have two copies
of the F508del mutation.
Combination therapies (lumacaftor-ivacaftor and tezacaftor-ivacaftor) each result in similarly small improvements in clinical outcomes
in people with CF; specifically improvements quality of life (moderate-quality evidence), in respiratory function (high-quality evidence)
and lower pulmonary exacerbation rates (moderate-quality evidence). Lumacaftor-ivacaftor is associated with an increase in early
transient shortness of breath and longer-term increases in blood pressure (high-quality evidence). These adverse effectswere not observed
for tezacaftor-ivacaftor. Tezacaftor-ivacaftor has a better safety profile, although data are not available for children younger than 12
years. In this age group, lumacaftor-ivacaftor had an important impact on respiratory function with no apparent immediate safety
concerns, but this should be balanced against the increase in blood pressure and shortness of breath seen in longer-term data in adults
when considering this combination for use in young people with CF.
P L A I N L A N G U A G E S U M M A R Y
CFTR correctors, a therapy for cystic fibrosis targeted at specific mutations
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Review question
We looked at drugs (or combination of drugs) that aim to correct the basic defect for the commonest mutation (F508del) that causes
cystic fibrosis (CF). We assessed the impact on clinical outcomes that are important to people with CF (e.g., survival, quality of life,
lung function and safety).
Background
The CF gene makes a protein that has important function in many parts of the body by helping the movement of salts across cells.
People with CF are either not able to make this protein or make a protein that is defective. A common mutation of the CF gene is
F508del and over 80% of people with CF have at least one copy of this gene variant. When the CF gene is affected by F508del, a full
length of protein is made but it is not able to move through the cell correctly. Laboratory experiments suggest that if this protein can
be transported to the cell wall then it may be able to function, restore salt movement and correct the chronic problems experienced by
people with CF. We examined a number of agents that might correct the F508del mutation.
Search date
Evidence is current to: 24 February 2018.
Study characteristics
We included 13 studies (2215 children and adults with CF) which lasted between 1 day and 24 weeks (with an extension study of
two studies up to 96 weeks). Seven studies (317 participants) looked at single agents (monotherapy: 4PBA (also known as Buphenyl),
CPX, lumacaftor and cavosonstat) versus placebo (a dummy treatment containing no active medicine) and six recent studies (1898
participants) assessed combination therapy (lumacaftor-ivacaftor or tezacaftor-ivacaftor) versus placebo. In 12 studies participants had
two copies of the F508del mutation and in one study they had one F508del mutation and a second different mutation.
Key results
Monotherapy versus placebo
These studies did not report any deaths or any clinically relevant improvements in quality of life scores. There was not enough evidence
to show an effect on lung function. Side effects were reported in all studies, but it is difficult to assess their relevance due to the range
of effects and the small number of participants in the studies.
Combination therapy versus placebo
No deaths were reported in either the lumacaftor-ivacaftor or tezacaftor-ivacaftor studies in people with two copies of the F508del
mutation and there were improvements in quality of life and lung function. Rates of pulmonary exacerbations (a flare up of symptoms)
were also lower. Neither combination therapy was associated with severe side effects, although people on lumacaftor-ivacaftor regularly
experienced shortness of breath for one to two weeks at the start of treatment, which usually resolved without further intervention. Of
more concern was that in longer studies some people receiving lumacaftor-ivacaftor experienced a rise in blood pressure; of these, two
people (out of more than 500 who received the combination in these studies) discontinued lumacaftor-ivacaftor treatment because of
high blood pressure. These side effects were not reported for the tezacaftor-ivacaftor combination. Tezacaftor-ivacaftor therapy has not
yet been assessed in children with CF younger than 12 years of age.
Quality of the evidence
We judged the overall quality of the evidence for the outcomes measured to vary from low to high. Study design was generally poorly
reported, which did not allow us to make clear judgements on any potential bias, but we had fewer concerns with the six larger and
more recent studies. We did find that some results were omitted from the analysis or not reported in seven studies. Some findings
were based on single studies that were too small to show important effects and for five studies the results may not be applicable to all
individuals with CF due to the ages of people recruited into the studies (i.e. adults only, children only) or an unusual design used in
which people receive monotherapy and then combination therapy.
3Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Lumacaftor compared with placebo for cystic fibrosis
Patient or population: adults and children with cyst ic f ibrosis
Settings: outpat ients
Intervention: lumacaf tor
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Lumacaftor
Survival
Follow-up: 14 to 28
days
No deaths reported. No deaths reported. NA 147
(2 studies)
⊕⊕©©
low1
Quality of life - total
score
Follow-up: 14 to 28
days
Outcome not reported. NA A higher score indi-
cates a better outcome.
Quality of life - CFQ-
R respiratory domain:
absolute change f rom
baseline
Follow-up: 14 to 28
days
There was a stat ist ically signif icant decrease
in the CFQ-R respiratory domain in the 50 mg
lumacaf tor group compared to placebo. No dif -
ferences were found in the other dose groups (25
mg, 100 mg, 200 mg) compared to placebo
NA 85
(1 study)
⊕⊕©©
low1
A higher score indi-
cates a better outcome.
FEV1 % predicted: rela-
t ive change f rom base-
line
Follow-up: 14 to 28
days
Outcome not reported. NA
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FEV1 % predicted: ab-
solute change f rom
baseline
Follow-up: 14 to 28
days
The mean change f rom
baseline was 1.7% pre-
dicted.
The mean change f rom
baseline was 1.90%
predicted lower (4.13
lower to 0.33 higher)
NA 61
(1 study)
⊕⊕⊕©
moderate2
Adverse events
Follow-up: 14 to 28
days
There were no stat ist ically signif icant dif f erences
between groups in terms of part icipants experi-
encing any specif ic adverse event
In 1 of the studies, 1 part icipant f rom each of
the lumacaf tor arms - 1 part icipant in each of the
discont inued the study drug due to respiratory
adverse ef fects. No part icipants discont inued
f rom the placebo group
NA 115
(2 studies)
⊕©©©
very low1,2,3
Time to first pulmonary
exacerbation
Follow-up: 14 to 28
days
Outcome not reported (see comment). NA Time to f irst pulmonary
exacerbat ion was not
reported. There was
no stat ist ically signif -
icant dif f erence be-
tween groups in the
number of part ici-
pants experiencing pul-
monary exacerbat ions
* The basis for the assumed risk is the mean placebo group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CFQ-R: Cyst ic Fibrosis Quest ionnaire-Revised; CI: conf idence interval, EQ-5D-3L: 5-Dimension-3 Level, FEV1: f orced expiratory volume at one second; MD: mean dif ference.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
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1. Downgraded twice due to risk of bias: in one study data were select ively reported and of ten presentat ion of data did
not allow for inclusion in analysis (Clancy 2012). There are also incomplete outcome data in the study with part icipants
unaccounted for in analysis.
2. Downgraded once due to indirectness: design of the study means that monotherapy treatment was measured for only 14
days before a combinat ion therapy phase was started (Boyle 2014).
3. Downgraded once due to imprecision: few events occurred therefore CIs for occurrence of specif ic events are very wide
(Analysis 1.2; Analysis 1.3).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
6
C
o
rre
c
to
rs
(sp
e
c
ifi
c
th
e
ra
p
ie
s
fo
r
c
la
ss
II
C
F
T
R
m
u
ta
tio
n
s)
fo
r
c
y
stic
fi
b
ro
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is the most common inherited life-shortening
illness with a prevalence of 1 in 2000 at birth in Northern Euro-
peans (Bobadilla 2002) and varying prevalence in other popula-
tions depending on ethnic composition. The affected gene codes
for a protein called the cystic fibrosis transmembrane conductance
regulator (CFTR) (Riordan 1989; Southern 1997). CFTR protein
is transported to the outer cell membrane, where it has a role in
the transport of salts (anions, chloride and bicarbonate) in and out
of the cell (Rogan 2011). This role is important in all epithelial
cells; particularly those lining the airways, pancreatic ducts, sweat
gland, bile ducts in the liver and vas deferens.
In the lungs of people with CF (pwCF), defective salt transport
leads to a reduction in airway surface liquid volume. This, in turn,
leads to compromisedmucociliary clearance, which makes the air-
way susceptible to infection, which initiates a cycle of inflamma-
tion, chronic infection and progressive lung damage. Eventually
this causes respiratory failure, which is the commonest cause of
premature death for pwCF. In addition to the airway problems,
the abnormal transepithelial salt transport can lead to complica-
tions in other organs. This can result in malnutrition and diabetes
(through pancreatic damage), salt depletion (through excess loss
in sweat) and subfertility.
Over 2000 mutations have been identified in the CFTR gene.
Thesemutations are classified according to the impact they have on
the synthesis, processing, or function of the CFTR gene (CFMD
2013). Classes of CFTR mutation are described in more detail in
the additional tables (Table 1) (Rowntree 2003; Southern 2007).
Most CFTR mutations are associated with a complete loss of
CFTR protein and result in a classical CF phenotype. SomeCFTR
mutations are associated with residual function and these tend to
be associated with less severe phenotype, e.g. patients may be pan-
creatic sufficient and not require pancreatic replacement therapy.
The commonest CF causing mutation, F508del (also known as
1F508 or phe508del), is found in the majority of pwCF (up to
80% to 90% of some populations, e.g. pwCF from a Northern
European heritage). For individuals with F508del, a full length of
protein is transcribed but recognised as misfolded by the cell and
is degraded before reaching the cell membrane, where it needs to
be positioned to effect transepithelial salt transport. Hence this is
a severe mutation associated with no meaningful CFTR function.
This type of mutation is called a class II mutation (or trafficking
defect) andmuch research has exploredmasking themolecular de-
fect, bypassing the cellular mechanisms and enabling the F508del
protein to traffic to the cell membrane, where it may have some
normal salt transport capability.
Description of the intervention
Increasing understanding of how different mutations affect the
production, structure, and function of CFTR has led to the con-
cept of mutation-specific therapies (Table 1). For class II muta-
tions a full length of protein is produced, but recognised as abnor-
mal by the cell and degraded before reaching the cell membrane.
This is called a defect in intracellular trafficking. Scientists have
recognised that certain laboratory manoeuvres can affect this pro-
cess, e.g. reducing cell temperature, and the trafficking defect can
be overcome (Colledge 1995). In such circumstances the F508del
protein may reach the cell membrane, where it has some ability
to transport salt. This has lead to the search for molecules that
can overcome the F508del trafficking defect and these drugs have
been called ’correctors’.
Two distinct scientific approaches have resulted in the recognition
of candidate drugs with this mode of action (Amaral 2007):
1. testing of compounds known to affect CFTR or other ion
channels (either pharmaceutical drugs or chemicals which occur
naturally in plants, herbs, fruits or food components);
2. high throughput screening, which involves testing large
numbers of diverse chemicals, on laboratory cell lines, to identify
which of these may overcome the intracellular trafficking defect.
These approaches have resulted in the identification of small
molecules that may be taken orally, and have been examined in
phase 1 and phase 2 clinical trials (Rubenstein 1997; Van Goor
2011).
How the intervention might work
Correction of the basic CF defect may lead to normalisation of
airway surface liquid, and correction of mucociliary clearance, re-
ducing the susceptibility to airway infection and inflammation.
In addition to correctors, other drugs which aim to treat theCFTR
defect are also under investigation. These include potentiators for
class III and IVmutations, which enhance the function ofmutated
CFTR protein embedded in the cell membrane by increasing the
time the CFTR salt channel remains open and therapies for class I
mutations, which act to prevent structural abnormalities of CFTR
that occur when premature stop codons terminate protein synthe-
sis. Cochrane Reviews assessing these interventions are published
(Aslam 2017; Patel 2015).
If correctors are successful at facilitating the F508del protein to
reach the cell membrane, it may still have sub-optimal function.
It is possible that CFTR correctors may need to be combined
with other agents, such as potentiators to achieve a clinical benefit
pwCFwhohave the F508delmutation. This review examines both
correctors on their own and in combination with other agents.
Why it is important to do this review
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CFTR correctors are novel therapies and it is important that ran-
domised controlled trials (RCTs) are conducted and critically ap-
praised. This will provide clear evidence to assess the benefits and
harms of CFTR correctors. It is important that funding bodies
have a clear evidence base on which to assess new therapies for CF
that aim to correct the basic defect. In addition, critical appraisal
of studies will help inform future study design.
New therapies that correct the F508del mutation will have a pos-
itive impact on an important proportion of the CF population
(Southern 1997). Given the number of pwCF who will be pre-
scribed this treatment, there will be an important healthcare cost.
Experience from other licensed agents that correct the underlying
CF defect, suggests that these costs may be considerable (NICE
2016).
This review aims to collate evidence fromRCTs that have evaluated
the benefits and harms of CFTR correctors in pwCF and class II
CFTR mutations.
O B J E C T I V E S
To evaluate the effects of CFTR correctors on clinically important
outcomes, both benefits and harms, in children and adults with
CF and class II CFTR mutations (most commonly F508del).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We have included RCTs of parallel design (published or unpub-
lished). We have not included quasi-RCTs. Additionally, we have
not included cross-over studies as we do not feel this study de-
sign is appropriate given that the intervention aims to correct the
underlying defect. If the intervention is effective it will have an
important impact on the course of the disease. This has been es-
tablished from the data from trials examining ivacaftor for people
with class III mutations.
Types of participants
We have included studies involving children or adults with CF, as
confirmed either by the presence of two disease-causingmutations,
or by a combination of positive sweat test and recognised clinical
features of CF. We have included studies that include participants
with any level of disease severity. Participants should have at least
one class II mutation.
Types of interventions
A CFTR corrector is defined as a drug which aims to increase the
amount of CFTR expressed at the epithelial cell apical membrane,
by reducing or preventing degradation of CFTR by normal in-
tracellular mechanisms. The main mutation targeted by this ap-
proach is F508del.
We have included studies in which CFTR correctors are compared
with either placebo or another intervention.We have also included
studies in which CFTR correctors are administered alongside an-
other class of drug that also aims to improve CFTR function (e.g.
potentiators).
Types of outcome measures
Primary outcomes
1. Survival
2. Quality of life (QoL) (measured using validated
quantitative scales or scores (e.g. Cystic Fibrosis Questionnaire-
Revised (CFQ-R) (Quittner 2009))
i) total QoL score
ii) different sub-domains which may be reported
3. Physiological measures of lung function (L or per cent (%)
predicted for age, sex and height)
i) forced expiratory flow rate at one second (FEV1)
(relative change from baseline)
ii) FEV1 absolute values (rather than change from
baseline)
iii) forced vital capacity (FVC) (absolute values and
change from baseline)
iv) lung clearance index (LCI) (post hoc change)
v) other relevant physiological measures of lung function
Secondary outcomes
1. Adverse effects
i) graded by review authors as mild (therapy does not
need to be discontinued)
ii) graded by review authors as moderate (therapy is
discontinued, and the adverse effect ceases)
iii) graded by review authors as severe (life-threatening or
debilitating, or which persists even after treatment is
discontinued)
iv) other adverse effects of therapy (of any severity) that
are not classifiable according to these categories
2. Hospitalisation
i) number of days
ii) number of episodes
iii) time to next hospitalisation
3. School or work attendance (i.e. number of days missed)
4. Extra courses of antibiotics (measured as time to the next
course of antibiotics and the total number of courses of
antibiotics)
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i) oral
ii) intravenous
iii) inhaled
5. Sweat chloride (change from baseline) as a measure of
CFTR function
6. Radiological measures of lung disease (assessed using any
scoring system)
i) chest radiograph scores
ii) computerised tomogram (CT) score
7. Acquisition of respiratory pathogens
i) Pseudomonas aeruginosa
ii) Staphylococcus aureus
iii) Haemophilus influenzae
iv) other pathogen clinically relevant in CF
8. Eradication of respiratory pathogens (as defined by study
authors)
i) P aeruginosa
ii) S aureus
iii) H influenzae
iv) other pathogen clinically relevant in CF
9. Nutrition and growth (measured as relative change from
baseline) (including z scores or centiles)
i) weight
ii) body mass index (BMI)
iii) height
Search methods for identification of studies
We searched for all relevant published and unpublished studies
without restrictions on language (we did not exclude studies re-
ported in a language other than English), year or publication sta-
tus.
Electronic searches
We identified relevant studies from the Cochrane Cystic Fibrosis
and Genetic Disorders Group’s Cystic Fibrosis Trials Register us-
ing the terms: ’drugs that correct defects in CFTR transcription,
translation or processing’. Relevant studies have been tagged with
these terms for indexing purposes in the Group’s Cystic Fibrosis
Trials Register.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of the Cochrane Library),
weekly searches of MEDLINE, a search of Embase to 1995 and
the handsearching of two journals - Pediatric Pulmonology and
the Journal of Cystic Fibrosis. Unpublished work was identified by
searching the abstract books of three major cystic fibrosis confer-
ences: the International Cystic Fibrosis Conference; the European
Cystic Fibrosis Conference and the North American Cystic Fibro-
sis Conference. For full details of all searching activities for the
register, please see the relevant sections of the Cystic Fibrosis and
Genetic Disorders Group website.
Date of the most recent search: 24 February 2018.
We also searched clinical trial registries maintained by the Eu-
ropean Medicines Agency, the US National Institutes of Health
(NIH) and the WHO; further details are presented in the appen-
dices (Appendix 1).
Date of the most recent search: 25 January 2018.
Searching other resources
We screened references of included studies to identify additional
potentially relevant studies. We also contacted authors of included
studies, leaders in the field, and companies known to be developing
and investigating CFTR correctors, to identify any studies which
may have been missed by this search. We recorded response rates
from this contact process below (Results of the search).
Data collection and analysis
Selection of studies
Two authors (IS and SP or IS and KWS) independently assessed
the suitability of each potential study identified by the search. If
disagreement arose on the suitability of a study for inclusion in the
review, we attempted to reach a consensus by discussion, failing
which, a third author arbitrated.
Data extraction and management
Two authors (IS and SP or IS and SJN) independently extracted
relevant data from each included study. If disagreement arose on
data extraction, we attempted to reach a consensus by discussion,
failing which, a third author (KWS) arbitrated. Two authors (SP
and SN) entered the data into RevMan for analysis.
If studies had reported data on our primary outcome (survival),
we planned to report these as a binary outcome or a time-to-event
outcome. We planned on extracting QoL scores as relative change
from baseline ((measurement at end of treatment - measurement
at baseline) / measurement at baseline) x 100). We extracted data
presented as post-treatment values or change from baseline when
this was not possible.
With regards to the secondary outcome ’Extra courses of antibi-
otics’, we planned to extract data as time-to-the-next course of an-
tibiotics and the total number of courses of antibiotics. We noted
whether episodes of pulmonary exacerbations were physician-de-
fined or protocol-defined. If studies reported baseline and post-
treatment sweat chloride concentration values, we calculated the
relative change frombaseline values ((measurement at end of treat-
ment - measurement at baseline) / measurement at baseline) x
100).
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We reported data as immediate (up to and including one month),
short-term (over one month and up to six months) and longer-
term (over six months).
We attempted to extract the most precise data as possible for each
outcome; extraction of tabulated data was preferred. If data were
presented only graphically, two authors (SP andSJN) estimated the
relevant data from graphs and compared estimations for accuracy.
Assessment of risk of bias in included studies
Two authors (IS and SP or IS and SJN) assessed the risk of bias for
each study using the Cochrane risk of bias tool (Higgins 2011a).
This includes assessment of the following methodological aspects
of the included studies:
1. procedure for randomisation (selection bias);
2. allocation concealment (selection bias);
3. masking (blinding) of the intervention from participants,
clinicians, and trial personnel evaluating outcomes (performance
bias);
4. missing outcome data (attrition bias);
5. selective outcome reporting (reporting bias);
6. other sources of bias (e.g. the influence of funding sources
or industry on trial characteristics and presented results).
We also assessed whether all participants were included in an in-
tention-to-treat analysis, regardless of whether they completed the
treatment schedule or not. If disagreement arose on the assessment
of risk of bias of a study, we attempted to reach a consensus by
discussion, failing which, a third author (KWS) arbitrated.
Measures of treatment effect
For binary outcomes, we calculated a pooled estimate of the treat-
ment effect for each outcome using the pooled odds ratio (OR)
and 95% confidence intervals (CIs) or 99% CIs for analysis of
separate adverse events.
For continuous outcomes, we calculated the mean change from
baseline for each group or the mean post-intervention values and
standard deviation (SD) for each group. We converted standard
errors (SEs) to SDs. We produced a pooled estimate of treatment
effect by calculating the mean difference (MD) and 95% CIs.
In future updates of this review, if different trials present data for
the same outcomes in different forms (e.g. absolute values of lung
function measures, or change in these measures from a baseline),
we will combine these in a meta-analysis where appropriate.
Where the studies did not report change data, but instead pre-
sented absolute post-treatment data without baseline data (so it
was not possible to calculate change data) we planned to use ab-
solute post-treatment data instead of change from baseline. How-
ever, if the report presented baseline and post-treatment data for
any outcome, we calculated SDs for the change from baseline, for
example if the CI was available. If there was not enough informa-
tion available to calculate the SDs for the changes, we planned to
impute them from other trials in the review, where data were avail-
able and trials were similar (i.e. when they used the same measure-
ment scale, had the same degree of measurement error and had the
same time periods between baseline and final value measurement).
If neither of these methods were possible, we planned to calculate
a change-from-baseline SD, making use of an imputed correlation
coefficient (methods described in section 16.1.3.2 in theCochrane
Handbook of Systematic Reviews of Interventions (Higgins 2011b)).
Where time-to-event data were reported (e.g. survival time, time
to next hospitalisation, time to first exacerbation), we reported a
hazard ration (HR) and 95% CIs.
When reporting on outcomes we used the following subheadings
to describe the time points: immediate (up to and including one
month); short term (over one month and up to six months); and
longer term (over six months).
Unit of analysis issues
Within this review, we only included results from RCTs of parallel
design in which individual study participants are randomised. We
have not included cross-over studies as we do not feel this study
design is appropriate given that the intervention aims to correct
the underlying defect. If the intervention is effective it will have
an important impact on the course of the disease. This has been
established from the data from trials examining ivacaftor for people
with class III mutations (Patel 2015).
In one included study, continuous outcomes were analysed via a
mixed model repeated measures analysis (MMRM) based on the
average effect across themeasured time points (Ratjen 2017). Such
an analysis is longitudinal and uses all available data at every visit
and allows adjustment for covariates such as the baseline measure-
ment of the outcome. All analyses were also adjusted for baseline
weight (less than 25 kg versus 25 kg or over) and baseline FEV1
(% predicted - less than 90% versus 90% or above). Results pro-
vided by this model can be interpreted as treatment effect averaged
from each study visit until week 24. Within this review, results
are entered into the analysis via generic inverse variance and are
not pooled with other studies, due to the different approaches to
analysis.
Dealing with missing data
In order to allow an intention-to-treat analysis, we extracted data
on the number of participants with each outcome event, by al-
located treated group, irrespective of compliance and whether or
not the participant was later thought to be ineligible or otherwise
excluded from treatment or follow-up. If any data were missing or
unclear, we contacted the primary investigators for clarification.
Assessment of heterogeneity
We assessed heterogeneity through visual examination of the com-
bined data presented in the forest plots, and by considering over-
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lap of study-specific CIs, and the I² statistic (Higgins 2003) to-
gether with Chi² values (Deeks 2011). The I² statistic reflects the
likelihood that variation of results across studies are due to het-
erogeneity rather than by chance, and we interpreted this statistic
using the following simple classification:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
In order to identify selective outcome reporting, where possible,
we have compared outcomes described in the study protocol with
those reported in the publication. We have requested protocols
for specific studies from the primary investigators and recorded
the proportion of protocols that were available to us. If a protocol
was not available, we searched for information about outcomes
from trial registry databases. We also compared outcomes listed
in the ’Methods’ section of the final paper with those presented
in the ’Results’ section. If the published papers reported negative
findings either only partially, or not at all, we contacted primary
investigators for these data.
We would have assessed publication bias by constructing and as-
sessing the symmetry of a funnel plot. This would have been pos-
sible if we included more than 10 studies in a meta-analysis in the
review. We would have plotted the number of participants in the
study against a measure of treatment effect. If the funnel plot was
asymmetrical, we would consider whether this was due to publi-
cation bias, or whether methodology or small sample size caused
results of certain studies to show exaggerated treatment effects.
Data synthesis
As we intended to assess different CFTR correctors within this
review, we assumed that there would not be a single common true
effect. We also anticipated participants in each study would vary
due to different eligibility criteria. Therefore, regardless of I² value,
we intended to use a random-effects model to analyse data from
studies.
As the review progressed, we included a number of early-phase
studies of interventions (which were ultimately not taken forward)
in addition to large Phase 3 studies of combination therapies;
therefore, we felt it more appropriate to employ separate compar-
isons within the review. As only a relatively small number of stud-
ies were included in each comparison (and when meta-analysis
was undertaken), it was considered more appropriate to employ a
fixed-effect model.
Subgroup analysis and investigation of heterogeneity
We would have investigated any heterogeneity that we identified
using subgroup analyses of potential confounding factors, if suf-
ficient numbers (at least 10 studies included in a meta-analysis)
were available. For this review, these confounding factors would
be:
• age (children (defined as younger than 18 years of age)
versus adults);
• gender;
• different mutation classes (Table 1).
As we did not seek individual patient data from study investigators
and such information was not available within published reports,
we did not undertake a subgroup analysis on the basis of disease
severity. We may incorporate such an analysis in future updates of
this review.
Sensitivity analysis
In future updates of this review, if sufficient data are available, we
will examine the impact of bias on the results by comparing meta-
analyses including and excluding studies with concerns of high
risk of selection or reporting bias due to issues relating to randomi-
sation, allocation concealment, or masking of interventions from
participants or study personnel.
Summary of findings and quality of the evidence
(GRADE)
In a post hoc change fromprotocol, we have presented six summary
of findings tables (Summary of findings for the main comparison;
Summary of findings 2; Summary of findings 3; Summary of
findings 4; Summary of findings 5; Summary of findings 6).
We have presented two tables under the comparison of ’Cor-
rectors (monotherapy) compared to placebo;’ where lumacaftor
monotherapy is compared to placebo (Summary of findings for
the main comparison). We have presented lumacaftor results only
rather than other correctors in the table for this comparison due
to the relevance of this particular treatment at the time of writ-
ing (NICE 2016). A further table is also provided for cavosonstat
compared to placebo (Summary of findings 2).
We have presented four tables under the comparison of ’Correctors
plus potentiators in combination therapy compared to placebo’:
• lumacaftor (600 mg once daily or 400 mg once daily) plus
ivacaftor (250 mg twice daily) versus placebo reporting short-
term results (one month to six months) (Summary of findings 3);
• lumacaftor (200 mg twice daily) and ivacaftor (250 mg
twice daily) versus placebo reporting immediate-term results (up
to one month (Summary of findings 4);
• lumacaftor (200 mg) plus ivacaftor (150 mg or 250 mg
twice daily) versus placebo reporting immediate-term results (up
to one month) (Summary of findings 5).
• tezacaftor (100 mg once daily) and ivacaftor (150 mg twice
daily) versus placebo or ivacaftor (150 mg twice daily alone)
(Summary of findings 6).
Tables were presented separately for lumacaftor plus ivacaftor un-
der this comparison due to the differences in doses, measurement
times and approaches to analysis.
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The following outcomes were reported in all tables (chosen based
on relevance to clinicians and consumers): survival, QoL (total
score), QoL (respiratory domain), FEV1 (relative and absolute
change), adverse events and time to first pulmonary exacerbation.
For clarity in the tables, adverse events are not presented according
to the sub-domains in Effects of interventions; instead the authors
have inserted a general statement about the summary of findings
for these outcomes and the evidence is graded based on all of the
sub-domains combined.
We determined the quality of the evidence using the GRADE
approach; and downgraded evidence in the presence of a high
risk of bias in at least one study, indirectness of the evidence,
unexplained heterogeneity or inconsistency, imprecision of results,
high probability of publication bias. We evidence by one level if
they considered the limitation to be serious and by two levels if
very serious.
R E S U L T S
Description of studies
Results of the search
The search of specified databases identified 98 unique references
corresponding to 38 studies. No further studies were identified
from contacting CF researchers or from screening relevant refer-
ences. There were 13 studies (80 references) which met the eli-
gibility criteria for inclusion in this review (Boyle 2014; Clancy
2012; Donaldson 2014; Donaldson 2017; Donaldson 2018;
PROGRESS 2017; McCarty 2002; Ratjen 2017; Rubenstein
1998; Taylor-Cousar 2017; TRAFFIC 2015; TRANSPORT
2015; Zeitlin 2002). The results from two of these studies were
jointly reported in 15 papers (TRAFFIC 2015; TRANSPORT
2015).
We excluded 11 studies (17 references) (Berkers 2014;
Chadwick 1998; Lebecque 2011; Leonard 2012; Chilvers 2017;
NCT01899105; Nick 2014; Rowe 2017; Rubenstein 2006;
Sumner 2014; Ziady 2015).
We identified 13 relevant ongoing studies
(Meijer 2016; NCT02070744; NCT02323100; NCT02412111;
NCT02589236; NCT02718495; NCT02730208;
NCT02951195; NCT03093714; NCT03150719;
NCT03224351;NCT03227471;NCT03258424) and one study
is listed as awaiting classification pending further information
(Hunt 2017)
Results of the online electronic searches are displayed in a PRISMA
diagram (Figure 1).
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Figure 1. PRISMA study flow diagram
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Included studies
Study design
The 13 included studies ranged from Phase 1 to Phase 3 RCTs,
and all employed a parallel study design (Boyle 2014; Clancy
2012; Donaldson 2014; Donaldson 2017; Donaldson 2018;
PROGRESS 2017; McCarty 2002; Ratjen 2017; Rubenstein
1998; Taylor-Cousar 2017; TRAFFIC 2015; TRANSPORT
2015; Zeitlin 2002). The PROGRESS study was an extension
study of the TRAFFIC and TRANSPORT studies included in
the review (TRAFFIC 2015; TRANSPORT 2015), but with par-
ticipants in the placebo group from the initial trials randomised
to receive the active treatment at one of two doses (PROGRESS
2017).
A total of 2215 randomised participants were included in this re-
view. Study sample sizes ranged from 18 participants (Rubenstein
1998) to 563 participants (TRANSPORT 2015). One study was
composed of three cohorts - cohort 1 (n = 62), cohort 2 (n = 109)
and cohort 3 (n = 15); any reference to this study is to participants
randomised to cohort 1 only, since data for the placebo partici-
pants from cohorts 2 and 3 were pooled, undoing the effects of
randomisation and rendering them ineligible for inclusion in this
review (Boyle 2014). In the Phase 2 study of tezacaftor-ivacaftor,
only data from the heterozygous population are included (n = 18),
as the placebo groups in the homozygous arms of the trial were
pooled (Donaldson 2018).
The duration of the included studies ranged from 1 day (Phase
1 single-dose testing) (McCarty 2002) to 24 weeks (Ratjen 2017;
TRAFFIC 2015; TRANSPORT 2015) with an extension of two
of these studies of 96 weeks (PROGRESS 2017).
Two studies were undertaken at single centres (Rubenstein 1998;
Zeitlin 2002), but the remaining studies were conducted at mul-
tiple centres, ranging from at four (McCarty 2002) to 191 sites
(PROGRESS 2017). Five studies were conducted in the USA only
(Donaldson 2014; Donaldson 2017; McCarty 2002; Rubenstein
1998; Zeitlin 2002), four in North America and Europe (Clancy
2012; Donaldson 2018; Ratjen 2017; Taylor-Cousar 2017) and
the remainder across North America, Europe and Australia (Boyle
2014; PROGRESS2017; TRAFFIC 2015; TRANSPORT2015).
Full texts were available for 12 studies (Boyle 2014; Clancy
2012; Donaldson 2017; Donaldson 2018; PROGRESS 2017;
McCarty 2002; Ratjen 2017; Rubenstein 1998; Taylor-Cousar
2017; TRAFFIC 2015; TRANSPORT 2015; Zeitlin 2002) and
one as an online summary onClinicaltrials.gov (Donaldson 2014).
Participants
One study recruited pwCF with one F508del mutation (the other
mutation was classified as residual function (ivacaftor responsive))
(Donaldson 2018). All remaining studies recruited participants
who were homozygous for F508del.
One study recruited children between the ages of 6 to 11
years (Ratjen 2017), five studies recruited adolescents and adults
(PROGRESS 2017; Rubenstein 1998; Taylor-Cousar 2017;
TRAFFIC 2015; TRANSPORT 2015) and the remaining stud-
ies recruited only adults (Boyle 2014; Clancy 2012; Donaldson
2014; Donaldson 2017; Donaldson 2018;McCarty 2002; Zeitlin
2002).
Interventions
Monotherapy
The included studies examined the effects of 4-Phenylbutyrate
(4PBA) (Rubenstein 1998; Zeitlin 2002), 8-cyclopentyl-1, 3-
dipropylxanthine (CPX) (McCarty 2002), N6022 (Donaldson
2014), cavosonstat (N91115) (Donaldson 2017), lumacaftor
monotherapy (Boyle 2014; Clancy 2012), lumacaftor-ivacaftor
combination therapy (Boyle 2014; PROGRESS 2017; Ratjen
2017; TRAFFIC 2015; TRANSPORT 2015) and tezacaftor-
ivacaftor combination therapy (Donaldson 2018; Taylor-Cousar
2017).
Two studies compared 4PBA to placebo (Rubenstein 1998; Zeitlin
2002). In the earlier study, participants received either 19 g of
4PBA (split into three daily doses) or placebo for one week
(Rubenstein 1998). The subsequent Phase 2 study examined the
effects 4PBA given at either 20 g (n = 6), 30 g (n = 6) or 40 g (n
= 3), given in three daily doses for one week (Zeitlin 2002).
One study compared escalating doses of CPX to placebo (McCarty
2002). Participants were randomised to receive single doses of
either placebo (n = 8) or 1 mg (n = 4), 3 mg (n = 4), 10 mg (n =
4), 30 mg (n = 4), 100 mg (n = 5), 300 mg (n = 4) or 1000 mg (n
= 4) of CPX.
One study compared sequential ascending doses of N6022 to
placebo (Donaldson 2014). Participants were randomised to re-
ceive placebo (n = 19) or the active drug (intravenous solution of
N6022 in normal saline) at a dose of either 5 mg (n = 10), 10 mg
(n = 9), 20 mg (n = 9), 40 mg (n = 19). Both treatments were
administered by infusion pump over one to eight minutes once
per day for seven days.
The study of cavosonstat included both healthy volunteers and
pwCF (Donaldson 2017). Those with CF were randomised to
receive 50 mg placebo (n = 12) or cavosonstat at different doses
(50 mg (n = 12), 100 mg (n = 13), or 200 mg (n = 14)) twice daily
for 28 days.
14Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
One included study compared lumacaftor monotherapy at esca-
lating doses of 25 mg (n = 18), 50 mg (n = 18), 100 mg (n =
17) and 200 mg (n =19), to placebo (n = 17) for 28 days (Clancy
2012).
Combination therapy
Five studies have evaluated lumacaftor-ivacaftor combination ther-
apy (Boyle 2014; PROGRESS 2017; Ratjen 2017; TRAFFIC
2015; TRANSPORT 2015). In one cohort of a Phase 2 study,
participants received 200 mg lumacaftor once daily for 14 days,
followed by seven days of 200 mg lumacaftor once daily plus ei-
ther 150 mg (n = 20) or 250 mg (n = 21) of ivacaftor twice daily
(day 15 to 21), or placebo (Boyle 2014). In one Phase 3 study,
children received either a combination of lumacaftor 200 mg plus
ivacaftor 250 mg every 12 hours or placebo for 24 weeks (Ratjen
2017). Two Phase 3, three-arm studies (TRAFFIC and TRANS-
PORT) also compared lumacaftor-ivacaftor combination therapy
to placebo. In these studies, two separate doses of lumacaftor (600
mg once daily and 400 mg twice daily) were combined with twice
daily 250 mg of ivacaftor. The placebo group received lumacaftor-
matched placebo every 12 hours in combination with ivacaftor-
matched placebo every 12 hours (TRAFFIC 2015; TRANSPORT
2015). A long-term extension study (96 weeks) randomised those
in the placebo groups of the TRAFFIC and TRANSPORT studies
to one of the two lumacaftor-ivacaftor combination doses; those
already receiving an active treatment continued with their existing
treatment (PROGRESS 2017).
Two studies have evaluated tezacaftor-ivacaftor combination ther-
apy (Donaldson 2018; Taylor-Cousar 2017). A Phase 2 study in-
cluded a dose-escalation arm, a comparisonof various doses of teza-
caftor-ivacaftor in people homozygous for F508del, and a compar-
ison of tezacaftor-ivacaftor against ivacaftor alone in people with
one F508del mutation and one G551D mutation (Donaldson
2018). The Phase 3 study compared a combination of tezacaftor
100mg plus ivacaftor 150mg every 12 hours to amatched placebo
for 24 weeks (Taylor-Cousar 2017).
Outcomes
Lung function using FEV1 was reported in 11 studies (Boyle 2014;
Clancy 2012; Donaldson 2014; Donaldson 2017; Donaldson
2018; PROGRESS 2017; McCarty 2002; Ratjen 2017; Taylor-
Cousar 2017; TRAFFIC 2015; TRANSPORT 2015). One
study additionally reported LCI (Ratjen 2017). Eight studies
reported QoL, all of which utilised the respiratory domain of
the CFQ-R (Clancy 2012; Donaldson 2017; Donaldson 2018;
PROGRESS 2017; Ratjen 2017; Taylor-Cousar 2017; TRAFFIC
2015; TRANSPORT 2015).
Reporting of the pre-specified secondary outcomes in this re-
view varied across studies. All included studies monitored the
adverse effects of therapy, but the manner in which these sa-
fety outcomes were analysed and reported varied considerably.
Five studies reported outcomes relating to pulmonary exacerba-
tions (PROGRESS 2017; Rubenstein 1998; Taylor-Cousar 2017;
TRAFFIC 2015; TRANSPORT 2015). No studies specifically re-
ported on rates of hospitalisation. Eight studies reported changes
in sweat chloride, as a marker of CFTR function (Boyle 2014;
Clancy 2012; Donaldson 2014; Donaldson 2017; Ratjen 2017;
Rubenstein 1998; Taylor-Cousar 2017; Zeitlin 2002). No studies
reported radiological outcomes. Two studies reported microbio-
logical outcomes (Taylor-Cousar 2017; Zeitlin 2002). Five studies
reported BMI (PROGRESS 2017; Ratjen 2017; Taylor-Cousar
2017; TRAFFIC 2015; TRANSPORT 2015).
Funding sources
Eight studies were funded by pharmaceutical companies (
Donaldson 2014; Donaldson 2017; PROGRESS 2017; McCarty
2002; Ratjen 2017; Taylor-Cousar 2017; TRAFFIC 2015;
TRANSPORT 2015). Three studies were funded jointly by phar-
maceutical companies and other sources (Boyle 2014; Clancy
2012; Donaldson 2018). Two studies were not funded by phar-
maceutical companies at all: one was funded by the Cystic Fibrosis
Foundation (CFF) (Zeitlin 2002), and one jointly by the CFF and
the NIH (Rubenstein 1998).
Further information about the studies is presented in the tables
(Characteristics of included studies).
Excluded studies
We excluded 11 studies in total. Six studies were of cross-
over design (Berkers 2014; Lebecque 2011; Leonard 2012;
NCT01899105; Nick 2014; Rowe 2017), two studies were sin-
gle-assignment studies, i.e. participants were not randomised to
different study arms (Chilvers 2017; Rubenstein 2006), one study
was not randomised (Chadwick 1998), one study was a pre-clini-
cal laboratory study (Ziady 2015) and the remaining study was of
general gene therapy and not a mutation-specific therapy (Sumner
2014).
Ongoing studies
There are 13 studies listed as ongoing
(Meijer 2016; NCT02070744; NCT02323100; NCT02412111;
NCT02589236; NCT02718495; NCT02730208;
NCT02951195; NCT03093714; NCT03150719;
NCT03224351; NCT03227471; NCT03258424).
Monotherapy
Five ongoing clinical studies are currently evaluating four
monotherapy correctors. One study is comparing doses of a cor-
rector known as (R)-roscovitine to placebo in adults with CF with
either one or two copies of the F508del mutation (Meijer 2016).
A second study is comparing GPBA to placebo in people who
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are homozygous for F508del (NCT02323100). A third is com-
paring a corrector called FDL 169 to placebo in people who are
homozygous for F508del (NCT03093714). Two studies are eval-
uating PTI 428 (a particular type of CFTR corrector called an
amplifier, which augment the actions of other CFTR modulators)
(NCT02718495; NCT03258424).
Combination therapy
Four ongoing studies are evaluating the safety and efficacy of teza-
caftor-ivacaftor in pwCF; three of these are in people homozygous
for F508del (NCT02070744; NCT02730208; NCT03150719),
and one in heterozygous people who have one copy of the F508del
mutation and one mutation that has been demonstrated to be re-
sponsive to ivacaftor therapy (NCT02412111). One of the studies
is in people who have previously been taking lumacaftor-ivacaftor
but were not able to continue due to an adverse event or drug
reaction (NCT03150719).
Three ongoing placebo-controlled studies are evaluating triple
combination therapies, each adding a drug to a tezacaftor-ivacaftor
combination therapy in pwCF (NCT02951195; NCT03224351;
NCT03227471). One study is evaluating VX152 in combina-
tion with tezacaftor-ivacaftor in people homozygous for F508del
(NCT02951195). Two studies are evaluating triple therapies, both
in people who are homozygous for F508del and people with one
F508del mutation and a minimal function mutation that is un-
likely to respond to tezacaftor-ivacaftor, one of these is evaluating
VX-659 (NCT03224351) and the second is evaluating VX-445
(NCT03227471).
A Phase 2 placebo-controlled study is assessing the efficacy of
cavosonstat when added to pre-existing lumacaftor-ivacaftor ther-
apy in adults withCFwho are homozygous for the F508del-CFTR
mutation (NCT02589236).
Studies awaiting classification
One study is currently awaiting classification until further infor-
mation is available (Hunt 2017). In this RCT, 18 adults (11 fe-
males) with CF who were homozygous for the F508del mutation,
and whowere all receiving lumacaftor-ivacaftor combination ther-
apy were randomised to four weeks of either 40 mg sildenafil three
times daily ormatchedplacebo.Outcomesmeasured include sweat
chloride, FEV1 % predicted, BMI, exhaled nitric oxide, CFQ-R,
nasal potential difference and LCI. This study was described in
an abstract presented at a conference in 2017 and we will further
evaluate for inclusion once the full publication is available.
Risk of bias in included studies
We have summarised our risk of bias judgements in the figures
(Figure 2; Figure 3).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Sequence generation
We judged six studies to have a low risk of bias (Boyle 2014;
PROGRESS 2017; Ratjen 2017; Taylor-Cousar 2017; TRAFFIC
2015; TRANSPORT2015).Of these, one study used a computer-
generated randomisation schedule developed by an independent
party (Boyle 2014), and the others randomised participants via an
interactive web response system (PROGRESS 2017; Ratjen 2017;
Taylor-Cousar 2017; TRAFFIC 2015; TRANSPORT 2015).
As none of the remaining seven included studies reported de-
tails of random sequence generation we have judged the risk
of bias as unclear (Clancy 2012; Donaldson 2014; Donaldson
2017; Donaldson 2018;McCarty 2002; Rubenstein 1998; Zeitlin
2002).
Allocation concealment
We judged six studies to have a low risk of bias (Boyle 2014;
PROGRESS 2017; Ratjen 2017; Taylor-Cousar 2017; TRAFFIC
2015; TRANSPORT 2015). In the phase 2 lumacaftor-ivacaftor
study, site pharmacists dispensed drugs on the basis of an in-
teractive voice response system, making it unlikely that partici-
pants or study personnel would have been aware of group assign-
ments prior to recruitment into the study (Boyle 2014). The re-
maining lumacaftor-ivacaftor studies, and the tezacaftor-ivacaftor
study also employed an interactive web response system to allo-
cate participants to treatment groups (PROGRESS 2017; Ratjen
2017; Taylor-Cousar 2017; TRAFFIC 2015; TRANSPORT
2015). Methods to conceal group allocation were not reported
by the remaining seven studies, who also failed to report on ran-
dom sequence generation, so we judged these as having an un-
clear risk of bias (Clancy 2012; Donaldson 2014; Donaldson
2017; Donaldson 2018;McCarty 2002; Rubenstein 1998; Zeitlin
2002).
Blinding
Eight studies were judged to have a low risk of performance and
detection bias (Boyle 2014; Donaldson 2014; Donaldson 2017;
Donaldson 2018; PROGRESS 2017; Ratjen 2017; TRAFFIC
2015; TRANSPORT 2015). In the Boyle study, drug doses were
prepared by an independent unmasked pharmacist and dispensed
by site pharmacists who were masked to treatment assignment.
Site investigators and the study sponsor were also masked to treat-
ment assignment and to sweat chloride levels - data that could have
potentially disclosed treatment assignment. Participant blinding
was maintained by placebo which was matched to intervention by
the quantity of tablets and by size, colour, coating and packaging
(Boyle 2014). In the Donaldson study, participants, care givers,
investigators and outcome assessors were double-blinded via intra-
venous administration of placebo (saline) using the same volume
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as the active drug groups (Donaldson 2014). In the two Phase 3
lumacaftor-ivacaftor studies and the extension study, the partici-
pants and study team remained blinded to the treatment assign-
ments and the placebo was matched in appearance and packag-
ing to the active intervention. The online protocol further stated
that all site personnel, including the investigator, the site moni-
tor and the study team would remain blinded to treatment group
(PROGRESS 2017; TRAFFIC 2015; TRANSPORT 2015). In
the paediatric lumacaftor-ivacaftor study, double blinding was
achieved by using placebo tablets visually identical to the test prod-
uct (Ratjen 2017).
In the pilot 4PBA, CPX and the lumacaftor monotherapy studies,
there was insufficient information about how participant, study
personnel or outcome assessor blinding was maintained and so we
judged these three studies to have an unclear risk of performance
and detection bias (Clancy 2012; McCarty 2002; Rubenstein
1998).
Participants from the three intervention groups (20 g, 30 g and 40
g) in the Phase 2 4PBA study had different dosing schedules and
were given a different number of tablets. Therefore this study was
judged to have a high risk of performance bias. Also in this study,
there were insufficient data on blinding of outcome assessors and
we therefore judged it to have an unclear risk of detection bias
(Zeitlin 2002).
Incomplete outcome data
We judged nine studies to have a low risk of bias due to incomplete
outcome data (Donaldson 2014; Donaldson 2018; PROGRESS
2017; McCarty 2002; Ratjen 2017; Rubenstein 1998; Taylor-
Cousar 2017; TRAFFIC 2015; TRANSPORT 2015).
Three studies were judged to have an unclear risk of attrition
bias (Boyle 2014; Donaldson 2017; Zeitlin 2002). In the phase
2 lumacaftor-ivacaftor study, one out of 62 participants withdrew
(1.6%) due to an adverse effect, demonstrating a low withdrawal
rate. However, in the analysis only participants for whom data
were available were included. Although these participants were
excluded because of insufficient data rather than for reasons that
could potentially lead to the exclusion of participants with un-
favourable characteristics, e.g. adverse effects, we judged this study
as having an unclear risk of attrition bias because it was unclear
how these exclusions would have affected the balance between
groups in baseline characteristics (Boyle 2014). The cavosonstat
study was judged as having an unclear risk of bias in this domain
because two out of 51 participants are unaccounted for in the fi-
nal analysis, but it is unlikely that these would affect the overall
findings (Donaldson 2017). In the phase 2 4PBA study, all 19
randomised participants completed the final study visit, but risk
of attrition bias was unclear because there was no report of how
many of these participants were included in the analysis (Zeitlin
2002). We approached the primary author to clarify this, but did
not receive any additional information.
We judged the study of lumacaftor monotherapy to have a high
risk of attrition bias (Clancy 2012). Although only four out of 89
(5%) participants withdrew from the study due to adverse events
(demonstrating a low withdrawal rate), data for a number of out-
comes were excluded from the analysis. A total of 42 participants
were excluded from reports of adverse events; nine participants
were excluded from reports on change from baseline in sweat chlo-
ride concentration (demonstrated by figure 1b in the full-text ar-
ticle) and four participants were excluded from the information
on CFQ-R domain scores. Our judgement of a high risk of attri-
tion bias was due firstly to the high level of excluded participant
data and secondly to the lack of reasons for the exclusion of these
participant data. The study’s lead investigator was approached for
clarification, but we have received no response to date (Clancy
2012).
Selective reporting
Where study protocols were not available, or there were missing
outcome data, we approached the studies’ primary authors for
additional information.
We judged six studies to have a low risk of reporting bias (Boyle
2014; Donaldson 2017; Donaldson 2018; PROGRESS 2017;
McCarty 2002; Rubenstein 1998). For the Phase 2 lumacaftor-
ivacaftor study, the protocol was not available, but outcomes were
presented on the NIH trials registry (clinicaltrials.gov/); we did
not identify any missing outcomes for the included cohort (Boyle
2014). For the pilot 4PBA and CPX studies, protocols were not
available and planned outcomes were not listed on ongoing online
trials databases (McCarty 2002; Rubenstein 1998). So, we com-
pared the outcomes reported in the ’Methods’ sections to the out-
comes reported in the ’Results’ sections of the publications and did
not identify any missing outcomes (McCarty 2002; Rubenstein
1998). For the extension study of TRAFFIC and TRANSPORT,
we compared the list of outcomes provided on the NIH trials reg-
istry ( clinicaltrials.gov/) to the results reported in the published
paper; all listed outcomes were reported (PROGRESS 2017).
One study was judged to be at unclear risk of bias from selective
outcome reporting (Donaldson 2014). Only limited results were
available from the NIH trials registry ( clinicaltrials.gov/) and it
was unclear if all relevant information has been made available.
We judged six studies to have a high risk of bias from selective
outcome reporting (Clancy 2012; Ratjen 2017; Taylor-Cousar
2017; TRAFFIC 2015; TRANSPORT 2015; Zeitlin 2002). The
protocol for the Clancy lumacaftor study was not available, but
the planned outcomes were listed on the NIH trials registry (
clinicaltrials.gov/).We compared these outcomes to those reported
in the ’Results’ section of the published paper and ascertained
that no data were reported for FEF25−75% or FVC at 28 days
(Clancy 2012). The study protocol for the phase 2 4PBA studywas
not available and planned outcomes were not listed on ongoing
online trials databases (Zeitlin 2002).We compared the outcomes
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reported in the ’Methods’ section of the paper to the outcomes
reported in the ’Results’ section and identified that data were not
reported for the change from baseline in FEV1 or microbiology
scores at day seven (Zeitlin 2002).
In the two Phase 3 lumacaftor-ivacaftor studies, pre-specified
data were reported on the NIH trials registry (TRAFFIC 2015;
TRANSPORT 2015). In these studies, data for the outcomes;
absolute change from baseline in FEV1 and relative change from
baseline in FEV1 were combined at 16 and 24 weeks. Combina-
tion of this data was not pre-specified and the primary author was
contacted from clarification. Furthermore, some results had to be
extrapolated from graphical figures and some additional data were
only reported on clinicaltrials.gov for outcomes not reported in
the final paper. Also, investigators state that they measured FVC
(which was not listed as an end-point) and do not report this in
the joint paper (TRAFFIC 2015; TRANSPORT 2015).
In the paediatric combination study, several outcomes which were
listed in the methods of the full publication and also on the Clin-
icalTrials.gov entry for this study were not reported in the re-
sults section of the paper (Ratjen 2017). These outcomes include
LCI5.0, weight, height and time to first pulmonary exacerbation.
In the tezacaftor-ivacaftor combination study, a number of out-
comes were recorded according to the study protocol but were not
reported in the published paper (Taylor-Cousar 2017). These out-
comes were the CF respiratory symptom diary, duration of daily
physical activity (number of minutes), the Pittsburgh Sleep Qual-
ity Index (PSQI), SF-12 health survey, sputum microbiology, the
time-to-first and number of days with an exacerbation, the time
to first hospitalisation and the number of days hospitalised with
exacerbation, the number of exacerbations requiring IV therapy,
the time to the first IV therapy and the number of days on IV
therapy.
Other potential sources of bias
We judged there to be a low risk of other bias due to no sta-
tistically significant difference between baseline characteristics in
six studies (PROGRESS 2017; Rubenstein 1998; Taylor-Cousar
2017; TRAFFIC 2015; TRANSPORT 2015; Zeitlin 2002) and
due to well-matched baseline characteristics in a further four stud-
ies (Boyle 2014; Clancy 2012; Donaldson 2014; Ratjen 2017).
Futhermore, in both the TRAFFIC andTRANSPORT studies ad-
herence to treatment was high with similar compliance rates across
the different treatment groups (TRAFFIC 2015; TRANSPORT
2015).
In the remaining three studies, there was insufficient detail about
baseline characteristics or an apparent imbalance in baseline char-
acteristics, leading to an unclear risk of bias (Donaldson 2017;
Donaldson 2018; McCarty 2002).
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings - Lumacaftor monotherapy compared to placebo;
Summary of findings 2 Summary of findings - Cavosonstat
compared with placebo for cystic fibrosis; Summary of findings
3 Summary of findings - Lumacaftor plus ivacaftor (once daily)
compared with placebo for cystic fibrosis (short term); Summary
of findings 4 Summary of findings - Lumacaftor plus ivacaftor
(twice daily) comparedwith placebo for cystic fibrosis (short term);
Summary of findings 5 Summary of findings - Lumacaftor plus
ivacaftor compared with placebo for cystic fibrosis (immediate
term); Summary of findings 6 Summary of findings - tezacaftor
plus ivacaftor compared with placebo or ivacaftor alone
As described above, we identified two types of intervention relevant
for this review. The first group of studies examined single agents
that aimed to correct the F508del trafficking defect (commonly
referred to as “correctors”). The second group of studies examined
a combination of various correctors with ivacaftor (a drug known
to potentiate the function of the CFTR in the membrane). As
these interventions have different potential mechanisms of action,
we present the results separately for ’Correctors (monotherapy)
compared to placebo’ and ’Correctors plus potentiators (combina-
tion therapy) compared to placebo’. Results are summarised for all
doses reported separately and for treatment doses combined where
appropriate. In the summary of findings tables, the quality of the
evidence has been graded for pre-defined outcomes (see above)
and definitions of these gradings provided.
Correctors (monotherapy) compared to placebo
Seven studieswith 317participants contributed to this comparison
(Boyle 2014; Clancy 2012; Donaldson 2014; Donaldson 2017;
McCarty 2002; Rubenstein 1998; Zeitlin 2002).
Two studies (n = 37) compared 4PBA to placebo (Rubenstein
1998; Zeitlin 2002), one study (n = 66) compared N6022 to
placebo (Donaldson 2014), one study (n = 37) compared CPX
to placebo (McCarty 2002) and two studies (n = 151) compared
varying doses of lumacaftor alone to placebo (Boyle 2014; Clancy
2012). One study (n = 26) compared cavosonstat 200 mg (twice
daily) to placebo (Donaldson 2017). We only present this dose
comparison (200 mg) from this early-phase study as this is the
only dose that is being studied further and other doses are not
relevant to current clinical practice. Participants in one study (n
= 64) received lumacaftor monotherapy for 14 days followed by
combination therapy with ivacaftor for seven days, therefore this
study contributes to both comparisons of this review (Boyle 2014).
Important results for this comparison are summarised in the tables
(Summary of findings for the main comparison; Summary of
findings 2).
Primary outcomes
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1. Survival
No deaths were reported during any of the included studies (Boyle
2014; Clancy 2012; Donaldson 2014; Donaldson 2017;McCarty
2002; Rubenstein 1998; Zeitlin 2002).
2. QoL
a. Total QoL score
Data for this outcomewere not reported by any study (Boyle 2014;
Clancy 2012; Donaldson 2014; Donaldson 2017;McCarty 2002;
Rubenstein 1998; Zeitlin 2002).
b. Different sub-domains
i. Immediate term (up to and including one month)
Lumacaftor versus placebo
The study by Clancy (n = 89) reported on the change from base-
line scores for all CFQ-R domains at 28 days (Table 2). We have
presented these absolute change from baseline scores as we were
unable to calculate the relative change from baseline in CFQ-R
scores since baseline CFQ-R scores were not reported. Further-
more, no SDs or CIs were reported to allow calculation of SDs for
entry into the analysis (Clancy 2012).
Participants in the 25 mg group reported statistically significantly
lower CFQ-R scores for the role domain (MD -8.15) and respi-
ratory domain (MD -9.75) compared participants in the placebo
group. Participants in the 50 mg lumacaftor group reported sta-
tistically significantly lower CFQ-R scores for the eating domain
(MD -9.4), health perceptions domain (MD -12.0), respiratory
domain (MD -10.85) and treatment burden domain (MD -8.42)
compared to participants assigned to placebo. Participants in the
200 mg group reported statistically significantly lower CFQ-R
scores for the role domain (P < 0.05) compared participants in the
placebo group (Clancy 2012).
Cavosonstat versus placebo
Donaldson (n = 51) also reported data for both the respiratory
and eating domains of the CFQ-R at 28 days, but neither result
showed any difference between cavosonstat and placebo groups
(Analysis 2.1; Analysis 2.2) (Donaldson 2017).
ii. Short term (over one month and up to and including six
months)
Data for this outcomewere not reported by any study (Boyle 2014;
Clancy 2012; Donaldson 2014; Donaldson 2017;McCarty 2002;
Rubenstein 1998; Zeitlin 2002).
3. Physiological measures of lung function
a. FEV1 (relative change from baseline)
i. Immediate term (up to and including one month)
Lumacaftor versus placebo
The study by Clancy (n = 89) reported the mean relative change
from baseline in FEV1 after 28 days of treatment with escalating
doses of lumacaftor, but did not present the corresponding SDs
precluding analysis (Clancy 2012). No statistically significant dif-
ferences were reported between the placebo group and the differ-
ent lumacaftor dose groups: 25 mg, MD -2.53% predicted; 50
mg, MD -2.22% predicted; 100 mg, MD 0.25% predicted; and
200 mg, MD 0.40% predicted. No SDs or CIs were reported to
allow calculation of SDs for entry into the analysis (Clancy 2012).
Cavosonstat versus placebo
Donaldson (n = 51) presents data for cavosonstat versus placebo
pictorially in the graph (supplementary tables), but overlapping
SD lines render these data difficult to extract. The paper reports
that no treatment-related changes inFEV1 were seenwith cavoson-
stat compared to placebo (Donaldson 2017).
N6022 versus placebo
The study by Donaldson (n = 66) reported the mean relative
change from baseline in FEV1 % predicted after seven days of
treatment with sequential ascending doses of N6022 (5 mg, 10
mg, 20 mg or 40 mg per day) (Donaldson 2014). No statistically
significant differences were reported between the placebo group
and any of the N6022 dose groups (Analysis 3.1).
ii. Short term (over one month and up to and including six
months)
Data for this outcomewere not reported by any study (Boyle 2014;
Clancy 2012; Donaldson 2014; Donaldson 2017;McCarty 2002;
Rubenstein 1998; Zeitlin 2002).
b. FEV1 (absolute values)
i. Immediate term (up to and including one month)
Lumacaftor versus placebo
The Phase 2 study (n = 62) reported on the absolute change from
baseline in FEV1 after lumacaftor monotherapy (day 14) (Boyle
2014); there was no statistically significant difference between
treatment groups, MD -1.90 (95% CI -4.13 to 0.33) (Analysis
1.1) (moderate-quality evidence).
Cavosonstat versus placebo
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As previously stated, Donaldson (n = 51) reported that no treat-
ment-related changes in FEV1 were seen with cavosonstat com-
pared to placebo (Donaldson 2017) (low-quality evidence).
ii. Short term (over one month and up to and including six
months)
Data for this outcomewere not reported by any study (Boyle 2014;
Clancy 2012; Donaldson 2014; Donaldson 2017;McCarty 2002;
Rubenstein 1998; Zeitlin 2002).
c. FVC
Data for this outcome were not reported by six studies (Boyle
2014; Clancy 2012;Donaldson 2014;McCarty 2002; Rubenstein
1998; Zeitlin 2002).
Cavosonstat versus placebo
Similarly, to FEV1, Donaldson (n = 51) reported that no treat-
ment-related changes in FVC were seen with cavosonstat com-
pared to placebo (Donaldson 2017).
Secondary outcomes
1. Adverse effects
Adverse effects of therapy were reported by all included studies
(Boyle 2014; Clancy 2012; Donaldson 2014; Donaldson 2017;
McCarty 2002; Rubenstein 1998; Zeitlin 2002). The extent and
type of adverse event reporting varied between studies.
a. Mild (therapy does not need to be discontinued)
In Phase 2 trials of potential correctors (CPX, 4PBA, N6022,
lumacaftor and cavosonstat), there was no evidence of a statisti-
cally significant increase in adverse event reporting compared to
placebo (Boyle 2014; Clancy 2012; Donaldson 2014; Donaldson
2017; McCarty 2002; Rubenstein 1998; Zeitlin 2002). However,
a large number of events were reported and it is difficult to assess
the clinical relevance of these events with the small number of
participants in the trials. Further details are given below.
Lumacaftor versus placebo
Adverse events occurring in more than one participant in any
lumacaftor dose treatment group in the lumacaftor study by
Clancy are presented in the additional tables (Table 3) (Clancy
2012). We have combined the total number of participants with
adverse events occurring in the 100 mg and 200 mg lumacaftor
groups and compared this to the number of participants experi-
encing adverse effects in the placebo group (Analysis 1.2). Adverse
event data for participants receiving a lower dose (25 or 50 mg of
lumacaftor) were not included as there was no evidence of efficacy.
The most commonly reported side effect was cough; there was
no statistically significant difference in the number of participants
who reported cough between the participants assigned to either
100 mg or 200 mg lumacaftor and those assigned to placebo, OR
1.28 (99% CI 0.28 to 5.92) (Analysis 1.2) (Clancy 2012).
Data for 14 days of lumacaftor monotherapy (200 mg once daily)
demonstrated no statistically significant differences between par-
ticipants treated with lumacaftor therapy and placebo in the num-
ber of participants experiencing cough, oropharyngeal pain, nasal
congestion, dizziness, a prolonged prothrombin time, and upper
respiratory tract infection (Analysis 1.3) (Boyle 2014) (very low-
quality evidence).
Cavosonstat versus placebo
In the cavosonstat study, there was no statistically significant dif-
ference in cough, pulmonary exacerbation, chest discomfort, fa-
tigue in the treatment group compared to placebo (Analysis 2.3)
(Donaldson 2017) (very low-quality evidence). All adverse events
observed in this study were reported to be ’mild or moderate’ in
severity.
N6022 versus placebo
The number of Grade 1 (mild) adverse events across all N6022
doses and placebo were reported (Donaldson 2014). There was
no statistically significant difference between any of the N6022
doses and placebo in terms of the number of mild adverse events,
specific events were not reported (Analysis 3.2).
CPX versus placebo
Participants received a single dose of the assigned CPX dose level
(1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg or 1000 mg)
(McCarty 2002). Adverse events were recorded on the day of dos-
ing (day one), day two and followed up one week post-dosing.
Adverse effects that occurred in more than 3% of participants are
shown in the additional tables (Table 4). Combined data from
all CPX groups versus placebo demonstrated that the following
events were less common in the placebo group: abdominal pain,
OR 0.45 (99% CI 0.01 to 24.92); asthenia, OR 0.65 (99% CI
0.01 to 39.69); headache, OR 0.33 (99% CI 0.01 to 17.72); pain,
OR 0.45 (99% CI 0.01 to 24.92); diarrhoea, OR 0.65 (99% CI
0.01 to 39.69); lung disease, OR 0.45 (99% CI 0.01 to 24.92);
and rhinitis, OR 0.45 (99% CI 0.01 to 24.92) (Analysis 4.1).
Dizziness was more common amongst participants in the placebo
group, OR 9.33 (99% CI 0.32 to 268.92) (Analysis 4.1). The
difference between CPX groups (combined data) and placebo was
not statistically significant for any adverse event (McCarty 2002).
4PBA versus placebo
In the pilot 4PBA study (n = 18) (Rubenstein 1998), the differ-
ences between groups in the number of participants who reported
episodes of bad taste in their mouth and diarrhoea were not statis-
tically significant, OR 0.44 (99% CI 0.01 to 13.44) and OR 3.35
(99% CI 0.04 to 267.31) respectively (Analysis 5.1).
In the Phase 2 4PBA study (n = 19), participants randomised to
the 20 g cohort reported episodes of transient nausea, headache,
sleepiness and body odour after the initial dose; the transient nau-
sea, sleepiness and headache resolved with a dose of Tylenol® (ace-
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tominophen). No numerical data were reported regarding adverse
events, therefore no data can be entered into analysis for this study
(Zeitlin 2002).
b. Moderate (therapy is discontinued, and the adverse effect
ceases)
None of the participants in the Phase 2 lumacaftor-ivacaftor study,
the pilot 4PBA study or the CPX study the required study drug in-
terruption for the adverse effects of therapy (Boyle 2014;McCarty
2002; Rubenstein 1998).
Lumacaftor versus placebo
There were no statistically significant differences in terms of any
lumacaftor dose compared to placebo in the number of adverse
events requiring study drug discontinuation up to day 28 (Analysis
1.4) (Clancy 2012).
Cavosonstat versus placebo
In the cavosonstat study, there was no statistically significant dif-
ference in cough, pulmonary exacerbation, chest discomfort, fa-
tigue in the treatment group compared to placebo (Analysis 2.3)
(Donaldson 2017) (very low-quality evidence). All adverse events
observed in this study were reported to be ’mild or moderate’ in
severity.
N6022 versus placebo
The number of Grade 2 (moderate) adverse events across all
N6022 doses and placebowere reported (Donaldson 2014). There
was no statistically significant differences between any of the
N6022 doses and placebo in terms of the number of Grade 2 ad-
verse events; specific events were not reported (Analysis 3.3).
4PBA versus placebo
In the phase 4 4PBA study, participants who were discontinued
from a particular study dose were assigned a reduced dose and this
is discussed under severe adverse effects (Zeitlin 2002).
c. Severe (life-threatening or debilitating, or which persists
even after treatment is discontinued)
None of the participants from the CPX study or the cavoson-
stat study required study drug termination (Rubenstein 1998;
Donaldson 2017).
Lumacaftor versus placebo
In the Clancy study, adverse effects in eight participants were con-
sidered severe: fatigue (n = 1); sinus congestion (n = 1); muscu-
loskeletal discomfort (n = 1); cough (n = 2); and pulmonary exac-
erbation (n = 3). It is not stated which arm these participants were
randomised to. Four out of 89 participants (5%) - one participant
from each of the lumacaftor arms - discontinued the study drug
due to respiratory adverse effects. No participants discontinued
from the placebo group (Clancy 2012).
N6022 versus placebo
The number of Grade 3 or above (serious or life-threatening) ad-
verse events across all N6022 doses and placebo were reported
(Donaldson 2014). There was no statistically significant differ-
ences between any of the N6022 doses and placebo in terms of
the number of Grade 3 or above adverse events (Analysis 3.4). The
events were as follows: one participant with appendicitis in the 5
mg/day N6022 group and three participants with a pulmonary
exacerbation of CF one each in the placebo, 5 mg/day and 40 mg/
day N6022 groups.
4PBA versus placebo
None of the participants from the pilot 4PBA study required study
drug termination (McCarty 2002). In the Phase 2 4PBA study,
none of the participants in the 20 g group required study drug
termination (Zeitlin 2002). “Several” participants (exact number
not stated) in the 30 g group reported episodes of transient nau-
sea, headache, sleepiness and transient visual disturbances after the
initial dose. Two participants from the 30 g cohort required dose
reduction to 20 g due to headache (n = 1) and for an unknown
reason (n = 1). One participant who started in this group had
to discontinue medication after developing acute distal intestinal
obstruction syndrome on day two, but was replaced by another
participant. The three participants assigned 40 g of 4PBA reported
episodes of nausea, headache and visual disturbances and one par-
ticipant reported cramp in hands and fingers. One participant tol-
erated the dose whilst splitting the 40 g into six daily doses, one
participant had a dose reduction to 30 g daily and another partic-
ipant in this group was discontinued from the study due to intol-
erable symptoms (nausea, headache and visual disturbances). The
40 g cohort was terminated early following analysis of the data by
the safety monitoring committee (Zeitlin 2002).
d. Other adverse effects of therapy (of any severity) that are
not classifiable according to these categories
Lumacaftor versus placebo
Two studies also reported on the number of participants who expe-
rienced episodes of pulmonary exacerbations described as adverse
events (Boyle 2014; Clancy 2012). Results are presented in the
analyses and described below (see ’Extra courses of antibiotics’)
(Analysis 1.2; Analysis 1.3).
N6022 versus placebo
Donaldson reported on “none serious” adverse events on each dose
of N6022 and placebo (Donaldson 2014). Due to the small num-
bers of participants experiencing different adverse events, these
results are not entered into analysis and are reported in the addi-
tional tables (Table 5).
2. Hospitalisation
Data for this outcomewere not reported by any study (Boyle 2014;
Clancy 2012; Donaldson 2014; Donaldson 2017;McCarty 2002;
Rubenstein 1998; Zeitlin 2002).
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3. School or work attendance
Data for this outcomewere not reported by any study (Boyle 2014;
Clancy 2012; Donaldson 2014; Donaldson 2017 McCarty 2002;
Rubenstein 1998; Zeitlin 2002).
4. Extra courses of antibiotics
a. Time-to the next course of antibiotics
Data for this outcomewere not reported by any study (Boyle 2014;
Clancy 2012; Donaldson 2014; Donaldson 2017;McCarty 2002;
Rubenstein 1998; Zeitlin 2002).
b. Total number of courses of antibiotics
Lumacaftor versus placebo
In the lumacaftor study (n = 89), pulmonary exacerbations were
physician-defined and there was no statistically significant differ-
ence in the frequency of participants who developed pulmonary
exacerbations between those in the lumacaftor groups and the
placebo group, OR 1.50 (99% CI 0.16 to 14.31) (Analysis 1.2)
(Clancy 2012).
In the Boyle study (n = 62), it was unclear whether the reported
exacerbations were protocol-defined or physician-defined. At day
14, exacerbations were more common in participants receiving
200 mg lumacaftor once daily in comparison to participants re-
ceiving placebo, OR 2.72 (99%CI 0.05 to 156.17) (Analysis 1.3).
However, the difference between groups was not statistically sig-
nificant (Boyle 2014).
5. Sweat chloride (change from baseline) as a measure of
CFTR function
All included studies reported on sweat chloride concentration (
Boyle 2014; Clancy 2012; Donaldson 2014; Donaldson 2017;
McCarty 2002; Rubenstein 1998; Zeitlin 2002).
i. Immediate (up to one month)
Lumacaftor versus placebo
In the Clancy study (n = 89), data at seven days demonstrated
small reductions in the change from baseline in sweat chloride
concentration compared to placebo for the participants taking
25 mg lumacaftor, MD 1.7 mmol/L; 50 mg lumacaftor, MD -
1.5 mmol/L; 100 mg lumacaftor, MD -0.1mmol/L; and 200 mg
lumacaftor, MD -4.4 mmol/L (Clancy 2012). No SDs or CIs were
reported to allow the inclusion of these results into the analysis
(Clancy 2012). At 28 days, participants in the 25 mg lumacaftor
group demonstrated a marginal increase in sweat chloride concen-
tration compared to placebo, MD 0.1 mmol/L and those in the
50 mg lumacaftor group demonstrated a decreased sweat chloride
concentration compared to placebo, MD -4.61 mmol/L (Clancy
2012). These differences were not statistically significant and no
SDsorCIswere reported for inclusionof these results into the anal-
ysis (Clancy 2012). Data at one month demonstrated statistically
significant reductions in sweat chloride concentration compared
to placebo for participants in the once daily 100 mg lumacaftor
group, MD -6.13 mmol/L (95% CI -12.25 to -0.01) and once
daily 200 mg lumacaftor group, MD -8.21 (95% CI -14.30 to -
2.12) (Analysis 1.5) (Clancy 2012).
Boyle reported that at day 14, there was a small reduction in sweat
chloride concentration reported in participants taking 200 mg
lumacaftor once daily compared to placebo, MD -2.75 mmol/L
(95% CI -7.65 to 2.15) which was not statistically significant (
Analysis 1.6) (Boyle 2014). Results for up to21days (monotherapy
and combination therapy) are reported above (see ’Correctors plus
potentiators in combination therapy compared to placebo’).
Cavosonstat versus placebo
There was no statistically significant difference in sweat chloride
concentration between cavosonstat and placebo at 28 days (n =
51), MD -3.30 mmol/L (95% CI -9.13 to 2.53) (Analysis 2.4)
(Donaldson 2017).
CPX versus placebo
In the CPX study (n = 37), McCarty reported post-treatment
sweat chloride concentration values at the end of treatment on day
one (McCarty 2002). The baseline sweat chloride values in the
CPX group and the placebo group appear to have been pooled.
By calculating the values for relative change from baseline, we
have assumed that the baseline sweat chloride value represents the
baseline sweat chloride concentration value for each arm. At the
end of treatment on day one, there were no statistically significant
differences in sweat chloride concentration between the placebo
group and the 1mgCPXgroup,MD12.8%; the 3mgCPXgroup,
MD 7.5%; the 10 CPX mg group, MD 11.3%; the 30 CPX mg
group, MD 5.4%; the 100 CPX mg group, MD 5.1%; the 300
CPX mg group, MD 14.7%; and the 1000 CPX mg group, MD
-8.2%. No SDs or CIs were reported to allow calculation of SDs
for entry into the analysis (McCarty 2002).
4BPA versus placebo
In the pilot 4PBA study by Rubenstein (n = 18), there was no
statistically significant difference in sweat chloride concentration
at one week between participants in the 4PBA group and the
placebo group (P = 0.387). Data were plotted on a graph and
could not be extracted with accuracy (Rubenstein 1998).
The Phase 2 4PBA study by Zeitlin reported post-treatment sweat
chloride concentration values at day two, day three, day four and
day seven; we calculated the relative change from baseline values
at each time-point. There was no statistically significant difference
in sweat chloride concentration between the 20 g 4PBA group and
the placebo group after two days of treatment, MD -7.8%; three
days, MD -4.9%; four days, MD -3.3% and seven days, MD -
8.7%. Furthermore, there was no statistically significant difference
in sweat chloride concentration between the 30 g 4PBA group and
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the placebo group after two days of treatment, MD -25.9%; three
days,MD 0.5%; four days,MD -6.4% and seven days,MD -3.9%
(Zeitlin 2002). No SDs or CIs were reported to allow calculation
of SDs for entry into the analysis. Due to insufficient reporting of
data by both 4PBA studies, we were unable to include the results
in the analysis (Rubenstein 1998; Zeitlin 2002).
6. Radiological measures of lung disease
Data for this outcomewere not reported by any study (Boyle 2014;
Clancy 2012; Donaldson 2014; Donaldson 2017;McCarty 2002;
Rubenstein 1998; Zeitlin 2002).
7. Acquisition of respiratory pathogens
Data for the acquisition of S aureus, H influenzae or any other
clinically relevant pathogens except P aeruginosa, were not re-
ported by any study (Boyle 2014; Clancy 2012; Donaldson
2014; Donaldson 2017;McCarty 2002; Rubenstein 1998; Zeitlin
2002).
a. P aeruginosa
This was a pre-defined outcome of interest in the Phase 1/2 4PBA
study, but no study results were reported (Zeitlin 2002). Data for
this outcome were not reported the other studies (Boyle 2014;
Clancy 2012; Donaldson 2014; Donaldson 2017;McCarty 2002;
Rubenstein 1998).
8. Eradication of respiratory pathogens
Data for this outcomewere not reported by any study (Boyle 2014;
Clancy 2012; Donaldson 2014; Donaldson 2017;McCarty 2002;
Rubenstein 1998; Zeitlin 2002).
9. Nutrition and growth
Nodata for this outcome, either in terms of weight, BMI or height,
were reported by any study (Boyle 2014; Clancy 2012; Donaldson
2014; Donaldson 2017;McCarty 2002; Rubenstein 1998; Zeitlin
2002).
Correctors plus potentiators (combination therapy)
compared to placebo
Six studies with 1898 participants contributed to the efficacy re-
sults in this comparison (Boyle 2014; Donaldson 2018; Ratjen
2017; Taylor-Cousar 2017; TRAFFIC 2015; TRANSPORT
2015). A further study contributed additional safety data to this
comparison (see below) (PROGRESS 2017).
Four studies with 1376 participants compared lumacaftor plus
ivacaftor to placebo (Boyle 2014; Ratjen 2017; TRAFFIC 2015;
TRANSPORT 2015) and two studies with 522 participants com-
pared tezacaftor plus ivacaftor to placebo or ivacaftor alone (i.e.
tezacaftor placebo) (Donaldson 2018; Taylor-Cousar 2017).
Two three-arm studies (n = 1108) compared 600 mg once daily
lumacaftor plus 250 mg twice daily ivacaftor to 400 mg twice
daily lumacaftor plus 250 mg twice daily ivacaftor and to placebo
(TRAFFIC 2015; TRANSPORT2015). One study (n = 64) com-
pared lumacaftor 200 mg once daily plus 150 mg or 250 mg twice
daily ivacaftor to placebo (Boyle 2014). Participants in this study
received lumacaftor monotherapy for 14 days followed by combi-
nation therapy with ivacaftor for seven days, therefore this study
contributes to both comparisons of this review (Boyle 2014).
The paediatric combination study (n = 204) compared 200 mg
lumacaftor twice daily plus 250mg ivacaftor twice daily to placebo
for 24 weeks (Ratjen 2017). Primary and secondary outcomes of
this study were analysed via a mixed model for repeated measures
(MMRM), further details of this analysis approach are provided in
the tables (Characteristics of included studies). Results provided
by this model can be interpreted as treatment effect averaged from
each study visit until week 24.
The PROGRESS study was an extension to the TRAFFIC and
TRANSPORT studies (TRAFFIC 2015; TRANSPORT 2015),
in which participants from the original placebo groups were ran-
domised to one of the two interventions (PROGRESS 2017).Due
to the overlap of participants in these three studies, we have not
included efficacy data for the PROGRESS study under a compar-
ison of lumacaftor (plus ivacaftor) doses. We have included safety
data from this study as these are important longer-term results
for participants on this intervention; results for the PROGRESS
study are presented in the tables for information (PROGRESS
2017; Table 6; Table 7).
One study (n = 510) compared a combination of tezacaftor 100
mg plus ivacaftor 150 mg every 12 hours to a matched placebo
for 24 weeks (Taylor-Cousar 2017) and one study compared teza-
caftor (100 mg per day) plus ivacaftor (150 mg twice daily) against
placebo (150 mg twice daily ivacaftor alone) in people with one
F508del mutation and one G551D mutation (Donaldson 2018).
Important results for this comparison are summarised in the tables
(Summary of findings 3; Summary of findings 4; Summary of
findings 5; Summary of findings 6).
Primary outcomes
1. Survival
No deaths were reported during any of the included studies (
Boyle 2014; Donaldson 2018; Ratjen 2017; Taylor-Cousar 2017;
TRAFFIC 2015; TRANSPORT 2015) (high to moderate-quality
evidence).
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2. QoL
Five studies reported on QoL (Donaldson 2018; Ratjen 2017;
Taylor-Cousar 2017; TRAFFIC 2015; TRANSPORT 2015).
a. Total QoL score
Lumacaftor plus ivacaftor versus placebo
Two studies reported QoL according to the Euro Quality of Life
Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score
at six months (TRAFFIC 2015; TRANSPORT 2015). This in-
formation was not reported in the primary journal article, but is
available from the study record on ClinicalTrials.gov (TRAFFIC
2015; TRANSPORT 2015).
There was no statistically significant improvement in the abso-
lute change from baseline of EQ-5D-3L index score between the
lumacaftor 600 mg once daily plus 250 mg ivacaftor twice daily
group and placebo group, MD 0.00 (95% CI -0.01 to 0.02)
(Analysis 6.1), or the lumacaftor 400 mg twice daily plus 250 mg
ivacaftor twice daily group and placebo group, MD 0.00 (95% CI
-0.01 to 0.02) (Analysis 7.1), or when the two lumacaftor doses
were pooled at six months, MD 0.00 (95% CI -0.01 to 0.01)
(Analysis 8.1) (high-quality evidence).
b. QoL sub-domains
i. Immediate term (up to and including one month)
Lumacaftor plus ivacaftor versus placebo
In the TRAFFIC andTRANSPORT studies (n = 1108), at 28 days
participants in the both the lumacaftor 600mg once daily plus 250
mg ivacaftor twice daily group and the lumacaftor 400 mg twice
daily plus 250 mg ivacaftor twice daily group experienced statis-
tically significantly higher absolute changes from baseline in the
CFQ-R respiratory domain compared to the placebo group, MD
3.32 (95% CI 1.13 to 5.51) (Analysis 6.2) and MD 4.13 (95%
CI 1.94 to 6.31) (Analysis 7.2), respectively (TRAFFIC 2015;
TRANSPORT 2015). There was also a statistically significantly
higher absolute change from baseline in the CFQ-R respiratory
domain compared to the placebo group when the two lumacaftor
doses were pooled, MD 3.70 (95% CI 1.81 to 5.58) (Analysis
8.2).
Tezacaftor plus ivacaftor versus control
Taylor-Cousar (n = 510) reported on the CFQ-R respiratory do-
main at four weeks (Taylor-Cousar 2017) and found a statistically
significant difference in favour of the treatment group, MD 5.10
(95% CI 2.99 to 7.21) (Analysis 13.1).
Donaldson (n= 18) presents the within-group change from base-
line to Day 28 for the CFQ-R respiratory domain and at the end
of the study the difference in treatment effect between tezacaftor-
ivacaftor and placebo was 6.81 points (P = 0.2451) (Donaldson
2018). These data were extrapolated and we have requested confir-
mation of the exact data from the study investigators. Any unpub-
lished information we receive will be included in a future update.
ii. Short term (over one month and up to and including six
months)
Lumacaftor plus ivacaftor versus placebo
In the two studies (n = 1108) (TRAFFIC 2015; TRANSPORT
2015), the statistically significant difference in the absolute change
frombaseline in theCFQ-R respiratory domainwasmaintained to
six months in the 600 mg lumacaftor group compared to placebo,
MD3.04 (95%CI 0.76 to 5.32) (Analysis 6.2), but not in the 400
mg lumacaftor group compared to placebo, MD 2.18 (95% CI -
0.11 to 4.47) (Analysis 7.2). There was a statistically significantly
higher absolute change from baseline in the CFQ-R respiratory
domain compared to the placebo group when the two lumacaftor
doses were pooled, MD 2.62 (95% CI 0.64 to 4.59) (Analysis
8.2) (moderate-quality evidence). These data were extrapolated
and we have requested confirmation of the exact data from the
study investigators. Any unpublished information we receive will
be included in a future update.
The EQ-5D-3L Visual Analog Scale (VAS) domain score was
also reported at six months in two studies (TRAFFIC 2015;
TRANSPORT2015). Participants in the both the lumacaftor 600
mg group and the lumacaftor 400 mg group experienced statis-
tically significantly higher absolute changes from baseline in the
EQ-5D-3L VAS domain compared to the placebo group, MD
2.24 (95% CI 0.18 to 4.31) (Analysis 6.3) and MD 2.30 (95%
CI 0.25 to 4.36) (Analysis 7.3) respectively. There was also a sta-
tistically significantly higher absolute change from baseline in the
EQ-5D-3L VAS domain compared to the placebo group when
the two lumacaftor doses were pooled, MD 2.28 (95% CI 0.50
to 4.06) (Analysis 8.3). This information was not reported in the
primary journal article, but is available from the study record on
ClinicalTrials.gov (TRAFFIC 2015; TRANSPORT 2015). Im-
mediate-term data for this domain have been requested from the
study investigators and any unpublished information we receive
will be included in a future update.
The paediatric combination study also reported the absolute
change from baseline (up to and including 24 weeks) of the
CFQ-R respiratory domain (Ratjen 2017). The change within
the lumacaftor plus ivacaftor group was higher compared to the
placebo group, but this difference did not reach statistical signif-
icance, MD 2.50 (95% CI -0.10 to 5.10) (Analysis 11.1) (low-
quality evidence). Additional results at earlier time points (day
15, week 4, and week 16) were published graphically in the full
study publication, but the graphical plots were too small to allow
for accurate extraction of data (Ratjen 2017). Numerical data for
these time points have been requested from the study investigators
and any unpublished information we receive will be included in a
future update.
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Investigators in this study also list the absolute change inTreatment
Satisfaction Questionnaire for Medication (TSQM) domains as
a secondary outcome of the study, but results for this outcome
are not presented (Ratjen 2017). Numerical data for this outcome
have also been requested from the study investigators and any
unpublished information we receive will be included in a future
update.
Tezacaftor plus ivacaftor versus control
Taylor-Cousar (n = 510) also reported on the CFQ-R respiratory
domain at 24 weeks (Taylor-Cousar 2017); there was a statisti-
cally significant difference in favour of tezacaftor-ivacaftor, MD
5.10 (95% CI 3.20 to 7.00) (Analysis 13.1) (moderate-quality ev-
idence).
3. Physiological measures of lung function
a. FEV1 (relative change from baseline)
i. Immediate term (up to and including one month)
Lumacaftor plus ivacaftor versus placebo
Immediate-term data for this domain have been requested from
the investigators of two studies (TRAFFIC 2015; TRANSPORT
2015). Any unpublished information we receive will be included
in a future update.
Tezacaftor plus ivacaftor versus control
There was no statistically significant difference between tezacaftor
plus ivacaftor compared to ivacaftor alone at four weeks (n = 504),
MD 3.72 (95% CI -7.77 to 15.21) (Analysis 13.2) (Donaldson
2018).
ii. Short term (over one month and up to and including six
months)
Lumacaftor plus ivacaftor versus placebo
At six months, participants in the TRAFFIC and TRANSPORT
studies (n = 1108) in the both the lumacaftor 600 mg group and
the lumacaftor 400 mg group experienced statistically significantly
higher relative changes from baseline in FEV1 (% predicted) com-
pared to the placebo group, MD 5.63 (95% CI 3.80 to 7.47)
(Analysis 6.4) and MD 4.77 (95% CI 2.93 to 6.61) (Analysis 7.4)
respectively (TRAFFIC 2015; TRANSPORT 2015). There was
also a statistically significantly higher relative change from baseline
in FEV1 (% predicted) compared to the placebo group when the
two lumacaftor doses were pooled, MD 5.21 (95% CI 3.61 to
6.80) (Analysis 8.4) (high-quality evidence).
Tezacaftor plus ivacaftor versus control
At 24weeks, a statistically significantly higher relative change from
baseline in FEV1 (% predicted) compared to the placebo group in
the tezacaftor-ivacaftor study (n = 510), MD 6.80 (95% CI 5.30
to 8.30) (Analysis 13.2) (Taylor-Cousar 2017) (moderate-quality
evidence).
b. FEV1 absolute values
i. Immediate term (up to and including one month)
Lumacaftor plus ivacaftor versus placebo
In two studies (n = 1108), participants in the both the lumacaftor
600 mg group and the lumacaftor 400 mg group experienced
statistically significantly higher absolute changes from baseline in
FEV1 (% predicted) at 28 days compared to the placebo group,
MD 2.32 (95% CI 1.34 to 3.31) (Analysis 6.5) and MD 2.42
(95% CI 1.43 to 3.40) (Analysis 7.5), respectively (TRAFFIC
2015; TRANSPORT 2015). There was also a statistically signif-
icantly higher absolute change from baseline in FEV1 compared
to the placebo group when the two lumacaftor doses were pooled,
MD 2.37 (95% CI 1.52 to 3.22) (Analysis 8.5). These data were
extrapolated and we have requested confirmation of the exact data
from the study investigators. Any unpublished information we re-
ceive will be included in a future update.
The Phase 2 lumacaftor-ivacaftor study (n = 62) reported on the
absolute change frombaseline inFEV1 after lumacaftormonother-
apy (day 14) and lumacaftor (200 mg daily) and ivacaftor (150
mg or 250 mg twice daily) combination therapy (day 21) (Boyle
2014). Results for lumacaftor monotherapy are discussed above
(see ’Correctors (monotherapy) compared to placebo’).
Small, but non-statistically significant improvements in FEV1
were reported at day 21 for participants treated with 200 mg
lumacaftor once daily (day 1 to 21) and either 150 mg ivacaftor
twice daily (day 15 to 21), MD 2.80 (95% CI -1.39 to 6.99)
(Analysis 9.1) or 250 mg ivacaftor twice daily (day 15 to 21), MD
0.20 (95%CI -4.20 to 4.60) (Analysis 10.1) respectively andwhen
ivacaftor doses were combined, MD 1.57 (95% CI -2.13 to 5.27)
(Analysis 12.1) (Boyle 2014) (moderate-quality evidence).
Tezacaftor plus ivacaftor versus control
At four weeks, there was a statistically significantly higher absolute
change from baseline in FEV1 (% predicted) compared to the
control groups in the two tezacaftor-ivacaftor studies (n = 528),
pooled MD 3.59 (95% CI 2.40 to 4.78) (Analysis 13.3) (Taylor-
Cousar 2017).
ii. Short term (over one month and up to and including six
months)
Lumacaftor plus ivacaftor versus placebo
In the TRAFFIC and TRANSPORT studies (n = 1108), at six
months the statistically significant difference in absolute changes
from baseline in FEV1 (% predicted) were maintained in the both
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the lumacaftor 600 mg group and the lumacaftor 400 mg groups,
MD 3.34 (95% CI 2.30 to 4.38) (Analysis 6.5) and MD 2.80
(95% CI 1.75 to 3.84) (Analysis 7.5) respectively (TRAFFIC
2015; TRANSPORT 2015). There was also a statistically signif-
icantly higher absolute change from baseline in FEV1 (% pre-
dicted) compared to the placebo group when the two lumacaftor
doses were pooled, MD 3.07 (95%CI 2.17 to 3.97) (Analysis 8.5)
(moderate-quality evidence).
In the paediatric combination study, investigators reported a statis-
tically significantly higher absolute change from baseline in FEV1
(% predicted) in the lumacaftor plus ivacaftor group compared to
the placebo group up to and including 24 weeks (n = 204) (Ratjen
2017), MD 2.40 (95% CI 0.40 to 4.40) (Analysis 11.2) (low-
quality evidence). Additional results at earlier time points (day 15,
week 4, and week 16) were published graphically in the study re-
port, but the graphical plots were too small to allow for accurate
extraction of data (Ratjen 2017). Numerical data for these time
points have been requested from the study investigators and any
unpublished information we receive will be included in a future
update. Investigators in this study also reported early post-drug
dose declines in FEV1 (% predicted) at day one in the lumacaftor
plus ivacaftor group (Ratjen 2017). A markedly smaller decline
was observed post-dose at day 15, and no decline was observed
by week 16. These data are not available for all participants so are
not entered into analysis for this review; instead these results are
presented in the additional tables (Table 8).
Tezacaftor plus ivacaftor versus control
At 24 weeks, there was a statistically significantly higher absolute
change from baseline in FEV1 (% predicted) compared to the
placebo group in the tezacaftor-ivacaftor study, MD 4.00 (95%
CI 3.10 to 4.90) (Analysis 13.3) (Taylor-Cousar 2017) (moderate-
quality evidence).
c. FVC (absolute values and change from baseline)
Data for this outcome were not reported by any study in
this comparison (Boyle 2014; Donaldson 2018; Ratjen 2017;
Taylor-Cousar 2017; TRAFFIC 2015; TRANSPORT 2015).
However, it is stated in the protocol of the TRAFFIC andTRANS-
PORT studies that FVC data was collected (although not consid-
ered as an outcome). Any recorded data relevant to this outcome
has been requested from the study investigators and any unpub-
lished information we receive will be included in a future update.
d. LCI
Lumacaftor plus ivacaftor versus placebo
Only one study (n = 204) reported this outcome and its primary
outcome was LCI2.5, i.e. the number of lung volume turnovers
required to reach 2.5% of starting tracer gas concentration (Ratjen
2017). There was a statistically significantly larger reduction in
LCI2.5 in the lumacaftor plus ivacaftor group compared to the
placebo group up to and including 24 weeks, MD -1.10 (95% CI
-1.40 to -0.80) (Analysis 11.3). Additional results at earlier time
points (day 15, week 4, and week 16) were published graphically
in the full study report, but the graphical plots were too small
to allow for accurate extraction of data (Ratjen 2017). Numerical
data for these time points have been requested from the study
investigators and any unpublished information we receive will be
included in a future update.
The study investigators also list LCI5.0 as a secondary outcome of
the study, i.e. number of lung volume turnovers required to reach
5% of starting tracer gas concentration (Ratjen 2017). However,
results for this outcome are not presented. Numerical data for this
outcome have been requested from the study investigators and any
unpublished information we receive will be included in a future
update.
Secondary outcomes
1. Adverse events
Adverse eventswere reported by all studies examining combination
therapies (Boyle 2014; Donaldson 2018; Ratjen 2017; Taylor-
Cousar 2017; TRAFFIC 2015; TRANSPORT 2015). The type
and extent of adverse event reporting was not consistent across
studies making comparison between different treatment regimens
and interventions a challenge. For the Phase 3 studies a common
adverse events was defined by the researchers as one that occurred
in more than 10% of participants.
Lumacaftor plus ivacaftor versus placebo
TheTRAFFICandTRANSPORTstudies reportedno statistically
significant differences in the number of participants experiencing
adverse events during the study, either by lumacaftor dose or when
lumacaftor doses were pooled, OR 1.00 (99% CI 0.37 to 2.71)
(Analysis 6.6), OR 0.77 (99% CI 0.30 to 1.96) (Analysis 7.6)
and OR 0.87 (99% CI 0.38 to 2.02) (Analysis 8.6), respectively
(TRAFFIC 2015; TRANSPORT 2015) (high-quality evidence).
In the paediatric lumacaftor-ivacaftor study the overall rate of
reporting of adverse events was lower than for the TRAFFIC
and TRANSPORT studies with a similar profile, including in-
creased reporting of chest tightness on starting the lumacaftor-iva-
caftor intervention compared to placebo (Ratjen 2017). The stud-
ies also reported no statistically significant difference between the
lumacaftor plus ivacaftor group compared to placebo in the num-
ber of participants experiencing adverse events during the study,
OR 0.60 (99% CI 0.09 to 4.08) (Analysis 11.4) (low-quality evi-
dence).
Tezacaftor plus ivacaftor versus control
For the tezacaftor-ivacaftor studies, we present the most common
adverse events which occurred in at least 10% of participants in
either study (Analysis 13.4). Further less commonly occurring ad-
verse events are presented in the original trial reports; none of
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which showed any difference between groups (Donaldson 2018;
Taylor-Cousar 2017) (moderate-quality evidence).
a. Mild (therapy does not need to be discontinued)
Lumacaftor plus ivacaftor versus placebo
Boyle reported data for lumacaftor-ivacaftor combination ther-
apy at 21 days (day 14 to 21) (Boyle 2014). The combined anal-
ysis showed no statistically significant differences between par-
ticipants treated with lumacaftor-ivacaftor combination therapy
and placebo in the number of participants experiencing cough,
oropharyngeal pain, nasal congestion, dizziness, a prolonged pro-
thrombin time, and upper respiratory tract infection (Analysis 9.2;
Analysis 10.2; Analysis 12.2) (low-quality evidence).
For participants in the TRAFFIC and TRANSPORT studies re-
ceiving the lumacaftor-ivacaftor therapy, the most regularly re-
ported adverse events were respiratory in nature (e.g. chest tight-
ness) (TRAFFIC 2015; TRANSPORT 2015). Most respiratory
adverse events occurred shortly after starting lumacaftor-ivacaftor
therapy and for those who continued with the intervention they
were reported to be transient in nature. Dyspnoea was statistically
significantly more common in the lumacaftor 600 mg once daily
plus ivacaftor 250 mg twice daily group compared to placebo, OR
2.05 (99% CI 1.10 to 3.83) (Analysis 6.6) and when lumacaftor
doses were combined, OR 1.90 (99% CI 1.08 to 3.35) (Analysis
8.6). Cough was statistically significantly less common in the
lumacaftor 400 mg twice daily plus ivacaftor 250 mg twice daily
group compared to placebo, OR 0.58 (99% CI 0.39 to 0.88)
(Analysis 7.6) and when lumacaftor doses were combined, OR
0.65 (99% CI 0.46 to 0.92) (Analysis 8.6).
There were no statistically significant differences between
lumacaftor 600 mg once daily, lumacaftor 400 mg twice daily
plus 250 mg ivacaftor twice daily or lumacaftor doses combined
compared to placebo in terms of the number of participants expe-
riencing other adverse events: infective pulmonary exacerbation,
headache, haemoptysis, diarrhoea, abnormal respiration, increased
sputum, nasopharyngitis, oropharyngeal pain, abdominal pain,
fatigue, nausea, pyrexia, nasal congestion, upper respiratory tract
infection (Analysis 6.6; Analysis 7.6, Analysis 8.6).
In the TRAFFIC and TRANSPORT studies, in seven participants
receiving lumacaftor-ivacaftor therapy abnormal liver function (el-
evated liver enzyme) results led to a temporary discontinuation of
the intervention, after which liver function improved (to baseline
in six participants). Treatment was re-started in six of these par-
ticipants; in one participant abnormal liver function was associ-
ated with hepatitis E infection (TRAFFIC 2015; TRANSPORT
2015).
For the paediatric lumacaftor-ivacaftor study, the number of
treatment-emergent adverse events with an incidence over 10%
were reported (Ratjen 2017). Productive cough, nasal congestion,
oropharyngeal pain, upper abdominal pain, rhinorrhoea and in-
creased sputum were observed more frequently in the lumacaftor-
ivacaftor group compared to the placebo group, but there was
no statistically significant difference between the groups (Analysis
11.4). There was also no statistically significant differences be-
tween the groups in terms of cough, pyrexia, headache, upper res-
piratory tract infection, abdominal pain, nausea, vomiting, fatigue
and respiratory events (such as wheezing, dyspnoea, asthma and
chest discomfort) (Analysis 11.4).
Tezacaftor plus ivacaftor versus control
There were no statistically significant differences between teza-
caftor-ivacaftor and control groups (99% confidence intervals) in
the number of participants experiencing cough, pulmonary exac-
erbation, headache, nasal congestion or nasopharyngitis, increased
sputum, haemoptysis, pyrexia, oropharyngeal pain, nausea or fa-
tigue (Analysis 13.4) (Donaldson 2018; Taylor-Cousar 2017).
Taylor-Cousar specified respiratory compromise on initiation as
an adverse event in light of the reports from the TRAFFIC and
TRANSPORT studies, but there was no increased reporting of
this event (Taylor-Cousar 2017).
b. Moderate (therapy is discontinued, and the adverse effect
ceases)
Lumacaftor plus ivacaftor versus placebo
None of the participants in the Phase 2 lumacaftor-ivacaftor study
required study drug interruption for the adverse effects of therapy (
Boyle 2014). Itwas not stated in theTRAFFICandTRANSPORT
studies whether study drug interruption for the adverse effects
of therapy was required for any participants (TRAFFIC 2015;
TRANSPORT 2015). The combined safety data demonstrated
similar rates of serious adverse event reporting for participants
receiving placebo (28.6%) and those receiving the lumacaftor-
ivacaftor combination therapy (17.3% to 22.8%); however, the
characteristics of these events were different (Analysis 6.6; Analysis
7.6; Analysis 8.6).
In two studies, 14 participants on lumacaftor 600 mg once
daily plus ivacaftor 250 mg twice daily and 17 participants on
lumacaftor 400 mg twice daily plus ivacaftor 250 mg twice daily
discontinued the study due to adverse events. In total 31 of 738
(4.2%) of participants receiving lumacaftor-ivacaftor discontin-
ued compared to six of 370 (1.6%) participants receiving placebo
(TRAFFIC 2015; TRANSPORT 2015). The differences in the
discontinuation rates in the treatment groups were not statistically
significant compared to placebo at the 1% statistical significance
level to allow for multiple analyses related to adverse events, OR
2.38 (99% CI 0.67 to 8.50) (Analysis 6.6), OR 2.91 (99% CI
0.85 to 10.03) (Analysis 7.6) and OR 2.65 (99% CI 0.83 to 8.45)
(Analysis 8.6) respectively.
In the same studies, 84 participants on lumacaftor 600 mg
once daily plus ivacaftor 250 mg twice daily, 64 participants on
lumacaftor 400 mg twice daily plus ivacaftor 250 mg twice daily
and 106 participants on placebo experienced at least one ’serious’
adverse event (TRAFFIC 2015; TRANSPORT 2015). A ’serious’
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adverse event was defined as “death, life threatening adverse expe-
rience, in-patient hospitalization/prolongation of hospitalization,
persistent/significant disability or incapacity, congenital anomaly/
birth defect, important medical event”. The following adverse
events, which occurred on more than one occasion, were reported
to have resulted in discontinuation of the lumacaftor-ivacaftor
therapy: elevated serum creatinine kinase level (n = 4), haemopt-
ysis (n = 3), bronchospasm (n = 2), dyspnoea (n = 2), pulmonary
exacerbation (n = 2) (see below), and rash (n = 2). One participant
developed hypertension and discontinued the study (not included
in the initial reports of this study); other reasons for discontinua-
tion were not recorded (TRAFFIC 2015; TRANSPORT 2015).
There was no statistically significant difference between the num-
ber of adverse events between participants on lumacaftor 600 mg
once daily plus ivacaftor 250 mg twice daily compared to placebo,
OR 0.73 (99% CI 0.47 to 1.13) (Analysis 6.6). Statistically sig-
nificantly fewer participants experienced serious adverse events on
lumacaftor 400 mg twice daily plus ivacaftor 250 mg twice daily
compared to placebo, OR 0.52 (99% CI 0.33 to 0.83) (Analysis
7.6); this was also true when lumacaftor doses were combined,
OR 0.62 (99% CI 0.42 to 0.91) (Analysis 8.6).
For the paediatric study of lumacaftor-ivacaftor, therewas no statis-
tically significant difference reported between groups in the num-
ber of serious adverse events reported, OR 1.18 (99% CI 0.38 to
3.63) (Analysis 11.4). There were 13 participants who had serious
adverse events in the lumacaftor plus ivacaftor group; these were
considered to be treatment-related in two participants (one drug
interaction and one obstructive airways disorder). In the placebo
group, 11 participants had serious adverse events; these were con-
sidered to be treatment-related in three participants (one distal
intestinal obstruction syndrome, two elevated aminotransferases)
(Ratjen 2017). In this study six out of 103 participants discon-
tinued, three due to adverse events. One participant discontinued
due to an early respiratory event, a second due to persistently ab-
normal liver function tests and the reasons for the remaining four
who discontinued were not recorded (Ratjen 2017).
In the longer-term follow-up study to the TRAFFIC and TRANS-
PORT studies (PROGRESS), in which participants were ran-
domised to two different lumacaftor-ivacaftor dose regimens, the
paper reported that 7% of the participants withdrew because of
adverse events during the 96 week-study period; in one participant
this was due to hypertension (PROGRESS 2017).
Tezacaftor plus ivacaftor versus control
In the Phase 3 tezacaftor-ivacaftor study, seven out of 251 par-
ticipants receiving tezacaftor-ivacaftor discontinued compared to
eight out of 258 participants in the placebo group (Taylor-Cousar
2017). Reasons for discontinuation in the tezacaftor-ivacaftor
group included abdominal pain (n = 2), raised serum creatinine
phosphokinase (n = 1), raised liver enzymes (n = 1) and a gener-
alised tonic-clonic seizure (n = 1).
c. Severe (life-threatening or debilitating, or which persists
even after treatment is discontinued)
Lumacaftor plus ivacaftor versus placebo
For trials evaluating lumacaftor-ivacaftor, there were no adverse
events reported, that in our assessment, were life-threatening or
debilitating. When treatments were discontinued the reported ad-
verse events resolved (Boyle 2014; Ratjen 2017; TRAFFIC 2015;
TRANSPORT 2015).
Tezacaftor plus ivacaftor versus control
In the large tezacaftor-ivacaftor study (n = 510) one life-threaten-
ing adverse event (haemoptysis) was reported in a participant in
the tezacaftor-ivacaftor treatment group (Taylor-Cousar 2017).
d. Other adverse effects of therapy (of any severity) that are
not classifiable according to these categories
All studies reported on the number of participants who experi-
enced episodes of pulmonary exacerbations described as adverse
events (Boyle 2014;Donaldson 2018;Ratjen 2017;Taylor-Cousar
2017; TRAFFIC 2015; TRANSPORT 2015). Results are pre-
sented in the analyses (Analysis 6.6; Analysis 7.6; Analysis 8.6;
Analysis 9.2; Analysis 10.2; Analysis 12.2; Analysis 11.4; Analysis
13.4) and described below (see ’Extra courses of antibiotics’).
Lumacaftor plus ivacaftor versus placebo
After a second participant on lumacaftor-ivacaftor was with-
drawn with hypertension, the researchers for the TRAFFIC and
TRANSPORT and PROGRESS studies reported the blood pres-
sure measurements for the participants over the total study period
(PROGRESS 2017; TRAFFIC 2015; TRANSPORT 2015). Av-
erage blood pressure data were presented from participants over
the total 120-week study period of TRAFFIC and TRANSPORT
and PROGRESS for participants who continued on lumacaftor-
ivacaftor, but only for those who received the 400 mg twice daily
dose, as this was the dose for which the company received a prod-
uct licence (PROGRESS 2017). There was a statistically signifi-
cant mean (SE) increase in systolic blood pressure of 5.1 (1.5) mm
Hg and in diastolic blood pressure of 4.1 (1.2) mm Hg (n = 80)
(PROGRESS 2017).
2. Hospitalisation
Data for this outcome were reported in two lumacaftor-ivacaftor
studies (TRAFFIC 2015; TRANSPORT 2015) and for the teza-
caftor-ivacaftor study (Taylor-Cousar 2017), but not by the re-
maining studies in this comparison (Boyle 2014;Donaldson 2018;
Ratjen 2017).
Lumacaftor plus ivacaftor versus placebo
Excerbations were protocol-defined in the TRAFFIC and
TRANSPORT studies as exacerbations leading to hospitalisa-
tion or treatment with intravenous antibiotics (TRAFFIC 2015;
TRANSPORT 2015). We present information relating to events
leading to hospitalisation here and information relating to all pul-
monary exacerbations below (see ’Extra courses of antibiotics’).
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The study publications reported on the rate of events per partici-
pant leading to hospitalisation over 48 weeks, graphically pooled
across both studies (TRAFFIC 2015; TRANSPORT 2015). We
estimate that the event rate per participant over 48 weeks in the
placebo group was 0.45. The corresponding event rate in the
lumacaftor 600 mg once daily plus ivacaftor 250 mg twice daily
group was 0.27 (equal to a 39% decrease compared to the placebo
group, P = 0.003). In the lumacaftor 400 mg twice daily plus
ivacaftor 250 mg twice daily the event rate was 0.18 (equal to a
61% decrease compared to the placebo group, P < 0.001). The
presentation of data did not allow us to estimate the rate over
the two lumacaftor doses combined. These data were extrapolated
and we have requested confirmation of the exact data from the
study investigators. Any unpublished information we receive will
be included in a future update.
Tezacaftor plus ivacaftor versus control
The rate of pulmonary exacerbations that led to hospitalisation
or treatment with intravenous antibiotic agents (or both) was also
lower in the tezacaftor-ivacaftor group than in the placebo group
(0.29 versus 0.54 events per year; rate ratio, 0.53; 95% CI, 0.34
to 0.82) (Taylor-Cousar 2017).
3. School or work attendance
Data for this outcomewere not reported by any study (Boyle 2014;
Donaldson 2018; Ratjen 2017; Taylor-Cousar 2017; TRAFFIC
2015; TRANSPORT 2015).
4. Extra courses of antibiotics
Excerbations were protocol-defined in two studies as exacerba-
tions leading to hospitalisation or treatment with intravenous an-
tibiotics (TRAFFIC 2015; TRANSPORT 2015). Therefore we
present information relating to pulmonary exacerbations (as well
as information specifically relating to antibiotic use) here. In the
other studies, it was unclear whether reported exacerbations were
protocol-defined or physician-defined (Boyle 2014; Ratjen 2017).
a. Time-to the next course of antibiotics
The paediatric combination study listed the time to first pul-
monary exacerbation as a secondary outcome of the study, but re-
sults for this outcome are not presented (Ratjen 2017). Numerical
data for this outcome have been requested from the trial investiga-
tors and any unpublished information we receive will be included
in a future update.
Lumacaftor plus ivacaftor versus placebo
In the TRAFFIC and TRANSPORT studies, when compared to
placebo the time-to-first pulmonary exacerbation was statistically
significantly longer in both in the lumacaftor 600 mg once daily
plus ivacaftor 250 mg twice daily group, hazard ratio (HR) 0.70
(95% CI 0.57 to 0.87) (Analysis 6.7) and the lumacaftor 400 mg
twice daily plus ivacaftor 250mg twice daily group,HR0.61 (95%
CI 0.49 to 0.76) (Analysis 7.7) (both moderate-quality evidence).
Similarly, the rate of exacerbations was statistically significantly
lower in both the active intervention groups compared to placebo;
the lumacaftor 600mg once daily plus ivacaftor 250mg twice daily
group, rate ratio 0.70 (95%CI 0.57 to 0.87) (Analysis 6.8) and the
lumacaftor 400 mg twice daily plus ivacaftor 250 mg twice daily
group, rate ratio 0.61 (95% CI 0.49 to 0.76) (Analysis 7.8). This
information was not reported in the primary journal article, but is
available from the study record on ClinicalTrials.gov (TRAFFIC
2015; TRANSPORT 2015). Information regarding time to first
pulmonary exacerbation was reported only as a hazard ratio and P
value; the SE used in this analysis was estimated using themethods
of Parmar (Parmar 1998).
Tezacaftor plus ivacaftor versus control
The time-to-first pulmonary exacerbation was statistically signif-
icantly longer in the tezacaftor-ivacaftor group compared to the
placebo group, HR 0.64 (95% CI, 0.46 to 0.89) (Taylor-Cousar
2017) (Analysis 13.5) (moderate-quality evidence).
b. Total number of courses of antibiotics
Lumacaftor plus ivacaftor versus placebo
In two studies, both the lumacaftor 600 mg once daily plus
250 mg ivacaftor twice daily and 400 mg twice daily plus 250
mg ivacaftor twice daily groups experienced statistically signifi-
cantly fewer pulmonary exacerbations than the placebo group,OR
0.66 (99% CI 0.45 to 0.97) (Analysis 6.6) and OR 0.57 (99%
CI 0.39 to 0.84) (Analysis 7.6), respectively (TRAFFIC 2015;
TRANSPORT 2015). This statistically significant difference was
also observed for the two lumacaftor doses combined compared
to placebo, OR 0.62 (99% CI 0.44 to 0.86) (Analysis 8.6).
These studies also reported the rate of events per participant lead-
ing to intravenous antibiotic treatment over 48 weeks graphically
pooled across the two studies (TRAFFIC 2015; TRANSPORT
2015). These data were extrapolated and we have requested confir-
mation of the exact data from the study investigators. Any unpub-
lished information we receive will be included in a future update.
We estimate that the event rate per participant over 48 weeks in
the placebo group was 0.58. The corresponding event rate in the
lumacaftor 600 mg once daily plus ivacaftor 250 mg twice daily
group was 0.32 (equal to a 45% decrease compared to the placebo
group, P < 0.001) and in the lumacaftor 400 mg twice daily plus
ivacaftor 250 mg twice daily was 0.18 (equal to a 56% decrease
compared to the placebo group, P < 0.001).
The presentation of data did not allow us to estimate the time
to first pulmonary exacerbation or rate of exacerbations over the
two lumacaftor doses combined. These data were extrapolated
and we have requested confirmation of the exact data from the
study investigators. Any unpublished information we receive will
be included in a future update.
Data from the Phase 2 lumacaftor-ivacaftor study on the number
of exacerbations were reported at day 21 (Boyle 2014). These
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data demonstrated no statistically significant differences between
treatment groups from participants receiving 200 mg lumacaftor
once daily plus either 150 mg or 250 mg of ivacaftor twice daily or
ivacaftor doses combined compared to placebo, OR 2.22 (99%CI
0.08 to 58.11) (Analysis 9.2), OR 1.05 (99% CI 0.03 to 44.10)
(Analysis 10.2) and OR 1.62 (99% CI 0.08 to 34.55) (Analysis
12.2), respectively.
There were no statistically significance differences between treat-
ment groups in the number of pulmonary exacerbations experi-
enced in the paediatric combination study,OR 1.11 (99%CI 0.44
to 2.81) (Ratjen 2017) (Analysis 11.4).
Tezacaftor plus ivacaftor versus control
The larger study (n = 510) also reported rate of pulmonary exac-
erbations that led to hospitalisation or treatment with intravenous
antibiotic agents (or both); see secondary outcome ’Hospitalisa-
tion’ above for further details (Taylor-Cousar 2017).
5. Sweat chloride (change from baseline) as a measure of
CFTR function
Lumacaftor plus ivacaftor versus placebo
Two studies did not report this outcome (TRAFFIC 2015;
TRANSPORT 2015).
Boyle reported that following lumacaftor (day 1 to 21) and iva-
caftor (day 15 to 21) combination therapy, data at 21 days demon-
strated reductions in sweat chloride concentration in the 150 mg
ivacaftor group, MD -5.00 mmol/L (95% CI -11.60 to 1.60)
(Analysis 9.3) and 250 mg ivacaftor group, MD -10.90 mmol/L
(95% CI -17.60 to -4.20) (Analysis 10.3), the latter of which was
statistically significant (Boyle 2014). There was also a statistically
significant reduction in sweat chloride concentration when iva-
caftor doses were combined MD -7.95 (95% CI -13.81 to -2.09)
(Analysis 12.3)
The paediatric combination study reported a statistically signifi-
cantly greater absolute reduction in sweat chloride concentration
from baseline in the lumacaftor plus ivacaftor group compared to
the placebo group, up to and including four weeks, MD -20.80
(95% CI -23.40 to -18.20) (Analysis 11.5). Additional results (at
time points day 15, week 16, and week 24) were published graph-
ically in the study publication, but the graphical plots were too
small to allow for accurate extraction of data (Ratjen 2017). Nu-
merical data for these time points have been requested from the
study investigators and any unpublished information we receive
will be included in a future update.
Tezacaftor plus ivacaftor versus control
Therewas a statistically significant reduction in sweat chloride con-
centration in the tezacaftor-ivacaftor groups at four weeks com-
pared to the control groups, pooled MD -9.24 mmol/L (95% CI
-11.12 to -7.35) (Analysis 13.6) (Donaldson 2018; Taylor-Cousar
2017); thiswasmaintained at 24weeks in theTaylor-Cousar study,
MD -10.10 mmol/L (95% CI -11.40 to -8.80) (Analysis 13.6)
(Taylor-Cousar 2017).
6. Radiological measures of lung disease (assessed using any
scoring system)
Data for this outcomewere not reported by any study (Boyle 2014;
Donaldson 2018; Ratjen 2017; Taylor-Cousar 2017; TRAFFIC
2015; TRANSPORT 2015).
7. Acquisition of respiratory pathogens
No study reported on the acquisition of any respiratory pathogens
(Paeruginosa, Saureus,Hinfluenzae, or any other clinically relevant
pathogen in CF) (Boyle 2014; Donaldson 2018; Ratjen 2017;
Taylor-Cousar 2017; TRAFFIC 2015; TRANSPORT 2015).
8. Eradication of respiratory pathogens
Data for this outcomewere not reported by any study (Boyle 2014;
Donaldson 2018; Ratjen 2017; Taylor-Cousar 2017; TRAFFIC
2015; TRANSPORT 2015).
9. Nutrition and growth
a. Weight
Lumacaftor plus ivacaftor versus placebo
Data for this outcomewere reported by three studies (Ratjen 2017;
TRAFFIC 2015; TRANSPORT 2015).
Two studies presented results for the absolute change from base-
line in weight (kg) at six months (TRAFFIC 2015; TRANSPORT
2015). Participants in both the lumacaftor 600 mg once daily plus
250 mg ivacaftor twice daily group and the 400 mg twice daily
plus 250 mg ivacaftor twice daily group experienced a statisti-
cally significantly higher absolute weight gain from baseline com-
pared to the placebo group, MD 0.80 kg (95% CI 0.42 to 1.18)
(Analysis 6.9) and MD 0.65 kg (95% CI 0.27 to 1.03) (Analysis
7.9), respectively. There was also a statistically significantly higher
absolute weight gain from baseline compared to the placebo group
when the two lumacaftor doses were pooled, MD 0.72 kg (95%
CI 0.39 to 1.05) (Analysis 8.7).
The paediatric combination study listed absolute change in weight
and absolute change in weight-for-age z score as a secondary out-
come of the study, but results for this outcome are not presented
(Ratjen 2017). Numerical data for this outcome have been re-
quested from the study investigators and any unpublished infor-
mation we receive will be included in a future update.
b. BMI
Data for the absolute change from baseline in BMI were reported
by four studies (Ratjen 2017; Taylor-Cousar 2017; TRAFFIC
2015; TRANSPORT 2015); one study additionally reported ab-
solute change in BMI-for-age z score (Ratjen 2017).
i. Immediate term (up to and including one month)
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Lumacaftor plus ivacaftor versus placebo
At 28 days, there was no statistically significant difference in the
absolute change in BMI from baseline between the lumacaftor
600 mg once daily plus 250 mg ivacaftor twice daily and placebo
groups, MD 0.01 (95% CI -0.07 to 0.09) (Analysis 6.10) or the
lumacaftor 400 mg twice daily plus 250 mg ivacaftor twice daily
and placebo groups, MD 0.02 (95% CI -0.06 to 0.10) (Analysis
7.10). There was also no statistically significant difference in abso-
lute change in BMI from baseline compared to the placebo group
when the two lumacaftor doses were pooled, MD 0.02 (95% CI
-0.05 to 0.08) (Analysis 8.8).
Tezacaftor plus ivacaftor versus control
There was no statistically significant difference between tezacaftor-
ivacaftor and placebo in terms of change from baseline in BMI in
the Taylor-Cousar study at four weeks, MD -0.03 (95% CI -0.13
to 0.07) (Analysis 13.7) (Taylor-Cousar 2017).
ii. Short term (over one month and up to and including six
months)
Lumacaftor plus ivacaftor versus placebo
Despite no immediate differences between treatment groups, at
six months participants in the both the lumacaftor 600 mg once
daily plus 250mg ivacaftor twice daily and 400mg twice daily plus
250 mg ivacaftor twice daily groups experienced a statistically sig-
nificantly higher absolute change in BMI from baseline compared
to the placebo group, MD 0.29 (95% CI 0.16 to 0.43) (Analysis
6.10) and MD 0.25 (95% CI 0.12 to 0.39) (Analysis 7.10) re-
spectively. There was also a statistically significantly higher abso-
lute change in BMI from baseline compared to the placebo group
when the two lumacaftor doses were pooled; MD 0.27 (95% CI
0.16 to 0.39) (Analysis 8.8)
At sixmonths Rajten reported no statistically significant difference
between groups in the absolute change in BMI or the absolute
change in BMI-for-age z score, MD 0.10 (95% CI -0.10 to 0.30)
(Analysis 11.6) and MD 0.00 (95% CI -0.10 to 0.10) (Analysis
11.7) respectively. Additional results for BMI at earlier time points
(day 15,week 4, andweek 16)were published graphically in the full
paper, but the graphical plots were too small to allow for accurate
extraction of data (Ratjen 2017). Numerical data for these time
points have been requested from the study investigators and any
unpublished information we receive will be included in a future
update.
Tezacaftor plus ivacaftor versus control
There was no statistically significant difference between tezacaftor-
ivacaftor and placebo in terms of change from baseline in BMI in
the Taylor-Cousar study at 24 weeks, MD -0.06 (95% CI -0.08
to 0.20) (Analysis 13.7) (Taylor-Cousar 2017).
c. Height
Lumacaftor plus ivacaftor versus placebo
This outcome was not reported in three studies (Boyle 2014;
TRAFFIC 2015; TRANSPORT 2015). One study listed the ab-
solute change in height and absolute change in height-for-age z
score as a secondary outcome of the study, but results for this out-
come are not presented (Ratjen 2017). Numerical data for this
outcome have been requested from the study investigators and any
unpublished information we receive will be included in a future
update.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Cavosonstat compared with placebo for cystic fibrosis
Patient or population: adults and children with cyst ic f ibrosis
Settings: outpat ients
Intervention: cavosonstat 200 mg
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Cavosonstat
Survival
Follow-up: 28 days
No deaths reported. No deaths reported. NA 26
(1 study)
⊕⊕©©
low1,2
Quality of life: total
score
Follow-up: NA
Outcome not reported. NA A higher score indi-
cates a better outcome.
Quality of life: CFQ-
R respiratory domain:
absolute change f rom
baseline
Follow-up: 28 days
The mean absolute
change f rom baseline
in CFQ-R respiratory do-
main was -4.6 points in
the placebo group
The mean absolute
change f rom baseline
in CFQ-R respiratory do-
main was 3.80 higher
(11.30 lower to 18.90
higher) in the Cavoson-
stat group than the
placebo group
NA 26
(1 study)
⊕©©©
very low1,2,3
A higher score indi-
cates a better outcome.
FEV1 % predicted: rela-
t ive change f rom base-
line
Follow-up: NA
Outcome not reported. NA
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FEV1 % predicted: ab-
solute change f rom
baseline
Follow-up: 28 days
There were no treatment-related changes in FEV1
(% predicted) compared to placebo.
NA 26
(1 study)
⊕⊕©©
low1,2
A graphical f igure of
change f rom baseline
in FEV1 (% predicted)
is provided but numer-
ical data cannot be ex-
tracted to include in
analysis due to overlap-
ping lines
Adverse events: occur-
ring in at least 10%
of cavosonstat treated
part icipants
Follow-up: 28 days
There was no stat ist ically signif icant dif f erence
between groups in terms of cough, pulmonary
exacerbat ion, chest discomfort and fat igue
NA 26
(1 study)
⊕©©©
very low1,2,4
Time to first pulmonary
exacerbation
Follow-up: NA
Outcome not reported. NA
*The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CFQ-R: Cyst ic Fibrosis Quest ionnaire-Revised; CI: conf idence interval; NA: not applicable.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Downgraded once due to potent ial risk of bias: unclear details related to methodological design and some unbalanced
baseline characterist ics.
2. Downgraded once due to indirectness: adults only were recruited into the study, therefore, results are not applicable to
children.
3. Downgraded once due to imprecision: wide CIs around the result .
4. Downgraded once due to imprecision: very wide CIs around results (due to small event numbers).
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Lumacaftor plus ivacaftor compared with placebo for cystic fibrosis
Patient or population: adults and children with cyst ic f ibrosis
Settings: outpat ients
Intervention: lumacaf tor (600 mg once daily or 400 mg once daily) plus ivacaf tor (250 mg twice daily)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Lumacaftor plus iva-
caftor
Survival
Follow-up: 6 months
No deaths reported. No deaths reported. NA 1108
(2 studies)
⊕⊕⊕⊕
high
Quality of life - (Eu-
roQol) EQ-5D-3L Index
Score (total score): ab-
solute change f rom
baseline
Follow-up: 6 months
The mean absolute
change f rom baseline
ranged f rom 0.0006 to
0.0017 points
The mean absolute
change f rom baseline
was 0.00 points higher
(0.01 lower to 0.01
higher)
NA 1061
(2 studies)
⊕⊕⊕⊕
high
A higher score indi-
cates a better outcome.
Quality of life - CFQ-
R respiratory domain:
absolute change f rom
baseline
Follow-up: 6 months
The mean absolute
change f rom baseline
ranged f rom 1.1 to 2.81
points
The mean absolute
change f rom baseline
was 2.62 points higher
(0.64 higher to 4.59)
NA 1076
(2 studies)
⊕⊕⊕©
moderate1
A higher score indi-
cates a better outcome.
There was also a stat is-
t ically signif icant dif f er-
ence between groups at
28 days,MD 3.70 points
(95% CI 1.81 to 5.58)
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FEV1 % predicted: rela-
t ive change f rom base-
line
Follow-up: 6 months
The mean relat ive
change f rom baseline
ranged f rom -0.34% to
0%
The mean relat ive
change f rom baseline
was 5.21% higher (3.
61% higher to 6.80%
higher)
NA 1072
(2 studies)
⊕⊕⊕⊕
high
FEV1 % predicted: ab-
solute change f rom
baseline
Follow-up: 6 months
The mean absolute
change f rom baseline
ranged f rom -0.44 to -0.
15% predicted
The mean absolute
change f rom baseline
was 3.07% predicted
higher (2.17 higher to 3.
97 higher)
NA 1072
(2 studies)
⊕⊕⊕©
moderate1
There was also a stat is-
t ically signif icant dif f er-
ence between groups at
28 days, MD 2.37% pre-
dicted (95% CI 1.52 to
3.22)
Adverse events
Follow-up: 6 months
Cough was stat ist ically signif icant ly more com-
mon in the placebo group compared to the
lumacaf tor-ivacaf tor group
Dyspnoea was stat ist ically signif icant ly more
comment in the lumacaf tor-ivacaf tor group com-
pared to the placebo group
There were no stat ist ically signif icant dif f erences
between groups in terms of number of part ici-
pants experiencing adverse events, serious ad-
verse events or other adverse events
Long-term open-label follow-up data of the 2 stud-
ies showed a stat ist ically signif icant increase in
early transient shortness of breath. In part ici-
pants allocated a 400 mg twice-daily dose, there
was a stat ist ically signif icant rise in blood pres-
sure
NA 1108
(2 studies)
⊕⊕⊕⊕
high
Time to first pulmonary
exacerbation
Follow-up: 6 months
Time to f irst pulmonary exacerbat ion was stat ist i-
cally signif icant ly longer in both in the lumacaf tor
600 mg once daily plus ivacaf tor 250 mg twice
daily and the lumacaf tor 400 mg twice daily plus
ivacaf tor 250 mg twice daily groups
NA 1108
(2 studies)
⊕⊕⊕©
moderate1
Presentat ion of data
did not allow an anal-
ysis of the lumacaf tor
doses pooled
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* The basis for the assumed risk is the mean placebo group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CFQ-R: Cyst ic Fibrosis Quest ionnaire-Revised; CI: conf idence interval; EQ-5D-3L: 5-Dimension-3 Level; EuroQol: Euro Quality of Life Scale; FEV1: f orced expiratory volume at
one second; MD: mean dif ference.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Downgraded once due to risk of bias f rom select ive report ing: data contribut ing to analyses were extrapolated f rom
published graphs or est imated. We have requested conf irmation of the exact data f rom the study invest igators. Any
unpublished information we receive will be included in a future update and this judgement will be reconsidered.
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Lumacaftor plus ivacaftor compared with placebo for cystic fibrosis
Patient or population: adults and children with cyst ic f ibrosis
Settings: outpat ients
Intervention: lumacaf tor (200 mg twice daily) plus ivacaf tor (250 mg twice daily)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Survival
Follow-up: 24 weeks
No deaths reported. No deaths reported. NA 204
(1 study)
⊕⊕⊕©
moderate1
Quality of life - total
score
Follow-up: 24 weeks
Outcome not reported. NA A higher score indi-
cates a better outcome.
Quality of life - CFQ-
R respiratory domain:
absolute change f rom
baseline
Follow-up: 24 weeks
See comment. The mean change
in the CFQ-R res-
piratory domain was
2.50 points higher
in the lumacaf tor-iva-
caf tor group compared
to the placebo group,
ranging f rom 0.10 lower
to 5.10 higher
NA 204
(1 study)
⊕⊕©©
low1,2
A higher score indi-
cates a better outcome.
Data were analysed via
a MMRM. Results pro-
vided by this model can
be interpreted as treat-
ment ef fect averaged
f rom each study visit
unt il week 24
FEV1 % predicted: rela-
t ive change f rom base-
line
Follow-up: 24 weeks
Outcome not reported. NA Relat ive change f rom
baseline in FEV1 was
listed in the methods of
the study but no numer-
ical results were pre-
3
9
C
o
rre
c
to
rs
(sp
e
c
ifi
c
th
e
ra
p
ie
s
fo
r
c
la
ss
II
C
F
T
R
m
u
ta
tio
n
s)
fo
r
c
y
stic
fi
b
ro
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
sented
if numerical data be-
comes available at a
later date, it will be in-
cluded in an update of
this review
FEV1 % predicted: ab-
solute change f rom
baseline
Follow-up: 24 weeks
See comment. The mean change
in FEV1 % pre-
dicted was 2.40 higher
in the lumacaf tor-iva-
caf tor group com-
pared to the placebo
group, ranging f rom 0.
40 higher to 4.40 higher
NA 204
(1 study)
⊕⊕©©
low1,2
Data were analysed via
a MMRM. Results pro-
vided by this model can
be interpreted as treat-
ment ef fect averaged
f rom each study visit
unt il week 24
Adverse events
Follow-up: 24 weeks
There was no stat ist ically signif icant dif f erence
between the groups in terms of product ive cough,
nasal congest ion, oropharyngeal pain, upper ab-
dominal pain, rhinorrhoea, increased sputum,
cough, pyrexia, headache, upper respiratory tract
infect ion, abdominal pain, nausea, vomit ing, fa-
t igue and respiratory events (such as wheezing,
dyspnoea, asthma and chest discomfort)
NA 204
(1 study)
⊕⊕©©
low2,3
Time to first pulmonary
exacerbation
Follow-up: 24 weeks
Outcome not reported. NA Time to f irst pulmonary
exacerbat ion was listed
in the methods of the
study but no numerical
results were presented
If numerical data be-
come available at a
later date, they will be
included in an update of
this review
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* The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CFQ-R: Cyst ic Fibrosis Quest ionnaire-Revised; CI: conf idence interval; FEV1: f orced expiratory volume at 1 second; MMRM : m ixed model for repeated measures; NA: not
applicable.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Downgraded once due to indirectness: children aged 6 - 11 years were recruited in this study, therefore, results are not
applicable to other age groups.
2. Downgraded once due to risk of bias f rom select ive report ing: lim ited data available which is adjusted for all visits. Further
graphical data were available in the publicat ion but could not be accurately extracted. We have requested conf irmation of the
exact data f rom the study invest igators. Any unpublished information we receive will be included in a future update and this
judgement will be reconsidered
3. Downgraded once due to imprecision; few events occurred therefore CIs for occurrence of specif ic events are very wide
(Analysis 11.4).
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Lumacaftor plus ivacaftor compared with placebo for cystic fibrosis
Patient or population: adults and children with cyst ic f ibrosis
Settings: outpat ients
Intervention: lumacaf tor (200 mg) plus ivacaf tor (150 mg or 250 mg twice daily)1
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Lumacaftor plus iva-
caftor1
Survival
Follow-up: 21 days1
No deaths reported. No deaths reported. NA 62
(1 study)
⊕⊕⊕©
moderate2
Quality of life: total
score
Follow-up: 21 days1
Outcome not reported. NA A higher score indi-
cates a better outcome.
Quality of life: respira-
tory domain
Follow-up: 21 days1
Outcome not reported. NA A higher score indi-
cates a better outcome.
FEV1 %predicted:
relat ive change f rom
baseline
Follow-up: 21 days1
Outcome not reported. NA
FEV1 % predicted: ab-
solute change f rom
baseline
Follow-up: 21 days1
The mean change f rom
baseline was 0.3.
The mean change f rom
baseline was 1.57%
predicted higher (-2.13
lower to 5.27 higher)
NA 59
(1 study)
⊕⊕⊕©
moderate2
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Adverse events
Follow-up: 21 days1
There were no stat ist ically signif icant dif f erences
between groups in terms of part icipants experi-
encing: cough, oropharyngeal pain, nasal conges-
t ion, dizziness, a prolonged prothrombin t ime,
and upper respiratory tract infect ion
NA 61
(1 study)
⊕⊕©©
low2,3
Time to first pulmonary
exacerbation
Follow-up: 21 days1
Outcome not reported (see comment). NA Time to f irst pulmonary
exacerbat ion was not
reported. There was
no stat ist ically signif -
icant dif f erence be-
tween groups in the
number of part ici-
pants experiencing pul-
monary exacerbat ions
* The basis for the assumed risk is the mean placebo group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; FEV1: f orced expiratory volume at 1 second.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. The design of the study was 14 days of lumacaf tor monotherapy (200 mg once daily) then a dose of ivacaf tor (150 mg
or 250 mg once daily) was added on for 7 days of combinat ion therapy. Results presented in this table are f rom the
combinat ion treatment period only.
2. Downgraded once due to indirectness: design of the study means that combinat ion treatment was measured for only 7
days and prior lumacaf tor monotherapy phase (see footnote 1) may have inf luenced results of the combinat ion phase.
3. Downgraded once due to imprecision: few events occurred therefore CIs for occurrence of specif ic events are very wide
(Analysis 12.2).
4
3
C
o
rre
c
to
rs
(sp
e
c
ifi
c
th
e
ra
p
ie
s
fo
r
c
la
ss
II
C
F
T
R
m
u
ta
tio
n
s)
fo
r
c
y
stic
fi
b
ro
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Tezacaftor plus ivacaftor compared with placebo or ivacaftor alone for cystic fibrosis
Patient or population: adults and children with cyst ic f ibrosis
Settings: outpat ients
Intervention: tezacaf tor (100 mg daily) plus ivacaf tor (150 mg twice daily)
Comparison: placebo (i.e. tezacaf tor placebo) or ivacaf tor (150 mg twice daily)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo or ivacaftor
alone
Tezacaftor plus iva-
caftor
Survival
Follow-up: up to 24
weeks
No deaths reported. No deaths reported. NA 522
(2 studies)
⊕⊕⊕©
moderate1,2
Quality of life: total
score
Follow-up: NA
Outcome not reported. NA A higher score indi-
cates a better outcome.
Quality of life: CFQ-
R respiratory domain:
absolute change f rom
baseline
Follow-up: up to 24
weeks
See comment. The mean absolute
change f rom baseline
in CFQ-R respiratory do-
main score in the teza-
caf tor-ivacaf tor group
was 5.10 points higher
(3.20 higher to 7.
00 higher) than the
placebo group (result
f rom 1 study with 510
individuals)
NA 522
(2 studies)
⊕⊕⊕©
moderate1,2
A higher score indi-
cates a better outcome
Dif ference in abso-
lute change f rom base-
line calculated by
least-squares regres-
sion, hence assumed
risk not presented
The mean absolute
change f rom baseline
in CFQ-R respiratory do-
main score in the teza-
caf tor plus ivacaf tor
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group was also sta-
t ist ically signif icant ly
higher than the placebo
group at 4 weeks: MD
5.10 (95% CI 2.99 to 7.
21)
The second study (n
= 18) showed that
the treatment ef fect
of tezacaf tor-ivacaf tor
versus placebo was 6.
81 points of CFQ-R res-
piratory domain (P = 0.
2451) up to day 28
FEV1 % predicted: rela-
t ive change f rom base-
line
Follow-up: up to 24
weeks
See comment. The mean relat ive
change f rom baseline
in FEV1 % predicted
in the tezacaf tor-iva-
caf tor group was 6.80%
higher (5.30% higher to
8.30% higher) than the
placebo group (result
f rom 1 study with 510
individuals)
NA 522
(2 studies)
⊕⊕⊕©
moderate1,2
Dif ference in relat ive
change f rom base-
line calculated by
least-squares regres-
sion, hence assumed
risk not presented
The second study (n =
18) showed no stat ist i-
cally signif icant dif f er-
ence between groups in
mean relat ive change
f rom baseline in FEV1 %
predicted MD 3.72 (95%
CI -7.77 to 15.21).
FEV1 % predicted: ab-
solute change f rom
baseline
Follow-up: up to 24
weeks
See comment The mean absolute
change f rom baseline
in FEV1 % predicted in
the tezacaf tor plus iva-
caf tor group was 4.00 %
predicted higher (3.10
higher to 4.90 higher)
NA 522
(2 studies)
⊕⊕⊕©
moderate1,2
Dif ference in abso-
lute change f rom base-
line calculated by
least-squares regres-
sion, hence assumed
risk not presented
The mean absolute
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than the placebo group
(result f rom one study
with 510 individuals)
change f rom baseline
in FEV1 % predicted in
the tezacaf tor-ivacaf tor
group was also sta-
t ist ically signif icant ly
higher than the placebo
group at 4 weeks, MD
3.59 (95% CI 2.40 to 4.
78), 2 studies, n = 528,
I² =0%
Adverse events: most
commonly occurring
events (occurring in at
least 10% of part ici-
pants)
Follow-up: up to 24
weeks
The most commonly occurring adverse events in
both groups were cough and pulmonary exacer-
bat ion
There were no stat ist ically signif icant dif f erences
between groups (99% conf idence intervals) in
the number of part icipants experiencing cough,
pulmonary exacerbat ion, headache, nasal con-
gest ion or nasopharyngit is, increased sputum,
haemoptysis, pyrexia, oropharyngeal pain, nau-
sea or fat igue
NA 527
(2 studies)
⊕⊕⊕©
moderate1,2
Time to first pulmonary
exacerbation
Follow-up: up to 24
weeks
The hazard rat io for pulmonary exacerbat ion in
the tezacaf tor plus-ivacaf tor group, as compared
with the placebo group was 0.64 (95%CI 0.46 to
0.89)
NA 504
(1 study)
⊕⊕⊕©
moderate1,2
A hazard rat io below 1
favours the tezacaf tor-
ivacaf tor group
* The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; MD: mean dif ference; NA: not applicable.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
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1. Downgraded once due to indirectness: 1 study recruited individuals over the age of 12 (Taylor-Cousar 2017) and 1 study
recruited individuals over the age of 18 with one F508del mutat ion and one G551D mutat ion (Donaldson 2018). Therefore,
results are not applicable to children under the age of 12 and some results are not applicable to individuals homozygous
for F508del.
2. One study has some unclear details related to methodological design and had unbalanced treatment group sizes and
baseline characterist ics (Donaldson 2018). However, this study contributed a small proport ion of the evidence of this
comparison (n = 18, 3% of evidence) compared to the second study in the comparison (n = 509, 97% of evidence, overall low
risk of bias) (Taylor-Cousar 2017). Therefore, no downgrading is made due to potent ial risks of bias in the smaller study.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
The class IImutationof theCFTR gene, F508del, is prevalent (par-
ticularly in the Northern European population) and is the com-
monest cause of CF. A therapy that corrects the F508del molecular
defect would potentially have a profound impact on the field of
CF, providing a therapeutic option for many pwCF.
Summary of main results
We identified 13 eligible RCTs evaluating correctors for pwCF and
class II CFTR mutations (Boyle 2014; Clancy 2012; Donaldson
2014; Donaldson 2017; Donaldson 2018; PROGRESS 2017;
McCarty 2002; Ratjen 2017; Rubenstein 1998; Taylor-Cousar
2017;TRAFFIC2015;TRANSPORT2015;Zeitlin2002). Seven
studies examinedmonotherapy of a number of different correctors
(Boyle 2014; Clancy 2012; Donaldson 2014; Donaldson 2017;
McCarty 2002;Rubenstein 1998;Zeitlin2002). Seven studies (in-
cluding the multi-arm Boyle trial) examined combination therapy
of either lumacaftor-ivacaftor or tezacaftor-ivacaftor (Boyle 2014;
Donaldson 2018; PROGRESS 2017; Ratjen 2017; Taylor-Cousar
2017; TRAFFIC 2015; TRANSPORT 2015). Four of these were
well-powered Phase 3 studies that enrolled pwCF (including one
of children aged 6 to 11 years) with two copies of the F508del
mutation (F508del homozygotes) (Ratjen 2017; Taylor-Cousar
2017; TRAFFIC 2015; TRANSPORT 2015).
Monotherapy versus placebo
Early phase trials evaluated various potential molecules 4PBA
(Rubenstein 1998; Zeitlin 2002), CPX (McCarty 2002), N6022
(Donaldson 2014), cavosonstat (Donaldson 2017) and lumacaftor
(Clancy 2012; Boyle 2014). There was no statistically significant
impact on clinical outcomes (including sweat chloride) with either
4BPA, CPX or N6022 and phase 3 studies of these drugs were not
conducted. In one small Phase 1 study of cavosonstat monother-
apy, there was a reduction in sweat chloride of -4.1 mmol (P =
0.032) at the highest dose (200 mg), and there were no important
safety concerns (Donaldson 2017); and we have identified an on-
going study of this agent (NCT02589236). There was a modest
improvement in sweat chloride with lumacaftor alone compared
with placebo after four weeks,MD -8.21mmol/L ( 95%CI -14.30
to -2.12) ( Clancy 2012), but not sufficient to warrant investiga-
tion of this agent as monotherapy in later phase studies. Although
there was not a statistically significant increase in adverse events
the size of the studies was not sufficient to provide confidence on
the safety profiles of these agents.
Combination therapy versus placebo
Early phase studies of lumacaftor combined with ivacaftor demon-
strated a greater magnitude of effect with a reduction in sweat
chloride of MD -10.9 mmol/L ( 95% CI -17.6 to -4.2) com-
pared to lumacaftor monotherapy ( Boyle 2014). The efficacy and
safety of the lumacaftor-ivacaftor combination therapy were ex-
amined in two multicentre placebo-controlled RCTs, enrolling
over 1000 adults and young pwCF, homozygous for F508del
(TRAFFIC 2015; TRANSPORT 2015). In participants allocated
to the lumacaftor-ivacaftor combination, combined trial data
demonstrated no difference with regards to change in a generic
measure of QoL ( measured by the EQ-5L-3D tool). There was a
statistically significant improvement in the respiratory domain of
the CF-specific QoL measure ( CFQ-R) at 24 weeks, MD 2.62 (
95%CI 0.64 to 4.59). An improvement of four points on this scale
is considered theminimal clinically important difference (MCID)
for this outcome measure ( Quittner 2009; Ramsey 2011).
With respect to respiratory function (as measured by % predicted
FEV1), there were statistically significant differences from baseline
in favour of the lumacaftor-ivacaftor combination over placebo in
both relative change, MD 5.21 (95% CI 3.61 to 6.80) and ab-
solute change, MD 3.07 (95% CI 2.17 to 3.97). Improvement
in FEV1 is considered an important surrogate measure for pwCF.
The European Medicines Agency (EMA) has suggested that “as
FEV1 is linked to mortality, any statistically significant difference
between placebo and active treatment is potentially clinically rele-
vant” (EMA 2012). In the study protocol, the MCID in absolute
change in FEV1 used to calculate the sample sizes for the TRAF-
FIC andTRANSPORTwas 5%(TRAFFIC 2015;TRANSPORT
2015). This magnitude of improvement in respiratory function
was not achieved with the lumacaftor-ivacaftor combination. In a
post hoc change to the protocol, the primary outcome for TRAF-
FIC and TRANSPORT was altered from absolute change from
baseline in FEV1 at 24 weeks to an average of the FEV1 values at
16 and 24 weeks.
A number of important secondary outcomes were reported that
were included in this review. In the TRAFFIC and TRANS-
PORT studies, pulmonary exacerbations were reported more fre-
quently in participants allocated to placebo compared to those
receiving lumacaftor-ivacaftor combination therapy (TRAFFIC
2015; TRANSPORT 2015); pulmonary exacerbations are a chal-
lenging outcome to record accurately, but one that is impor-
tant to pwCF. Additionally, BMI improved in participants al-
located to the lumacaftor-ivacaftor combination therapy after
24 weeks ( Analysis 1.10; Analysis 2.10; Analysis 3.8). Data on
school or work attendance, acquisition or eradication of microbial
pathogens, or radiological outcomes were not reported.
Overall the safety data reported for the lumacaftor-ivacaftor com-
bination were reassuring, but there was clear evidence of increased
reporting of early respiratory compromise, OR 2.05 (99% CI 1.1
to 3.8) (TRAFFIC 2015; TRANSPORT 2015). The aetiology of
this event is unclear and it was reported to settle after a few weeks if
the intervention was continued (TRAFFIC 2015; TRANSPORT
2015). Two participants were withdrawn because of hypertension
(including one in the follow-up study (PROGRESS 2017)). For
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participants (n = 80) receiving 400 mg twice a day of lumacaftor
there was a statistically significant mean (SE) increase in systolic
blood pressure of 5.1 (1.5) mmHg and in diastolic blood pressure
of 4.1 (1.2) mm Hg (PROGRESS 2017).
For the children ( aged 6 to 11 years) enrolled in the Phase 3 study
of lumacaftor-ivacaftor combination therapy, the safety profile re-
ported was similar to the TRAFFIC and TRANSPORT studies,
including transient early respiratory compromise and infrequent
elevation in serum transaminases ( liver enzymes) ( Ratjen 2017).
The efficacy data for this study are discussed below in the section
on applicability.
The efficacy outcomes ( primary and secondary) for the tezacaftor-
ivacaftor Phase 3 study were very similar to those reported with
lumacaftor-ivacaftor ( Taylor-Cousar 2017). After 24 weeks the
participants allocated to tezacaftor-ivacaftor had a 4.0% improve-
ment in their absolute change in FEV1 compared to those who
received placebo ( Analysis 12.1). There was no increased report-
ing of adverse events, in particular the early transient dyspnoea
reported with the lumacaftor-ivacaftor combination, and no in-
creased withdrawals of tezacaftor-ivacaftor participants compared
to those receiving placebo.
Overall completeness and applicability of
evidence
Monotherapy versus placebo
The single-agent studies have enrolled participants with two copies
of the F508del mutation. These studies have not been taken for-
ward on larger more representative populations in Phase 3 studies.
New agents (such as cavosonstat) are currently being assessed in
early phase studies (Donaldson 2017).
Combination therapy versus placebo
The Phase 3 studies of both lumacaftor and tezacaftor com-
bined with ivacaftor have examined this therapy for people
with two copies of the F508del mutation (F508del homozy-
gotes) (Ratjen 2017; Taylor-Cousar 2017; TRAFFIC 2015;
TRANS{ORT 2015). There have been no Phase 3 studies for
pwCF who are compound heterozygotes of F508del with another
CF-causing mutation. One cross-over study has examined com-
pound heterozygotes who have F508del with a ivacaftor-sensitive
residual function mutation, to evaluate any potential additive im-
pact of tezacaftor on the recognised ivacaftor benefit (Rowe 2017).
We excluded this study because of concerns over study design, in
particular carryover effects of an intervention (ivacaftor) that has
been shown to correct the basic defect in CF.
The Phase 3 studies of both the lumacaftor and ivacaftor combi-
nation therapy are well-powered and provide clear statistical evi-
dence of improvement in clinical outcomes, even if these are lim-
ited in magnitude compared to the changes anticipated in the pro-
tocols and to those reported for individuals with G551D receiving
ivacaftor ( Ratjen 2017; TRAFFIC 2015; TRANSPORT 2015).
These Phase 3 studies were conducted across a large number of CF
centres in North America, Europe and Australia, and the results
are applicable to pwCF who are homozygous for F508del in these
regions with mild to moderate lung disease.
The Phase 3 studies of lumacaftor-ivacaftor enrolled children and
adults ( age range 6 to 64 years) ( Ratjen 2017; TRAFFIC 2015;
TRANSPORT 2015)). For lumacaftor-ivacaftor, results were con-
sistent across age groups, although for the study of 6 to 11 year
olds the absolute change in FEV1 was less marked, MD 2.4%
(95% CI 0.4 to 4.4) (Ratjen 2017). The primary outcome for the
study on children was change in LCI; although this measure is a
well-validated research outcome assessing respiratory function, it
is not yet routinely used in clinical practice. The children allo-
cated to lumacaftor-ivacaftor demonstrated a statistically signifi-
cant reduction in LCI compared to those receiving placebo, least
squares mean difference -1.09 (95% CI -1.43 to -0.75). Although
this difference is statistically significant, it is difficult to assess the
clinical relevance of this result for young pwCF.
The tezacaftor-ivacaftor study enrolled adults and young pwCF (
from 12 years and with a mean age of approximately 26 years) (
Taylor-Cousar 2017).
This review has examined evidence for efficacy and safety.We have
not included outcomes relating to cost-effectiveness.
Quality of the evidence
Monotherapy versus placebo
The quality of the evidence of the early phase studies included in
this review were difficult to appraise and interpret due to limited
reporting and complex study design, including numerous dose
regimens. For the early phase studies of 4PBA, CPX an N6022;
relevant outcome data to this review were limited and the risk of
bias for various domains was difficult to judge.
The quality of the evidence from a short-term study of cavosonstat
compared to placebo was low to very low due to concerns over
unclear methodological design, indirectness (lack of applicability
of results to children) and limited outcome data resulting in wide
CIs around effect sizes (Summary of findings 2).
Combination therapy versus placebo
The studies included in this review were difficult to appraise and
interpret due to very complex study designs that incorporated
several drug doses.
We judged the quality of the evidence from the three large mul-
ticentre RCTs of lumacaftor-ivacaftor combination therapy to be
moderate to high (Summary of findings 3). Not all outcomes
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were reported in the final study publication; some were available
in the online supplement, some were extrapolated from graph-
ical figures and others were available on the NIH database (
ClinicalTrials.gov). Although the time-point for assessment of the
primary outcome changed after the data had been collected, from
FEV1 at 24 weeks to an aggregate of 16 and 24 weeks (which was
in fact a larger treatment effect), we did not judge this to reflect a
high risk of bias. This was because the results at 24 weeks were also
statistically significant, and the amended protocol states that “This
change was made during final review by senior management. It is
important to note that this change was made based on theoretical
considerations alone. No data analysis was used to support this
change and, in fact, the spirometry data were maintained at the
designated vendor and were not available to any Vertex person-
nel”.
We judged the quality of the evidence from an additional large
multicentre RCT of lumacaftor-ivacaftor combination therapy to
be moderate to low (Summary of findings 4). The study recruited
children aged 6 to 11 years, so results are not applicable to other
age groups. Not all outcomes were reported in the final study
report and additional data could not be extracted from graphical
figures. Furthermore the analysis approach takenwithin this review
adjusted for earlier time points in the analysis at 24weeks, therefore
results should be interpreted as the treatment effect averaged from
each study visit until week 24.
We judged the quality of the evidence from two tezacaftor-iva-
caftor combination therapy studies (including one large multicen-
tre RCT) to be of moderate quality (Summary of findings 6); re-
sults are not applicable to children under the age of 12 and some
results are not applicable to individuals homozygous for F508del.
Furthermore, in the large tezacaftor-ivacaftor combination study,
a number of outcomes which were not presented in the summary
of findings table of this review were recorded according to the
study protocol, but not presented in the published study report
(Taylor-Cousar 2017).
We judged the quality of the evidence froma small, very short-term
study of lumacaftor-ivacaftor combination therapy and from a
small study of lumacaftor monotherapy to be very low tomoderate
due to concerns over incomplete outcome data, selective reporting
and limited outcome data resulting in wide CIs around effect
sizes (Summary of findings for the main comparison; Summary of
findings 5).
Potential biases in the review process
The review authors conducted a comprehensive literature search
of online journal databases using the Cystic Fibrosis and Genetic
Disorders Review Group’s Cystic Fibrosis Trials Register and the
ongoing online trials databases (Appendix 1) and also of manual
searching of journal conference abstracts. Two authors individ-
ually applied the inclusion and exclusion criteria to the identi-
fied studies and excluded studies that were not relevant. Included
studies were appraised more thoroughly and data extracted inde-
pendently using a pre-determined form. The authors assessed the
risk of bias of the included studies and if they failed to reach a
consensus on the risk of bias, a third author (KWS) arbitrated.
The analyses were undertaken by two review authors (SP, IS) and
checked for appropriateness by the review statistician (SN). This
approach minimized the risks of bias in the review process.
None of the authors have received direct or indirect payments from
the companies responsible for the development of any agents in-
cluded in this review; however, KWS has attended and has organ-
ised educational events that have received financial support from
Vertex, the company that has developed and is evaluating some of
the agents included in this review.
Not all results were reported in a format from which they could
be accurately extracted, and so we have had to extrapolate data
for several important outcomes from graphs and figures. We are
awaiting confirmation from Vertex that these estimates are accu-
rate.
This review has assessed all available published study data. Study
authors were contacted for relevant unpublished information and
individual participant data. None have been made available to
date. We are not aware of any unpublished trials.
Agreements and disagreements with other
studies or reviews
The National Institute for Health and Care Excellence ( NICE)
in the UK has undertaken a health technology appraisal for
lumacaftor-ivacaftor which was published on 27 July 2016 (
NICE 2016). The appraisal included the TRAFFIC, TRANS-
PORT and PROGRESS studies (PROGRESS 2017; TRAFFIC
2015; TRANSPORT2015); the report concluded that the quality
of these studies was generally good and that the results were gener-
alisable to a UK population with mild-moderate disease severity.
The evidence review group (ERG) noted that there were statisti-
cally significant effects on key outcomes compared with standard
care alone, but it was unclear how clinically significant the effects
were. Adverse event data were recorded as per the published pa-
pers, but withdrawals due to hypertension and the overall increase
in blood pressure in participants receiving 400mg twice a day were
not recorded. In addition, the ERG examined a detailed cost-ef-
fectiveness assessment (including an estimate of incremental cost-
effectiveness ratio) and concluded, on that basis, that lumacaftor-
ivacaftor is not recommended, within its marketing authorisation,
for treating CF in people 12 years and older who are homozygous
for F508del mutation of the CFTR gene.
An evaluation of the safety of lumacaftor and ivacaftor highlighted
the finding of “transaminitis” ( raised transaminases) in ivacaftor
and combination studies ( Talamo Guervara 2017). In addition,
the review reported non-congenital cataracts identified in pre-clin-
ical studies and in children taking ivacaftor and combined therapy.
The review also highlighted that lumacaftor is a strong inducer of
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the liver enzyme, cytochrome P3A and the implications for co-
prescribing of drugs metabolised through this route.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Data from the Phase 3 studies of both lumacaftor and tezacaftor
combined with ivacaftor suggest that these compounds are influ-
encing the basic defect associated with the F508del mutation; with
small but consistent and statistically significant improvements in
key clinical outcomes. The size of these studies and the low- to
moderate-quality evidence from the studies gives us good confi-
dence in the validity of these results. Overall the drugs appeared
well-tolerated, but there were some important adverse effects, in
particular with the lumacaftor-ivacaftor combination. The adverse
events noted with lumacaftor-ivacaftor were not recorded in the
tezacaftor-ivacaftor study and, from the available data, this com-
bination appears to have a better safety profile.
From our appraisal of the available data, the combination of
lumacaftor or tezacaftor with ivacaftor can be considered for the
management of people with cystic fibrosis (pwCF) homozygous
for F508del, with mild to moderate lung disease. These results
cannot be translated automatically to pwCFwith more severe lung
disease. This agrees with the NICE appraisal of lumacaftor-iva-
caftor, although the evidence review group did not support the
routine use of lumacaftor-ivacaftor on the basis of their detailed
cost-effectiveness assessment (NICE 2016). Lumacaftor-ivacaftor
(trade name, Orkambi™) has been approved for use in other
countries, including the USA, Canada and Germany. It is useful
to compare the results of the available studies of correctors with
studies examining ivacaftor for pwCF with one class 3 mutation
(G551D). The absolute change in forced expiratory volume in
one second (FEV1) after ivacaftor therapy compared to placebo
was 16.9% ( 95% confidence interval 13.6 to 20.2) ( Patel 2015).
The evidence from this systematic review demonstrates that teza-
caftor-ivacaftor for treating pwCF with two F508del mutations
and mild to moderate lung disease results in similar clinical ben-
efit but with an improved safety profile compared to lumacaftor-
ivacaftor.
In children younger than 12 years of age, there are no data to as-
sess tezacaftor-ivacaftor. In a study of lumacaftor-ivacaftor in chil-
dren aged 6 to 11 years, there was some evidence of clinical effi-
cacy (decreasing lung clearance index (LCI) value), but the clinical
relevance of these changes is not clear. The reports of increased
adverse events for lumacaftor-ivacaftor in this age group and in
older pwCF should be taken into account when considering this
intervention for this age group until further data or an alternative
agent (e.g., tezacaftor-ivacaftor) is available.
Implications for research
It is important that post-market surveillance is undertaken for
all agents that correct the F508del mutation. It is clear that
lumacaftor-ivacaftor is associated with a number of important ad-
verse effects, some of which necessitated the withdrawal of therapy.
Although tezacaftor-ivacaftor appears to have a more favourable
safety profile there are no data in children and close monitoring is
required for all individuals on this drug combination.
Evidence of efficacy for the population of pwCF who have two
copies of the F508del mutation cannot be automatically translated
to pwCF who have one copy of F508del or another class II muta-
tion (such as G85E) and research strategies need to be developed
that assess impact on these individuals. Small numbers of potential
participants for these studies makes this a challenge.
As new mutation-specific therapies emerge, it is important that
lessons learnt from this review are taken on board. Investigators
should report clearly on methodological approaches to reduce the
risk of bias, in particular with regards to random sequence gener-
ation, allocation concealment and blinding; they should also en-
sure that randomisation is maintained when analysing data. It is
important that future studies examine and clearly report on out-
comes relevant to pwCF and their families.
With novel therapies and approaches, reporting of adverse events is
critical and this should be undertaken in a robust, comprehensive
and consistent manner.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boyle 2014
Methods Phase 2 placebo-controlled RCT with 3 different cohorts. Only cohort 1 was included in
this review (n = 62). (The following information will refer to cohort 1 only - see ’Notes’.
)
Parallel design.
Multicentre study conducted at 69 different sites inNorth America, Europe andAustralia
Duration: Cohort 1 lasted 21 days.
Participants Mutation: participants homozygous for F508del mutation.
Age: participants in Cohort 1 have a mean age of 29.1 years.
Gender split: 50% of participants are male
Lung function: all participants in Cohort 1 have a FEV1 ≥ 40% of predicted normal
for age, gender, and height and a mean (range) predicted FEV1 of 66.9% (32.8 - 117.1)
.
Sweat chloride levels: participants inCohort 1 have amean (range) level of 101.9mmol/
L (87.5 - 121.0)
Interventions Intervention 1: lumacaftor (also known as VX-809, a CFTR corrector) alone.
Intervention 2: lumacaftor in combination with ivacaftor (also known as VX-770, a
CFTR potentiator)
Intervention 3: placebo.
Cohort 1 (n = 62)
Study drug participants: 200 mg lumacaftor once daily for 14 days; then from day 15,
participants continue to take 200 mg of lumacaftor in addition to either 150 mg or 250
mg of ivacaftor twice daily until day 21
Placebo participants: placebo for 21 days.
Outcomes Primary outcomes
1. Change in sweat chloride when ivacaftor is administered in combination with
lumacaftor*
2. Safety and tolerability assessments based on adverse events, plasma samples (haema-
tology, clinical chemistry, coagulation), urinalysis, ECGs, and vital signs*
Secondary outcomes
1. Change in % predicted FEV1*
2. Change in sweat chloride of increasing doses of lumacaftor administered alone*
3. PK parameters (including exposure, concentration and half-life) of lumacaftor and
metabolite in plasma in the presence and absence of ivacaftor
4. PK parameters (including exposure, concentration and half-life) of ivacaftor and
metabolites in plasma in the presence of lumacaftor
Funding source Vertex Pharmaceuticals, and the Cystic Fibrosis Foundation Therapeutics Development
Network
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Notes * denotes outcomes relevant to this review.
Only data fromCohort 1 were included in this review. This was because data for placebo
participants fromCohorts 2 and 3 were pooled, although randomisation in these cohorts
occurred separately. This meant that the effects of randomisation in these cohorts were
undone. Data for participants in Cohorts 2 and 3 were excluded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random sequence was generated by a
computer by an independent party
Allocation concealment (selection bias) Low risk “Site pharmacists dispensed drugs on the
basis of an interactive voice response sys-
tem”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Drug doses were prepared by an indepen-
dent unmasked pharmacist and dispensed
by site pharmacists who were masked to
treatment assignment. Participant blind-
ing was maintained by placebo which was
matched to intervention by the quantity
of tablets and by size, colour, coating and
packaging
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Site investigators and the study sponsor
were also masked to treatment assignment
and to sweat chloride levels - data that could
have potentially disclosed treatment assign-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Participant data were excluded from the
analysis due to insufficient data, e.g. partic-
ipants were excluded from the analysis of
sweat chloride concentration if insufficient
amount of sweat were provided.We judged
this trial as having an unclear risk of attri-
tion bias because it was unclear how these
exclusions would have affected the balance
between groups in baseline characteristics
Selective reporting (reporting bias) Low risk We compared the outcomes
reported on the US NIH trials registry (
www.clinicaltrials.gov) to the outcomes re-
ported in the results of the published paper
as the protocol was not available. No selec-
tive outcome reporting was identified
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Other bias Low risk Similar baseline characteristics.
Clancy 2012
Methods Phase 2a placebo-controlled RCT.
Parallel design.
Multicentre study conducted at 25 study locations over North America and Europe
Duration: 28 days.
Participants Mutation: all 89 randomised participants had a confirmed diagnosis of CF and all but
1 were homozygous for the F508del mutation
Age: median (range) age of 26 (18 - 54) years.
Gender split: 60% of the participants were males.
Lung function: a baseline FEV1 > 40% predicted was an eligibility criteria; but scores
ranged from 34.2 to 126.3 with a median of 71
Sweat chloride levels: 103.5 (66.0 - 129.0) mmol/L.
Nutritional status: median (range) baseline BMI of 22 (16 - 34).
Interventions Intervention 1: placebo (n = 17).
Intervention 2: lumacaftor (VX-809) 25 mg once daily (n = 18).
Intervention 3: lumacaftor 50 mg once daily (n = 18).
Intervention 4: lumacaftor 100 mg once daily (n = 17).
Intervention 5: lumacaftor 200 mg once daily (n = 19).
Outcomes Primary outcome
1. Evaluation of safety and tolerability of lumacaftor based on adverse events*, haema-
tology, clinical chemistry, urinalysis, ECGs, vital signs, and physical examinations
Secondary outcomes
1. Evaluation of the pharmacodynamic impact of lumacaftor on CFTR function
2. Change from baseline in sweat chloride concentration*
3. Nasal potential difference (optional)
4. Spirometry* (FEV1, FEF25−75%, FVC)
5. Change from baseline in CFQ-R score*
Funding source Vertex Pharmaceuticals, and grants from the NIH.
Notes * denotes outcomes relevant to this review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk There was insufficient information on how
participant or study personnel blinding
were maintained
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk There was insufficient information on how
outcome assessor blind was maintained
Incomplete outcome data (attrition bias)
All outcomes
High risk In the adverse events table, the total num-
ber of participants shown (n = 45) is less
than the total number of participants ran-
domised (n = 89)
In Figure 1B the number of participants
analysed in the outcome ’Change from
baseline in sweat chloride’ (n = 63) is
less than the total number of participants
randomised to the intervention (n = 72).
Therefore, 9 participants have been unac-
counted for
In the table of results of total CFQ-R scores,
1 participant appears to be excluded from
each of the treatment groups
Selective reporting (reporting bias) High risk No results have been presented for
FEF25−75% or FVC despite being stated as
an outcome.
Other bias Low risk Baseline characteristics well matched ex-
cept for the less severe lung disease in 25
mg and placebo groups
Donaldson 2014
Methods Double-blind, placebo-controlled RCT.
Parallel design.
Duration: 7 days.
Multicentre: 17 sites in USA.
Participants 66 participants.
Mean (SD) age: 29 (8) years.
Gender split: 40 female and 26 male.
Disease severity: mean (SD)%predicted FEV1 70 (21)%, andmean (SD) sweat chloride
101 (11) mmol/L.
There were no statistically significant differences among the treatment groups at baseline
Interventions Intervention: 4 sequential ascending doses of N6022 were assessed (5, 10, 20, and 40
mg/day) given by intravenous infusion once daily
Control: placebo (normal saline).
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Outcomes Primary outcome
Safety and tolerability (over 7 treatment days and 7 days of follow-up)*
Secondary outcomes
Change from baseline in % predicted FEV1 (at Day 7)*
Change from baseline in biomarkers of CFTR Function measured as sweat chloride
mEq/L (at Day 7)
Funding source Sponsored by Nivalis Therapeutics.
Notes * denotes outcomes relevant to this review.
4 sequential ascending doses of N6022 were assessed (5, 10, 20, and 40mg/day) followed
by a confirmatory cohort of participants at the highest dose. An independent Data
Monitoring Committee adjudicated dose escalation at the completion of each cohort
after review of unblinded safety data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind (participant, caregiver, in-
vestigator, outcomes assessor) achieved
with intravenous administration of placebo
(saline) using the same volume as the active
drug groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind (participant, caregiver, in-
vestigator, outcomes assessor) achieved
with intravenous administration of placebo
(saline) using the same volume as the active
drug groups
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants completed the
7 days of follow-up
Selective reporting (reporting bias) Unclear risk No full text publication of the study avail-
able. Limited results (without any statisti-
cal analysis) available on the ongoing trials
database (www.clinicaltrials.gov). Unclear
if all relevant information has been made
available
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Other bias Low risk Baseline characteristics across the 5 treat-
ment groups seem fairly well-balanced de-
spite small numbers in each group
Donaldson 2017
Methods Phase 1 double-blind RCT.
Parallel design.
Duration: 28 days treatment.
Multicentre (10 centres).
Participants 51 adults with CF randomised.
Mutation: CF homozygous for the F508del-CFTR mutation.
Age: over 18 years.
Gender: 32 out of 51 participants were female.
Lung function: FEV1 ≥ 40% of predicted normal for age, gender, and height (Hank-
inson standards). pre- or post-bronchodilator value, at screening
Sweat chloride: ≥ 60 mEq/L.
Interventions Intervention: cavosonstat 2x daily 50 mg, 100 mg, or 200 mg.
Control: placebo 2x daily.
Outcomes Primary outcome (no prespecified sample size)
Safety (AE and SAE) *
Secondary outcomes (at 28 days)
Sweat chloride *
FEV1∗
*CFQ-R
Funding source Sponsored by Nivalis Therapeutics.
Notes * Denotes an outcome relevant to this review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description of method.
Allocation concealment (selection bias) Unclear risk No description of method.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Likely low risk as double-blind and
placebo-controlled but further information
about this aspect of methodology not de-
scribed
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Likely low risk as double-blind and
placebo-controlled but further information
about this aspect of methodology not de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 participants unaccounted for in analysis,
but unlikely to have affected result
Selective reporting (reporting bias) Low risk Likely low risk - all outcomes reported, but
they appear to have been measured at other
time-points that are not reported (7 days
and 14 days)
Other bias Unclear risk “Approximately two-thirds of CF subjects
were female; however, there was a greater
proportion of males in the 200 mg BID
dose group. Other baseline characteristics
were similar across the treatment groups.”
Unclear if this gender imbalance may have
influenced the results
Donaldson 2018
Methods Double-blind, placebo-controlled Phase 2 RCT, which included a dose-ranging arm
Parallel design.
Duration: 28 days treatment followed by 28 days observation.
Multicentre.
Participants Mutation: participants homozygous for F508del mutation, and heterozygous partic-
ipants with 1 F508del mutation and 1 G551D mutation. Only the 18 heterozygous
participants are included in the analysis of this review (this is because the placebo partic-
ipants in the homozygous arms of the trial were pooled, and this was judged to negate
the effects of randomisation)
Age: heterozygous participants - active drug armmean (SD) age 26.6 (7.0) years, placebo
arm mean (SD) age 34.5 (7.6) years
Gender split: heterozygous participants - active drug arm 6/14 (43%) participants fe-
male; placebo arm 3/4 (75%) female
Lung function, mean (SD): heterozygous participants - active drug arm baseline FEV1
59.1 (16.6)% predicted, placebo arm baseline FEV1 62.6 (12.7)% predicted.
Sweat chloride levels, mean (SD): heterozygous participants - active drug arm baseline
52.9 (19.6); placebo arm baseline 56.7 (22.1)
Interventions Intervention: tezacaftor 100 mg/day and ivacaftor 150 mg.
Control: ivacaftor 150 mg (heterozygous arm only).
Outcomes Primary outcome
Safety through day 56*
Secondary outcomes
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Absolute change in FEV1 at day 28*
Relative change in FEV1 at day 28*
Change in CFQ-R respiratory domain (day 28)*
Funding source Vertex Pharmaceuticals and grants from the NIH.
Notes * Denotes outcomes relevant to this review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described.
Allocation concealment (selection bias) Unclear risk Method not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Matched placebo - double-blind RCT.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Matched placebo - double-blind RCT.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants included in
analysis.
Selective reporting (reporting bias) Low risk All outcomes appear to have been reported.
Other bias Unclear risk Baseline characteristics of heterozygous
participants somewhat imbalanced across
groups (e.g. sex, age, FEV1). However, this
imbalance may be due to small numbers
(active drug arm n = 14 and placebo arm n
= 4) and unclear if the imbalance has influ-
enced results
McCarty 2002
Methods Phase 1, placebo-controlled RCT.
Parallel design.
Multicentre conducted at 4 sites in North America.
Duration: single-dose assessment. Participants were monitored for 2 days followed up at
1 week
Participants Mutation: all 37 participants were homozygous for the F508del mutation and were
described as having mild CF
Age: 18 years or over; age range 18 - 38 years.
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Gender split: 21 males and 16 females.
Lung function: participants were eligible if they had a baseline FEV1 ≥ 60% predicted
and had not endured pulmonary colonisation by a drug resistant organism within 12
months of screening
Interventions Intervention 1: placebo.
Intervention 2: CPX in the following escalating doses:
1 mg CPX;
3 mg CPX;
10 mg CPX;
30 mg CPX;
100 mg CPX;
300 mg CPX;
1000 mg CPX.
Outcomes Primary outcome
1. Safety profile of CPX including occurrence of adverse events*
Secondary outcomes
1. Nasal potential difference values
2. Sweat chloride values (mEq/L) *
3. Analysis of blood haemoglobin and serum potassium
Funding source SciClone Pharmaceuticals, and grants from the NIH.
Notes * denotes outcomes relevant to this review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk There was insufficient information on how
participant or study personnel blinding
were maintained
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk There was insufficient information on how
outcome assessor blind was maintained
Incomplete outcome data (attrition bias)
All outcomes
Low risk No report of withdrawals and all originally
randomised participants were included in
the analysis
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Selective reporting (reporting bias) Low risk Protocol not available and outcomes not
reported on the ongoing online database
(www.clinicaltrials.gov). Reported results
corresponded to outcomes listed in meth-
ods section
Other bias Unclear risk Unclear whether baseline characteristics
were well matched.
PROGRESS 2017
Methods Phase 3 RCT.
Double-blinded rollover study (participants on active treatment continued their treat-
ment, participants on placebo were randomised to 1 of the 2 active interventions).
Parallel design.
Multicentre: 191 sites in 15 countries across North America, Australia and Europe
Duration: 96 weeks.
Participants Mutation: homozygous or heterozygous for the F508del mutation.
Age: 12 years and older.
Gender: both males and females.
Confirmed diagnosis of CF.
Participants have previously participated in TRAFFIC or TRANSPORT and completed
24 weeks of treatment
Interventions Intervention 1: 600 mg lumacaftor once daily + 250 mg ivacaftor every 12 hours
(continued treatment)
Intervention 2: 600 mg lumacaftor once daily + 250 mg ivacaftor every 12 hours (rolled
over from placebo)
Intervention 3: 400 mg lumacaftor every 12 hours + 250 mg ivacaftor every 12 hours
(continued treatment)
Intervention 4: 400 mg lumacaftor every 12 hours + 250 mg ivacaftor every 12 hours
(rolled over from placebo)
Outcomes Primary outcome measure
Treatment cohorts: safety of long-term treatment based on AEs, clinical laboratory values
(serum chemistry, haematology, coagulation studies, and urinalysis), standard digital
ECGs, vital signs, and pulse oximetry at 100 weeks
Secondary outcome measures
1. Absolute change from baseline in % predicted FEV1 at 96 weeks
2. Relative change from baseline in % predicted FEV1 at 96 weeks
3. Absolute change from baseline in CFQ-R respiratory domain score at 96 weeks
4. Absolute change from baseline in BMI at 100 weeks
5. Number of pulmonary exacerbations starting from the previous study through 96
weeks
8. Event of having at least 1 pulmonary exacerbation in the current study through 96
weeks
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PROGRESS 2017 (Continued)
Funding source Sponsored by Vertex Pharmaceuticals Inc.
Notes Long-term extension of the TRAFFIC and TRANSPORT studies in which participants
receiving an active treatment continued with this treatment and those receiving placebo
were randomised to receive 1 of the 2 active treatments from theTRAFFIC and TRANS-
PORT
Additional analyses were conducted comparing participants receiving 400mg lumacaftor
every 12 hours + 250 mg ivacaftor every 12 hours to an observational registry cohort of
matched controls. These analyses are not reported in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Only the placebo groups from the previous
studies were randomised
Participants randomly assigned (in a 1:1:1
ratio) to 1 of 3 study groups; the randomi-
sation was established by an interactive web
response system
Randomisation was stratified according to
age (< 18 years versus≥ 18 years), sex, and
pulmonary function (% predicted FEV1 at
screening, < 70 versus ≥ 70).
Allocation concealment (selection bias) Low risk Only the placebo groups from the previous
studies were randomised. The randomisa-
tion was established by an interactive web
response system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk These were double-blind studies in which
the participant and study team remained
blinded to the treatment assignments. In-
terventions were matched in appearance
and packaging
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk These were double-blind studies in which
the participant and study team remained
blinded to the treatment assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, all participants
randomised who received at least 1 dose of
study medication were included in analy-
sis. Missing data were investigated in sen-
sitivity analyses
Selective reporting (reporting bias) Low risk All listed outcomes reported in the results.
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Other bias Low risk A ’rate of change’ analysis showed that base-
line characteristics across the groups were
well balanced
Ratjen 2017
Methods Phase 3, placebo-controlled RCT.
Parallel design.
Multicentre: 54 sites in 9 countries (USA, Australia, Belgium,Canada,Denmark, France,
Germany, Sweden, and the UK)
Duration: 24 weeks.
Participants Mutation: all participants were homozygous for the F508del-CFTR mutation
Age: eligibility criteria 6 - 11 years, mean (SD) age was 8.8 (1.6) years
Gender split: 83 males and 121 females.
Lung function: participants must have a FEV1 (% predicted) of 70 or more, and LCI2.5
of 7.5 or more.
Interventions Intervention: lumacaftor 200 mg every 12 hours in combination with ivacaftor 250 mg
every 12 hours
Control: matched placebo.
Outcomes Primary outcome
Mean absolute change in LCI2.5 from baseline at all study visits up to and including
week 24*
Secondary outcomes
Absolute change in BMI up to and including week 24*
Absolute change in CFQ-R respiratory domain score up to and including week 24*
Absolute change in LCI5.0 up to and including week 24*
Absolute change in sweat chloride up to and including week 24*
Absolute change in FEV1 (% predicted) up to and including week 24*
Relative change in FEV1 (% predicted) up to and including week 24*
Absolute change in BMI-for-age z score up to and including week 24*
Absolute change in weight up to and including week 24*
Absolute change in weight-for-age z score up to and including week 24*
Absolute change in height up to and including week 24*
Absolute change in height-for-age z score up to and including week 24*
Absolute change in TSQM domains up to and including week 24
Time-to-first pulmonary exacerbation up to and including week 24
Event of having at least 1 pulmonary exacerbation up to and including week 24
Number of pulmonary exacerbations up to and including week 24
Number of participants with adverse events and serious adverse events up to week 24*
Funding source Vertex Pharmaceuticals.
Notes * denotes outcomes relevant to this review.
Analyses were performed as the absolute change from baseline (including all measure-
ments up to and includingweek 24, both on-treatmentmeasurements andmeasurements
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after treatment discontinuation) - was based on a MMRM, adjusted for the baseline
measurement of the outcome, baseline weight (less than 25 kg versus 25 kg or over and
baseline FEV1 (% predicted) (less than 90% compared to 90% or more), with treatment-
by-visit interaction as fixed effects, participant as a random effect
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Blocked randomisation was performed via
an interactive web response system, strati-
fied by baseline weight and FEV1 (% pre-
dicted).
Allocation concealment (selection bias) Low risk Randomisationwas performed centrally via
the interactive web response system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinding was achieved by using
placebo tablets visually identical to the test
product
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not stated whether outcome assess-
ment was blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were reported and an ITT
approachwas taken to analysis, with all ran-
domised participants who received at least
1 dose of the study drug included in anal-
ysis (1 participant in each group was ran-
domised but did not receive the study drug)
Selective reporting (reporting bias) High risk Several outcomes which are listed in the
methods (e.g. LCI5.0 , time-to-first pul-
monary exacerbation, absolute change in
TSQM domains) but are not presented in
the results
Other bias Low risk Baseline characteristics were similar across
the 2 groups.
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Methods A pilot, placebo-controlled RCT.
Parallel design.
Single centre.
Duration: 1 week.
Participants Mutation: homozygous for F508del mutation.
Age, mean (SD): participants were eligible if 14 years or older, placebo group 24.8 (4.
9) years; intervention group: 22.3 (5.9) years
Gender split: placebo group 4 males and 5 females; intervention group 5 males and 4
females
Lung function: baseline mean (SD) FVC % predicted placebo group: 65.5 (18.6);
intervention group 73.4 (20.3). Baseline mean (SD) FEV1 % predicted placebo group
47.5 (22.1); intervention group 57.8 (27.2)
Interventions 18 participants were allocated to either intervention or placebo group (9 participants in
each group)
Intervention 1: placebo.
Intervention 2: sodium 4-phenylbutyrate (also known as Buphenyl or 4PBA) 19 g,
orally administered, in 3 daily doses of 6 g, 6 g, and 7 g
Outcomes 1. Changes from baseline in nasal potential difference in 1 week
2. Change from baseline in sweat chloride in 1 week*
3. 4BPA metabolites in plasma and urine after 1 week
4. Side effects*
Funding source NIH and Cystic Fibrosis Foundation.
Notes * denotes outcomes relevant to this review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study article states that “randomization
and blinding were performed by the Johns
Hopkins Hospital Investigational Drug
Pharmacy” but exact method of randomi-
sation has not been described
Allocation concealment (selection bias) Unclear risk Study article states that “randomization
and blinding were performed by the Johns
Hopkins Hospital Investigational Drug
Pharmacy” but exact method of allocation
concealment has not been described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind. Study article
states that “randomization and blinding
were performedby the JohnsHopkinsHos-
pital Investigational Drug Pharmacy” but
exact method of blinding has not been de-
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scribed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as double-blind. Study article
states that “randomization and blinding
were performedby the JohnsHopkinsHos-
pital Investigational Drug Pharmacy” but
exact method of blinding has not been de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere analysedwith 9participants each
group, equivalent to the number originally
randomised
Selective reporting (reporting bias) Low risk Protocol not available and outcome not
presented on the ongoing trials database
(www.clinicaltrials.gov/). Outcomes re-
ported in the ’methods’ were reported in
the ’results’ so selective reporting bias is low
Other bias Low risk “... baseline characteristics between the
groups were similar with respect to age,
gender, pancreatic sufficiency, and baseline
pulmonary function.”
Taylor-Cousar 2017
Methods Placebo-controlled RCT.
Parallel design.
Duration: 24 weeks.
Multicentre in North America and Europe.
Participants 510 participants diagnosed with CF.
Age: inclusion criteria 12 years and older, 23% were aged 12 - 18 years
Mutation: homozygous for F508del.
Gender: 49% female.
Mean FEV1 at baseline: 60% (9.4% had baseline FEV1 < 40% predicted, 2% had
baseline FEV1 > 90% predicted).
Mean baseline sweat chloride: 100.5.
Mean BMI: 21.
Interventions Intervention: 100 mg tezacaftor 1x daily and 150 mg ivacaftor 2x daily.
Control: placebo.
Outcomes Primary outcome
Absolute change in FEV1 % predicted (from baseline through week 24)
Secondary outcomes
Relative change in FEV1 % predicted (from baseline through week 24)
Number of pulmonary exacerbations (through week 24)
Absolute change in BMI (from baseline at week 24)
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Absolute change in CFQ-R respiratory domain score (from baseline through week 24)
Safety and tolerability assessments based on AEs, clinical laboratory values (i.e., haema-
tology, serum chemistry, coagulation studies, vitamin levels, lipid panel, and urinalysis)
, standard 12-lead ECGs, vital signs, pulse oximetry, and spirometry
Time-to-first pulmonary exacerbation (through week 24)
Absolute change in sweat chloride (from baseline through week 24)
Absolute change in BMI z score (from baseline at week 24 (in participants under 20
years of age at time of screening))
Absolute change in body weight (from baseline at week 24)
PK parameters of VX-661, M1-661, M2-661, ivacaftor, and M1-ivacaftor
Absolute change in CFRSD severity score (from baseline through week 24)
Absolute change in duration of physical activity during the day (from baseline through
week 24)
Absolute change in duration of sleep time and sleep quality during the night (from
baseline through week 24)
Absolute change in PSQI score (from baseline through week 24 (in participants under
18 years of age))
Absolute change in QoL assessment (SF-12) physical, mental, and utility component
scores (at weeks 12 and 24)
Absolute change in inflammatory mediators (from baseline at week 24)
Absolute change in sputum microbiology (from baseline at week 24)
Absolute change in serum IRT (from baseline at week 24)
Funding source Vertex Pharmaceuticals.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Statistician separate to study team pro-
duced a list of randomisation codes and al-
locations assigned via web-based interac-
tive system (information provided in on-
line protocol)
Allocation concealment (selection bias) Low risk Web-based interactive system.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Matched placebo - all relevant people
blinded (participants and study personnel)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Matched placebo - all relevant people
blinded (participants and study personnel)
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant who was randomised but did
not receive the trial intervention was ex-
cluded from efficacy and safety analyses.
A further 5 participants who were ran-
domised and received the trial intervention
were found to have an ineligible or un-
confirmed CFTR genotype were excluded
from efficacy analyses. Small numbers of
excluded participants (up to 6 out of 510)
unlikely to have introduced bias
Selective reporting (reporting bias) High risk The following outcomes were measured
(according to the protocol), but not re-
ported
• CF respiratory symptom diary
• Number of minutes of physical
activity daily
• PSQI
• SF12
• Sputum microbiology
• Various outcome analyses related to
exacerbation (number of days with
exacerbation, time-to-first exacerbation,
time to first hospitalisation, number of
days hospitalised with exacerbation,
number of exacerbations requiring IV
therapy, number of days on IV therapy,
time to first IV therapy)
Other bias Low risk Final manuscript written with the assis-
tance of medical writers funded by the
sponsor, however, this is unlikely to have
introduced bias
TRAFFIC 2015
Methods Double-blind, placebo-controlled Phase 3 RCT.
Parallel design.
Multicentre: 90 sites in North America, Australia and Europe
Estimated sample size: 559.
Duration: 24 weeks.
Participants 549 participants with a confirmed diagnosis of CF and stable disease (as judged by the
investigator)
Mean age (range): treatment arm 1 24.7 (12 - 54) years; treatment arm 2 25.5 (12 -
57) years; placebo 25.0 (12 to 64 years)
Gender: 295 (54%) males; 254 (46%) females.
Mutation: homozygous for the F508del mutation.
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Lung function: FEV1 between ≥ 40% and ≤ 90% of predicted normal for age, sex,
and height
Interventions Intervention 1 (n = 183): 600 mg of lumacaftor 1x daily and 250 mg of ivacaftor every
12 hours
Intervention 2 (n = 182): 400 mg of lumacaftor every 12 hours and 250 mg of ivacaftor
every 12 hours
Intervention 3 (n = 184): lumacaftor-matched placebo every 12 hours in combination
with ivacaftor-matched placebo every 12 hours
Outcomes Primary outcome measure
Absolute change in % predicted FEV1 (% predicted) at 24 weeks
Secondary outcome measures
1. Relative change in % predicted FEV1 (% predicted) at 24 weeks
2. Absolute change in BMI at 24 weeks
3. Number of pulmonary exacerbations at 24 weeks
4. Absolute change in CFQ-R respiratory domain score at 24 weeks
5. Absolute change in BMI z score at 24 weeks
6. Absolute change in body weight at 24 weeks
7. Time-to-first pulmonary exacerbation at 24 weeks
8. Event of having at least 1 pulmonary exacerbation through week 24
9. Absolute change in EuroQol 3 Level (EQ 5D 3L) at 24 weeks
10. Absolute change in TSQM domains at 24 weeks
11. Safety and tolerability assessments based on adverse events, clinical laboratory values
(haematology, serum chemistry, coagulation studies, and urinalysis), standard digital
ECGs, ambulatory ECGs, vital signs, and pulse oximetry up to 28 weeks
12. PK parameters of lumacaftor, M28 lumacaftor, ivacaftor, M1 ivacaftor, and M6
ivacaftor at 16 weeks
Funding source Sponsored by Vertex Pharmaceuticals Inc.
Notes Known as TRAFFIC study.
The TRAFFIC and TRANSPORT studies were identical with the following exceptions:
TRAFFIC included ambulatory ECG screening at days 1 and 15 in approximately 165
participants in the USA; TRANSPORT included additional pharmacokinetics assess-
ments performed in approximately 28 adolescents in the USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomly assigned (in a 1:1:1
ratio) to 1 of 3 study groups; the randomi-
sation was established by an interactive web
response system
Randomisation was stratified according to
age (< 18 years versus≥ 18 years), sex, and
pulmonary function (% predicted FEV1
(% predicted) at screening, < 70 versus ≥
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70).
Allocation concealment (selection bias) Low risk The randomisation was established by an
interactive web response system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk These were double-blind studies in which
the participant and study team remained
blinded to the treatment assignments.
Placebo was matched in appearance and
packaging
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk These were double-blind studies in which
the participant and study team remained
blinded to the treatment assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Correct number of participants included in
the analysis (i.e. those who received at least
one dose of the study drug - ITT)
Prior to first dose 10 out of 559 participants
withdrew: 2 withdrew from treatment arm
1; 5 withdrew from treatment arm 2; 3
withdrew from placebo group
Post first dose 25 out of 549 participants
withdrew (with reasons): 11 from treat-
ment arm 1; 10 withdrew from treatment
arm 2; 4 withdrew from placebo group
Selective reporting (reporting bias) High risk Additional data available
on www.clinicaltrials.gov for outcomes not
reported in the final paper such as:
1. absolute change in EQ-5D-3L score
from baseline at week 24;
2. absolute change inTSQMdomains from
baseline at week 24;
3. time to first exacerbation;
4. event of having at least one pulmonary
exacerbation.
Some results had to be extrapolated from
graphical figures, we await confirmation
from the study sponsor of the accuracy of
the results
Investigators state that they measured FVC
(which was not listed as an end-point) and
do not report this in the joint paper
Other bias Low risk Adherence to study treatment was high
and themean compliance rate (determined
by site personnel and ongoing study drug
count) was similar across lumacaftor-iva-
78Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
TRAFFIC 2015 (Continued)
caftor and placebo groups (99.1% versus
98.5%)
TRANSPORT 2015
Methods Double-blind, placebo-controlled Phase 3 RCT.
Parallel design.
Multicentre: 82 sites in North America, Australia and Europe
Estimated sample size: 563.
Duration: 24 weeks.
Participants 559 participants with confirmed diagnosis of CF and with stable disease (as judged by
the investigator)
Mean age (range): treatment arm 1 24.3 (12 - 48) years; treatment arm 2 25.0 (12 - 54)
years; placebo 25.7 (12 - 55) years
Gender: 268 (48%) males; 291 (52%) females.
Mutation: homozygous for the F508del mutation.
Lung function: FEV1 (% predicted) between ≥ 40% and ≤ 90% of predicted normal
for age, sex, and height
Interventions Intervention 1: 600 mg of lumacaftor 1x daily and 250 mg of ivacaftor every 12 hours
for 24 weeks
Intervention 2: 400 mg of lumacaftor every 12 hours and 250 mg of ivacaftor every 12
hours for 24 weeks
Intervention 3: placebo.
Outcomes Primary outcome measure
Absolute change in % predicted FEV1 (% predicted) at 24 weeks
Secondary outcome measures
1. Relative change in % predicted FEV1 (% predicted) at 24 weeks
2. Absolute change in BMI at 24 weeks
3. Number of pulmonary exacerbations at 24 weeks
4. Absolute change in CFQ-R respiratory domain score at 24 weeks
5. Absolute change in BMI z score at 24 weeks
6. Absolute change in body weight at 24 weeks
7. Time-to-first pulmonary exacerbation at 24 weeks
8. Event of having at least 1 pulmonary exacerbation at week 24
9. Absolute change in EQ 5D 3L at 24 weeks
10. Absolute change in TSQM domains at 24 weeks
11. Safety and tolerability assessments based on adverse events, clinical laboratory values
(haematology, serum chemistry, coagulation studies, and urinalysis), standard digital
ECGs, ambulatory ECGs, vital signs, and pulse oximetry up to 28 weeks
12. PK parameters of lumacaftor, M28 lumacaftor, ivacaftor, M1 ivacaftor, and M6
ivacaftor at 16 weeks
Funding source Sponsored by Vertex Pharmaceuticals Inc.
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Notes Known as TRANSPORT study.
The TRAFFIC and TRANSPORT studies were identical with the following exceptions:
TRAFFIC included ambulatory ECG screening at days 1 and 15 in approximately 165
participants in the USA; TRANSPORT included additional pharmacokinetics assess-
ments performed in approximately 28 adolescents in the USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomly assigned (in a 1:1:1
ratio) to 1 of 3 study groups; the randomi-
sation was established by an interactive web
response system
Randomisation was stratified according to
age (< 18 years versus≥ 18 years), sex, and
pulmonary function (% predicted FEV1
(% predicted) at screening, < 70 versus ≥
70).
Allocation concealment (selection bias) Low risk The randomisation was established by an
interactive web response system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk These were double-blind studies in which
the participant and study team remained
blinded to the treatment assignments.
Placebo was matched in appearance and
packaging
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk These were double-blind studies in which
the participant and study team remained
blinded to the treatment assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Correct number of participants included in
the analysis (i.e. those who received at least
one dose of the study drug - ITT)
Prior to first dose 4 out of 563 participants
withdrew: 2 withdrew from treatment arm
1; 2 withdrew from treatment arm 2; none
withdrew from placebo group
Post first dose 29 out of 559 participants
withdrew (with reasons): 9 from treatment
arm 1; 15 withdrew from treatment arm 2;
5 withdrew from placebo group
Selective reporting (reporting bias) High risk Additional data available
on www.clinicaltrials.gov for outcomes not
reported in the final paper such as:
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1. absolute change in EQ-5D-3L score
from baseline at week 24;
2. absolute change inTSQMdomains from
baseline at week 24;
3.. time to first exacerbation;
4. event of having at least 1 pulmonary ex-
acerbation.
Some results had to be extrapolated from
graphical figures, we await confirmation
from the study sponsor of the accuracy of
the results
Investigators state that they measured FVC
(which was not listed as an end-point) and
do not report this in the joint paper
Other bias Low risk Adherence to study treatment was high
and themean compliance rate (determined
by site personnel and ongoing study drug
count) was similar across lumacaftor-iva-
caftor and placebo groups (99.1% versus
98.5%)
Zeitlin 2002
Methods Phase 1/2 placebo-controlled RCT.
Parallel design.
Single centre.
Duration: 1 week.
This study follows on from a pilot study (see above) (Rubenstein 1998).
Participants 19 participants were supposed to be randomised in a 3:1 ratio to either study drug or
placebo. Randomisation to 40 g group discontinued due to safety reasons; therefore 6
participants were allocated to the 20 g and 30 g groups, 3 to the 40 g group and 4 to
the placebo group. It is unclear why only 4 participants were randomised to the placebo
group
Mutation: all participants were homozygous for the F508del mutation.
Age: mean (SD) age of 28.5 years.
Gender split: 12 males and 7 females.
Lung function: mean (SD) FEV1 % predicted of 63.7 (17.0).
Nutritional status: mean (SD) weight 62.6 (17.0) kg.
Interventions Intervention 1: placebo.
Intervention 2: 4-phenylbutyrate (4PBA) 20 g.
Intervention 3: 4-phenylbutyrate (4PBA) 30 g.
Intervention 4: 4-phenylbutyrate (4PBA) 40 g.
All active interventions split into 3 daily doses.
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Outcomes 1. Nasal epithelial chloride transport measured by nasal potential difference
2. Adverse events*
3. Absolute values in sweat chloride concentrations
4. Hepatic enzyme profile
5. Uric acid levels
6. Change from baseline in pulmonary function (% predicted FEV1 (% predicted))
7. Semi-quantitative scoring of sputum microbiology
Funding source Cystic Fibrosis Foundation.
Notes * denotes outcomes relevant to this review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated as randomised but it is not clear how
this was conducted
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Escalation to the next dose level was pre-
ceded by an examination of the safety pro-
file of the preceding dose. Therefore, study
personnel would have been aware of treat-
ment allocation
Also between the 3 intervention groups,
participants received a different number of
tablets and had different dosage schedules:
• 20 g daily dose was divided into 13
tablets to be taken in the morning and
afternoon and 14 tablets to be taken in
the evening;
• 30 g daily dose was divided into 20
tablets to be taken in the morning,
afternoon and evening;
• 40 g daily dose was initially
prescribed as 27 tablets to be taken in the
morning and afternoon and 26 tablets to
be taken in the evening.
Therefore it is unlikely that study person-
nel blinding and participant blinding was
maintained throughout the study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk There was insufficient information on how
outcome assessor blind was maintained
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All 19 participants completed the final
study visit, but it is unclear how many par-
ticipants were used in the analysis
Selective reporting (reporting bias) High risk Protocol not available. Pulmonary function
or microbiology scores at day 7 not re-
ported
Other bias Low risk “There were no significant differences in
gender, baseline age, weight, or FEV1 (%
predicted) among participants in the four
groups.”
AE: adverse event
BMI: body mass index
CF: cystic fibrosis
CFQ-R: Cystic Fibrosis Questionnaire-Revised
CFRSD: Cystic Fibrosis Respiratory Symptom Diary
CPX: 8-cyclopentyl-1, 3-dipropylxanthine
ECG: electrocardiograms
EQ 5D 3L: EuroQol 3 Level
FEF25−75%: forced expiratory flow
FEV1: forced expiratory volume in one second
FVC: forced vital capacity
IRT: immunoreactive trypsinogen
ITT: intention to treat
IV: intravenous
LCI: lung clearance index
mEq/L: millequivalents/L
MMRM: mixed effects model for repeated measurements
NIH: National Institutes of Health
PK: pharmacokinetic
PSQI: Pittsburgh Sleep Quality Index
QoL: quality of life
RCT: randomised controlled trial
SAE: serious adverse event
TSQM: Treatment Satisfaction Questionnaire for Medication
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Berkers 2014 Cross-over study with participants with gating defects and not a class II defect
Chadwick 1998 Investigators informed review authors that study was not randomised
Chilvers 2017 Single-group assignment.
Lebecque 2011 Cross-over design.
Leonard 2012 Cross-over design.
NCT01899105 Cross-over design.
Nick 2014 Cross-over study assessing CFTR mutations eligible for treatment with ivacaftor (not relevant to this review)
Rowe 2017 Cross-over design.
Rubenstein 2006 Participants were not randomised.
Sumner 2014 Gene therapy study, not a mutation-specific therapy.
Ziady 2015 Laboratory study conducted within cells donated by CF and non-CF donors. Not a study of people with CF
CF: cystic fibrosis
CFTR: cystic fibrosis transmembrane conductance regulator
Characteristics of studies awaiting assessment [ordered by study ID]
Hunt 2017
Methods Randomised placebo-controlled trial.
Duration: 4-week treatment period.
Participants 18 adults with mild to moderate CF who were homozygous for the f508-del mutation, and who were receiving
lumacaftor-ivacaftor combination therapy
Baseline characteristics:
Mean (SD) age: 28.7 (6.6) years.
Gender split: 65% (11/18) were female.
Mean (SD) % predicted FEV1: 85.2 (12.9)%.
Mean (SD) BMI: 23.2 (6.6).
Interventions Intervention: 40 mg sildenafil 3x daily.
Control: matched placebo.
84Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hunt 2017 (Continued)
Outcomes Sweat chloride, % predicted FEV1, BMI, exhaled nitric oxide, CFQR, nasal potential difference, LCI
Notes Presented as a poster at the 31st Annual North American Cystic Fibrosis Conference, Indianapolis, November 2017
Supported by NIH/NHLBI and NIH/NCRR Colorado CTSI Grant Number UL1 RR025780
NCT01132482.
BMI: body mass index
CF: cystic fibrosis
CFQR: cystic fibrosis questionnaire - revised
FEV1: forced expiratory volume in one second
LCI: lung clearance index
Characteristics of ongoing studies [ordered by study ID]
Meijer 2016
Trial name or title Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the
F508del-CFTR Mutation (ROSCO-CF)
Methods Phase 2, dose-ranging, multicentre, double-blind, placebo-controlled RCT
Duration: 3 months.
Multicentre study conducted in France.
Participants 36 adults with CF carrying 2 CF-causing mutations with at least 1 F508del-CFTR mutation and chronically
infected with Pseudomonas aeruginosa.
Interventions Roscovitine 200 mg or 400 mg compared to placebo.
Outcomes Primary outcome measure
Safety of increasing doses of roscovitine
Secondary outcome measures
Change in the concentration of P aeruginosa
Change in the concentration (CFU/mL) of P aeruginosa in the sputum at each visit from V1 (screening) up
to V7 (completion visit)
PK parameters: Cmax, time to reach Cmax, AUC (AUCt and AUCInf ), half-life (t1/2) for roscovitine and
its M3 metabolite
Pro- and anti-inflammatory cytokines
Change in C-reactive protein at each visit from V1 (screening) up to V7 (completion)
Change in CFQ-R at each visit from V1 up to V8 (safety follow-up)
Change in BMI at each visit from V1 (screening) up to V7 (completion visit)
Change in FEV1 at each visit from V1 (screening) up to V7 (completion visit)
Change in sweat chloride concentration at V2, V3, V5 and V7 (Completion)
Change in nasal potential difference at V1 (screening) and V6 (for participants included in Paris Cochin CF
Center)
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Pain questionnaire
Starting date February 2016.
Contact information Principle investigator: Dr Gilles Rault (gilles.rault@perharidy.fr).
Notes Estimated study completion date: October 2017.
Estimated primary completion date: August 2017 (Final data collection date for primary outcome measure)
NCT02070744
Trial name or title Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic
Fibrosis, Homozygous for the F508del-CFTR Mutation
Methods Double-blind, placebo-controlled, 3-part Phase 2 RCT.
Parallel design.
Multicentre: 20 sites.
Sample size: expected to enrol 40 participants.
Duration: 12 weeks of treatment.
Participants Age: 18 years or older.
Gender: both male and female.
Mutation: homozygous for the F508del mutation.
Lung function: FEV1 ≥ 40% and ≤ 90% of predicted normal for age, sex, and height
Participants must have stable CF disease as judged by the investigator
Interventions Experimental Group 1
Treatment: VX-661 + ivacaftor (every 12 hours schedule).
Control: VX-661 placebo + ivacaftor placebo (every 12 hours schedule)
Experimental Group 2
Treatment: VX-661 + ivacaftor (once daily and schedule).
Control: VX-661 placebo + ivacaftor placebo (once daily and schedule)
Outcomes Primary outcome measure
1. Safety as determined by AEs, physical examination, clinical laboratory values, standard digital ECGs, vital
signs and pulse oximetry at 16 weeks
Secondary outcome measures
1. Absolute change in % predicted FEV1 at 12 weeks
2. Relative change in % predicted FEV1 at 12 weeks
3. Absolute change in body weight at 12 weeks
4. Absolute change in BMI at 12 weeks
5. Absolute change in the respiratory domain of the CFQ-R at 12 weeks
6. PK parameters estimates of VX-661 and ivacaftor and their respective metabolites, derived from plasma
concentration-time data at 16 weeks
7. Absolute change in sweat chloride at 12 weeks
Starting date March 2014.
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Contact information No contact information provided.
Notes This study is listed as completed but no results are available on www.clinicaltrials.gov.
Sponsored by Vertex Pharmaceuticals Inc.
NCT02323100
Trial name or title Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis) (GPBA)
Methods Double-blind, placebo-controlled, 3-part Phase 2 RCT.
Parallel design.
Multicentre: 3 sites.
Sample size: expected to enrol 36 participants.
Duration: 7 days of treatment.
Participants Inclusion criteria
Age/gender: male or female ≥ 18 years of age.
Mutation: homozygous for F508del, and taking pancreatic enzyme replacement therapy
Lung function: FEV1 > 30% of predicted normal for age, gender, and height (Hankinson standards)
Interventions Low-dose glycerol phenylbutyrate versus high-dose glycerol phenylbutyrate versus placebo
Outcomes Primary outcome
Change in average measurement of nasal potential difference between day 7 and baseline (at 7 days)
Secondary outcomes
Change from baseline in other nasal potential difference measures (baseline potential difference, change in
amiloride, low chloride, and low chloride plus isoproterenol) (at 4 days, 7 days and 14 days)
Change from baseline in sodium and chloride transport
Change from baseline in average sweat chloride measurement (at 4 days, 7 days and 14 days)
Change from baseline in sweat chloride
Safety and tolerability (standard safety and tolerability lab values) (at 14 days)
Starting date December 2017.
Contact information Britany Zeglin (bzeglin1@jhmi.edu).
Notes
NCT02412111
Trial name or title A Phase 3 Study of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and OlderWith Cystic
Fibrosis, Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated
to be Clinically Responsive to Ivacaftor
Methods Double-blind, placebo-controlled Phase 2 RCT.
Parallel design.
Multicentre: 68 centres.
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Sample size: expected to enrol 156 participants.
Duration: unclear duration of treatment.
Participants Age: 12 years and older
Mutation: heterozygous for F508del-CFTR mutation and a second CFTR allele with a gating defect that is
clinically demonstrated to be ivacaftor responsive
Lung function: FEV1 ≥ 40% and ≤ 90% of predicted.
Interventions This study is evaluating VX-661 in combination with ivacaftor versus placebo with ivacaftor
GROUP 1: morning VX-661 100 mg/ivacaftor 150 mg fixed-dose tablet with ivacaftor matching placebo
tablet; evening ivacaftor 150 mg tablet
GROUP2: morningVX-661/ivacaftormatching placebo tablet plus ivacaftor 150mg tablet; evening ivacaftor
150 mg tablet
Outcomes Primary outcome
Absolute change in % predicted FEV1 (from baseline through week 8)
Secondary outcomes
Relative change in % predicted FEV1 (from baseline through week 8)
Absolute change in sweat chloride (from baseline through week 8)
Absolute change in CFQ-R respiratory domain score (from baseline through week 8)
Number of participants with AEs and serious AEs (up to 4 weeks after receiving last dose)
PK parameters of VX-661, M1-661, ivacaftor, and M1-ivacaftor
Starting date June 2015.
Contact information Sponsored by Vertex Pharmaceuticals - no contact details given
Notes
NCT02589236
Trial name or title Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation (SNO-
6)
Methods Double-blind, placebo-controlled, parallel RCT.
Participants Participants must have been treated with lumacaftor-ivacaftor for at least 8 weeks prior to day 1
Age: 18 years and older.
FEV1: 40% - 85% predicted.
Interventions Group 1: cavosonstat 200 mg 2x daily.
Group 2: cavosonstat 400 mg 2x daily.
Group 3: placebo.
Outcomes Primary outcome
Absolute change in FEV1 % predicted (from baseline to 12 weeks)
Secondary outcomes
Relative change in FEV1 % predicted (from baseline to 12 weeks)
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Absolute change in sweat chloride (from baseline to 12 weeks)
Absolute change in CFQ-R (respiratory symptom scale) (from baseline to 16 weeks)
Absolute change in BMI (from baseline to 12 weeks)
Absolute change in Patient Global Impression of Change (patient-reported outcome journal) (from baseline
to 12 weeks)
Incidence of treatment-emergent AEs (including clinical laboratory values, ECG, pulmonary exacerbations,
or vital sign changes) (from baseline to 16 weeks)
Number of pulmonary exacerbations (up to 12 weeks)
Starting date November 2015.
Contact information
Notes
NCT02718495
Trial name or title Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis
Methods Quadruple-blind, placebo-controlled, parallel design 3-arm Phase 2 RCT
Multicentre: 29 centres
Sample size: expected to enrol 136 participants.
Duration: 28 days of treatment.
Part A has 2 groups: the 1st group will enrol adults with CF into a single ascending dose treatment group;
the 2nd group will enrol adults with CF, including those on background treatment with ORKAMBI® and
those not on a CFTR modulator into a multiple ascending dose treatment group
Part B will enrol adults with CF currently on stable ORKAMBI® background therapy for a minimum of 3
months into a Phase II treatment group consisting of 2 cohorts
Part C will enrol adults with CF, including those on background treatment with KALYDECO® and those
not on a CFTR modulator, into a Phase II treatment group consisting of 3 cohorts
Participants Age: 18 years and older.
Mutation: not specified.
Lung function: FEV1 40% - 90% predicted.
Interventions PTI-428 versus placebo.
Outcomes Primary outcome
Safety and tolerability as assessed by adverse events, pulmonary function tests, safety labs (haematology,
chemistry, and urinalysis, ECGs, physical examinations, and vital signs)
Secondary outcomes
PK and pharmacodynamic parameters
Change in FEV1
Change in sweat chloride
Change in weight
Change in CFQ-R
Change in nasal epithelial CFTR mRNA and protein expression
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Starting date November 2017.
Contact information
Notes
NCT02730208
Trial name or title A Phase 2, Randomized, Placebo-Controlled, Double-blind Study to Evaluate the Effect of VX-661 in
Combination With Ivacaftor on Chest Imaging Endpoints in Subjects Aged 12 Years and Older With Cystic
Fibrosis, Homozygous for the F508del CFTR Mutation
Methods Placebo-controlled, double-blind Phase 2 RCT.
Participants 12 years and older.
Homozygous for F508del CFTR mutation.
Stable CF disease as judged by the investigator.
FEV1 ≥ 40% and≤ 90% of predicted; ≥ 70% of predicted normal for age, sex, and height during screening
Interventions Group 1: morning dose VX-661 100 mg/ivacaftor 150 mg and an evening dose (approximately 12 hours
after the morning dose) ivacaftor 150 mg
Group 2: placebo.
Outcomes Primary outcome
Change in CT imaging score (from baseline to week 72)
Secondary outcomes
Safety and tolerability assessments including number of participants with AEs and serious AEs (up to week
72)
Starting date September 2016.
Contact information Unclear of individual to contact - study conducted by Vertex Pharmaceuticals
Notes
NCT02951195
Trial name or title A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
Methods Double-blind, placebo and active-controlled, parallel group, multicentre Phase 2 RCT
Participants Inclusion criteria
Body weight ≥ 35 kg.
Sweat chloride value ≥ 60 mmol/L from test results obtained during screening
CFTR genotype: Cohorts 1A, 1B, 1C are heterozygous for F508del and a minimal function mutation known
or predicted not to respond to tezacaftor and/or ivacaftor; Cohorts 2A, 2B are homozygous for F508del
FEV1 ≥ 40% and ≤ 90% of predicted normal for age, sex, and height at the screening visit
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Stable CF disease as judged by the investigator.
Interventions Initial cohort: VX-152 100 mg administered every 12 hours, tezacaftor 100 mg 1x daily, ivacaftor 150 mg
every 12 hours versus placebo (i.e. no active VX-152, tezacaftor, or ivacaftor)
Subsequent cohorts: same combination with different doses of VX-152, adjusted as the study progresses
Outcomes Primary outcome
AEs and serious AEs (up to 8 weeks)
Secondary outcomes
Absolute change in sweat chloride concentrations (from baseline to day 15)
Absolute change in % predicted FEV1 (from baseline to day 15)
Relative change in % predicted FEV1 (from baseline to day 15)
Absolute change in CFQ-R respiratory domain score (from baseline to day 15)
PK and pharmacodynamic parameters
Starting date November 2016.
Contact information Vertex Pharmaceuticals (medicalinfo@vrtx.com).
Notes
NCT03093714
Trial name or title A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects
Methods Multicentre (14 sites), placebo-controlled, dose-escalation RCT
Participants Inclusion criteria
Male and female participants with CF.
Age 18 and above on the date of informed consent.
Weight ≥ 40 kg.
Homozygous for the F508del-CFTR mutation.
Interventions Group 1: FDL 169 test formulation at 3 doses (dose escalation).
Group 2: placebo.
Outcomes Primary outcome
Treatment-emergent AEs (up to 28 days)
Secondary outcomes
PK parameters
Starting date August 2017.
Contact information Jingwen Chai, Flatley Discovery Laboratory (jingwen.chai@flatleydiscoverylab.com).
Notes
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NCT03150719
Trial name or title A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -
Experienced Subjects With Cystic Fibrosis (CF)
Methods Double-blind, placebo-controlled, 3-part Phase 3b RCT.
Parallel design.
Multicentre: 32 centres.
Sample size: expected to enrol 90 participants.
Duration: 28 days of treatment.
Participants Age: 12 years and older.
Mutation: homozygous for F508del mutation.
Lung function: FEV1 ≥ 25% and ≤ 90% of predicted.
Interventions Group 1: tezacaftor 100 mg plus ivacaftor 150mg fixed-dose combination tablet in themorning plus ivacaftor
150 mg tablet in the evening
Group 2: placebo.
Outcomes Primary outcome
Respiratory AEs (at day 56)
Secondary outcomes
Absolute change in % predicted FEV1 (from baseline to the average of the day 28 and day 56 measurements)
Relative change in % predicted FEV1 (from baseline to the average of the day 28 and day 56 measurements)
Absolute change in CFQ-R respiratory domain score % predicted FEV1 (from baseline to the average of the
day 28 and day 56 measurements)
Tolerability (defined as the number and proportion of study participants who discontinue treatment) (up to
day 56)
AEs and serious AEs (AEs, abnormal laboratory values, vital signs or pulse oximetry) (safety follow-up (up to
28 days after last dose of study drug))
Starting date April 2017.
Contact information Vertex Pharmaceuticals (medicalinfo@vrtx.com).
Notes
NCT03224351
Trial name or title A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis
Methods Double-blind, placebo- and tezacaftor-ivacaftor (TEZ/IVA)-controlled, parallel design, 3-part, multicentre
Phase 2 RCT
Participants Inclusion criteria
Body weight ≥ 35 kg.
CFTR genotype: Part 1 and Part 3 - heterozygous for F508del and an MF mutation (F/MF); Part 2 -
homozygous for F508del (F/F)
FEV1 value ≥ 40% and ≤ 90% of predicted mean for age, sex, and height
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NCT03224351 (Continued)
Interventions Group 1: VX-659 4x daily with tezacaftor and ivacaftor for 4 weeks (80 mg, 240 mg, or 400 mg)
Group 2: placebo.
Outcomes Primary outcome
Safety and tolerability as assessed by number of participants with AEs and serious AEs (up to 20 weeks)
Absolute change in FEV1 % predicted (from baseline to day 29)
Secondary outcomes
Absolute change in sweat chloride concentrations (from baseline through day 29)
Relative change in FEV1 % predicted
Absolute change in CFQ-R respiratory domain score (from baseline at day 29)
PK and pharmacodynamic parameters
Starting date August 2017.
Contact information Vertex Pharmaceuticals (medicalinfo@vrtx.com).
Notes
NCT03227471
Trial name or title A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
Methods First-in-human, proof-of-concept RCT.
Parallel design.
Multicentre: 38 centres
Sample size: expected to enrol 224 participants.
Duration: 4 weeks of treatment.
The study includes 6 parts, of which the first 3 are conducted in healthy participants, and the last 3 in people
with CF
Participants Inclusion criteria
Age: 18 years and older.
Mutation: heterozygous for F508del and an MF mutation (F/MF), or Homozygous for F508del (F/F)
Lung function: FEV1 value ≥ 40% and ≤ 90% of predicted mean for age, sex, and height
Interventions Group 1: VX-445 in triple combination with tezacaftor and VX-561 for 4 weeks
Group 2: placebo.
Outcomes Primary outcomes
Safety and tolerability as assessed by number of participants with AEs and serious AEs
Absolute change in FEV1 % predicted (Parts D, E, and F only) (from baseline through day 29)
Secondary outcomes
Absolute change in sweat chloride concentrations (from baseline through day 29)
Relative change in FEV1 % predicted (from baseline through day 29)
Absolute change in CFQ-R respiratory domain score (from baseline through day 29)
Starting date January 2017.
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NCT03227471 (Continued)
Contact information Vertex Pharmaceuticals (medicalinfo@vrtx.com).
Notes
NCT03258424
Trial name or title Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on
KALYDECO® as Background Therapy
Methods Phase 1 placebo-controlled RCT.
Parallel design.
2 centres.
Sample size: expected to enrol 16 participants.
Duration: 14 days of treatment.
Participants Inclusion criteria
Age: 18 years and older.
Mutation: taking ivacaftor but no specific mutations specified as eligible/ineligible
Lung function: FEV1 40% - 90% predicted.
Interventions Group 1: 1x daily dosing of PTI-428.
Group 2: placebo for 14 days.
All participants continue on ivacaftor.
Outcomes Primary outcome
Safety and tolerability as assessed by adverse events, safety labs, ECGs, physical examinations, and vital signs
(at day 21)
Secondary outcomes
t1/2 of multiple oral doses (change from baseline to day 21)
Tmax of multiple oral doses (change from baseline to day 21)
Cmax of multiple oral doses (change from baseline to day 21)
AUC0-t of multiple oral doses (change from baseline to day 21)
Other outcomes
Nasal epithelial mRNA and protein expression over time (change from baseline to day 21)
Sweat chloride (change from baseline to day 21)
FEV1 (change from baseline to day 21)
Weight (change from baseline to day 21)
Starting date July 2017.
Contact information Proteostasis Clinical Trials (pticlinicaltrials@proteostasis.com).
Notes
AE: adverse event
AUC: area under the curve
BMI: body mass index
94Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CF: cystic fibrosis
CFTR: cystic fibrosis transmembrane conductance regulator
CFU: colony forming units
CFQ-R: Cystic Fibrosis Questionnaire-Revised
Cmax: maximum concentration
CT: computer tomography
ECG: electrocardiograms
FEV1: forced expiratory volume in one second
PK: pharmacokinetic
RCT: randomised controlled trial
TSQM: Treatment Satisfaction Questionnaire for Medication
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D A T A A N D A N A L Y S E S
Comparison 1. Lumacaftor versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 % predicted (absolute
change from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 At 14 days 1 61 Mean Difference (IV, Fixed, 95% CI) -1.90 [-4.13, 0.33]
2 Adverse effects: 100 mg and
200 mg lumacaftor groups
(combined data) versus placebo
1 Odds Ratio (M-H, Fixed, 99% CI) Subtotals only
2.1 Cough 1 53 Odds Ratio (M-H, Fixed, 99% CI) 1.28 [0.28, 5.92]
2.2 Headache 1 53 Odds Ratio (M-H, Fixed, 99% CI) 1.13 [0.16, 8.04]
2.3 Rales 1 53 Odds Ratio (M-H, Fixed, 99% CI) 3.2 [0.18, 57.82]
2.4 Productive cough 1 53 Odds Ratio (M-H, Fixed, 99% CI) 1.79 [0.27, 11.98]
2.5 Dyspnoea 1 53 Odds Ratio (M-H, Fixed, 99% CI) 3.2 [0.18, 57.82]
2.6 Pulmonary exacerbation 1 53 Odds Ratio (M-H, Fixed, 99% CI) 1.5 [0.16, 14.31]
2.7 Fatigue 1 53 Odds Ratio (M-H, Fixed, 99% CI) 1.21 [0.12, 12.09]
2.8 Fever 1 53 Odds Ratio (M-H, Fixed, 99% CI) 1.5 [0.16, 14.31]
2.9 Nasal congestion 1 53 Odds Ratio (M-H, Fixed, 99% CI) 0.58 [0.07, 4.93]
2.10 Wheezing 1 53 Odds Ratio (M-H, Fixed, 99% CI) 0.13 [0.01, 2.91]
2.11 Diarrhoea 1 53 Odds Ratio (M-H, Fixed, 99% CI) 0.27 [0.02, 3.31]
2.12 Oropharyngeal pain 1 53 Odds Ratio (M-H, Fixed, 99% CI) 0.27 [0.02, 3.31]
2.13 Upper respiratory tract
infection
1 53 Odds Ratio (M-H, Fixed, 99% CI) 1.45 [0.07, 31.52]
2.14 Sinus congestion 1 53 Odds Ratio (M-H, Fixed, 99% CI) 0.21 [0.01, 5.55]
2.15 Respiration abnormal 1 53 Odds Ratio (M-H, Fixed, 99% CI) 4.85 [0.10, 243.04]
2.16 Haemoptysis 1 53 Odds Ratio (M-H, Fixed, 99% CI) 0.44 [0.03, 6.54]
2.17 Constipation 1 53 Odds Ratio (M-H, Fixed, 99% CI) 2.54 [0.04, 147.25]
2.18 Abdominal pain 1 53 Odds Ratio (M-H, Fixed, 99% CI) 0.46 [0.01, 18.95]
2.19 Myalgia 1 53 Odds Ratio (M-H, Fixed, 99% CI) 0.46 [0.01, 18.95]
2.20 Post-tussive vomiting 1 53 Odds Ratio (M-H, Fixed, 99% CI) 2.54 [0.04, 147.25]
2.21 Nausea 1 53 Odds Ratio (M-H, Fixed, 99% CI) 1.48 [0.02, 106.10]
2.22 Nasopharyngitis 1 53 Odds Ratio (M-H, Fixed, 99% CI) 3.66 [0.07, 193.30]
2.23 Dizziness 1 53 Odds Ratio (M-H, Fixed, 99% CI) 3.66 [0.07, 193.30]
2.24 Back pain 1 53 Odds Ratio (M-H, Fixed, 99% CI) 1.48 [0.02, 106.10]
2.25 Upper abdominal pain 1 53 Odds Ratio (M-H, Fixed, 99% CI) 1.45 [0.07, 31.52]
2.26 Sputum abnormal 1 53 Odds Ratio (M-H, Fixed, 99% CI) 1.48 [0.02, 106.10]
2.27 Epistaxis 1 53 Odds Ratio (M-H, Fixed, 99% CI) 0.94 [0.04, 24.27]
2.28 C-reactive protein
increased
1 53 Odds Ratio (M-H, Fixed, 99% CI) 2.54 [0.04, 147.25]
2.29 Paranasal sinus
hypersecretion
1 53 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
2.30 Lung hyperinflation 1 53 Odds Ratio (M-H, Fixed, 99% CI) 2.54 [0.04, 147.25]
3 Adverse effects: 200 mg
lumacaftor group versus
placebo at 14 days
1 Odds Ratio (M-H, Fixed, 99% CI) Subtotals only
3.1 Cough 1 62 Odds Ratio (M-H, Fixed, 99% CI) 3.43 [0.19, 60.73]
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3.2 Pulmonary exacerbation 1 62 Odds Ratio (M-H, Fixed, 99% CI) 2.72 [0.05, 156.17]
3.3 Oropharyngeal pain 1 62 Odds Ratio (M-H, Fixed, 99% CI) 2.72 [0.05, 156.17]
3.4 Nasal congestion 1 62 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
3.5 Dizziness 1 62 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
3.6 Prothrombin time
prolonged
1 62 Odds Ratio (M-H, Fixed, 99% CI) 1.59 [0.02, 113.01]
3.7 Upper respiratory tract
infection
1 62 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4 Adverse effects requiring study
drug discontinuation at day 28
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 25 mg lumacaftor 1 35 Odds Ratio (M-H, Fixed, 95% CI) 3.0 [0.11, 78.81]
4.2 50 mg lumacaftor 1 35 Odds Ratio (M-H, Fixed, 95% CI) 3.0 [0.11, 78.81]
4.3 100 mg lumacaftor 1 34 Odds Ratio (M-H, Fixed, 95% CI) 3.18 [0.12, 83.76]
4.4 200 mg lumacaftor 1 36 Odds Ratio (M-H, Fixed, 95% CI) 2.84 [0.11, 74.42]
5 Change from baseline in sweat
chloride concentration after 28
days [mmol/L]
1 Mean Difference (Fixed, 95% CI) Subtotals only
5.1 100 mg lumacaftor 1 34 Mean Difference (Fixed, 95% CI) -6.13 [-12.25, -0.01]
5.2 200 mg lumacaftor 1 36 Mean Difference (Fixed, 95% CI) -8.21 [-14.30, -2.12]
6 Sweat chloride concentration
(mmol/L) (change from
baseline)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 At 14 days 1 51 Mean Difference (IV, Fixed, 95% CI) -2.75 [-7.65, 2.15]
Comparison 2. Cavosonstat (N91115) (200 mg twice daily) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CFQR respiratory domain:
absolute change from baseline
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 At 28 days 1 24 Mean Difference (IV, Fixed, 95% CI) 3.8 [-11.30, 18.90]
2 CFQR eating domain: absolute
change from baseline
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 At 28 days 1 24 Mean Difference (IV, Fixed, 95% CI) 2.4 [-2.75, 7.55]
3 Adverse events occurring in >
10% of participants
1 Odds Ratio (M-H, Fixed, 99% CI) Subtotals only
3.1 Cough 1 26 Odds Ratio (M-H, Fixed, 99% CI) 1.05 [0.13, 8.17]
3.2 Pulmonary exacerbation 1 26 Odds Ratio (M-H, Fixed, 99% CI) 0.26 [0.00, 20.03]
3.3 Chest discomfort 1 26 Odds Ratio (M-H, Fixed, 99% CI) 5.0 [0.08, 308.20]
3.4 Fatigue 1 26 Odds Ratio (M-H, Fixed, 99% CI) 3.0 [0.13, 71.47]
4 Sweat chloride 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 At 28 days 1 24 Mean Difference (IV, Fixed, 95% CI) -3.30 [-9.13, 2.53]
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Comparison 3. N6022 versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 % predicted (relative
change from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 5 mg/day N6022 1 29 Mean Difference (IV, Fixed, 95% CI) -2.0 [-5.31, 1.31]
1.2 10 mg/day N6022 1 28 Mean Difference (IV, Fixed, 95% CI) -1.7 [-4.73, 1.33]
1.3 20 mg/day N6022 1 28 Mean Difference (IV, Fixed, 95% CI) -2.2 [-5.28, 0.88]
1.4 40 mg/day N6022 1 38 Mean Difference (IV, Fixed, 95% CI) -1.0 [-3.06, 1.06]
2 Treatment-emergent adverse
events (mild)
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 5 mg/day N6022 1 29 Odds Ratio (M-H, Fixed, 95% CI) 0.48 [0.10, 2.30]
2.2 10 mg/day N6022 1 28 Odds Ratio (M-H, Fixed, 95% CI) 1.45 [0.28, 7.64]
2.3 20 mg/day N6022 1 28 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.12, 2.88]
2.4 40 mg/day N6022 1 38 Odds Ratio (M-H, Fixed, 95% CI) 1.25 [0.34, 4.59]
3 Treatment-emergent adverse
events (moderate)
1 123 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.41, 2.04]
3.1 5 mg/day N6022 1 29 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.18, 4.90]
3.2 10 mg/day N6022 1 28 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.20, 5.87]
3.3 20 mg/day N6022 1 28 Odds Ratio (M-H, Fixed, 95% CI) 2.71 [0.53, 13.85]
3.4 40 mg/day N6022 1 38 Odds Ratio (M-H, Fixed, 95% CI) 0.25 [0.04, 1.48]
4 Treatment-emergent adverse
events (serious / severe)
1 123 Odds Ratio (M-H, Fixed, 95% CI) 1.37 [0.35, 5.41]
4.1 5 mg/day N6022 1 29 Odds Ratio (M-H, Fixed, 95% CI) 4.5 [0.35, 57.11]
4.2 10 mg/day N6022 1 28 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.02, 17.51]
4.3 20 mg/day N6022 1 28 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.02, 17.51]
4.4 40 mg/day N6022 1 38 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 17.25]
Comparison 4. CPX versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse events occurring in more
than 3% of participants in all
treatment groups (combined
data) versus placebo
1 Odds Ratio (M-H, Fixed, 99% CI) Subtotals only
1.1 Abdominal pain 1 37 Odds Ratio (M-H, Fixed, 99% CI) 0.45 [0.01, 24.92]
1.2 Asthenia 1 37 Odds Ratio (M-H, Fixed, 99% CI) 0.65 [0.01, 39.69]
1.3 Headache 1 37 Odds Ratio (M-H, Fixed, 99% CI) 0.33 [0.01, 17.72]
1.4 Pain 1 37 Odds Ratio (M-H, Fixed, 99% CI) 0.45 [0.01, 24.92]
1.5 Diarrhoea 1 37 Odds Ratio (M-H, Fixed, 99% CI) 0.65 [0.01, 39.69]
1.6 Dizziness 1 37 Odds Ratio (M-H, Fixed, 99% CI) 9.33 [0.32, 268.92]
1.7 Lung disease 1 37 Odds Ratio (M-H, Fixed, 99% CI) 0.45 [0.01, 24.92]
1.8 Rhinitis 1 37 Odds Ratio (M-H, Fixed, 99% CI) 0.45 [0.01, 24.92]
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Comparison 5. 4PBA versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse effects after 1 week 1 Odds Ratio (M-H, Fixed, 99% CI) Subtotals only
1.1 Bad taste in mouth 1 18 Odds Ratio (M-H, Fixed, 99% CI) 0.44 [0.01, 13.44]
1.2 Diarrhoea 1 18 Odds Ratio (M-H, Fixed, 99% CI) 3.35 [0.04, 267.31]
2 Participants requiring study
drug termination or a reduced
dosage
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 30 g 4PBA 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life - Euro Quality
of Life Scale (EuroQol)
5-Dimension-3 Level
(EQ-5D-3L) Index Score
(absolute change from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 At 6 months 2 715 Mean Difference (IV, Fixed, 95% CI) 0.00 [-0.01, 0.02]
2 Quality of life - CFQ-R
respiratory domain (absolute
change from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 At 28 days 2 739 Mean Difference (IV, Fixed, 95% CI) 3.32 [1.13, 5.51]
2.2 At 6 months 2 725 Mean Difference (IV, Fixed, 95% CI) 3.04 [0.76, 5.32]
3 Quality of life - EQ-5D-3L VAS
Score (absolute change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 At 6 months 2 712 Mean Difference (IV, Fixed, 95% CI) 2.24 [0.18, 4.31]
4 FEV1 % predicted (relative
change from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 At 6 months 2 720 Mean Difference (IV, Fixed, 95% CI) 5.63 [3.80, 7.47]
5 FEV1 % predicted (absolute
change from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 At 28 days 2 739 Mean Difference (IV, Fixed, 95% CI) 2.32 [1.34, 3.31]
5.2 At 6 months 2 720 Mean Difference (IV, Fixed, 95% CI) 3.34 [2.30, 4.38]
6 Adverse events by end of study
(at 6 months)
2 Odds Ratio (M-H, Fixed, 99% CI) Subtotals only
6.1 Any adverse event 2 739 Odds Ratio (M-H, Fixed, 99% CI) 1.00 [0.37, 2.71]
6.2 Discontinuation due to an
adverse event
2 739 Odds Ratio (M-H, Fixed, 99% CI) 2.38 [0.67, 8.50]
6.3 At least 1 serious adverse
event
2 739 Odds Ratio (M-H, Fixed, 99% CI) 0.73 [0.47, 1.13]
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6.4 Infective pulmonary
exacerbation
2 739 Odds Ratio (M-H, Fixed, 99% CI) 0.66 [0.45, 0.97]
6.5 Cough 2 739 Odds Ratio (M-H, Fixed, 99% CI) 0.72 [0.49, 1.08]
6.6 Headache 2 739 Odds Ratio (M-H, Fixed, 99% CI) 1.00 [0.59, 1.68]
6.7 Haemoptysis 2 739 Odds Ratio (M-H, Fixed, 99% CI) 1.04 [0.60, 1.81]
6.8 Diarrhoea 2 739 Odds Ratio (M-H, Fixed, 99% CI) 1.18 [0.61, 2.28]
6.9 Abnormal respiration 2 739 Odds Ratio (M-H, Fixed, 99% CI) 1.91 [0.94, 3.88]
6.10 Increased sputum 2 739 Odds Ratio (M-H, Fixed, 99% CI) 0.74 [0.44, 1.24]
6.11 Dyspnoea 2 739 Odds Ratio (M-H, Fixed, 99% CI) 2.05 [1.10, 3.83]
6.12 Nasopharyngitis 2 739 Odds Ratio (M-H, Fixed, 99% CI) 0.55 [0.27, 1.10]
6.13 Oropharyngeal pain 2 739 Odds Ratio (M-H, Fixed, 99% CI) 1.52 [0.80, 2.89]
6.14 Abdominal pain 2 739 Odds Ratio (M-H, Fixed, 99% CI) 0.80 [0.39, 1.62]
6.15 Fatigue 2 739 Odds Ratio (M-H, Fixed, 99% CI) 1.03 [0.51, 2.08]
6.16 Nausea 2 739 Odds Ratio (M-H, Fixed, 99% CI) 1.04 [0.51, 2.11]
6.17 Pyrexia 2 739 Odds Ratio (M-H, Fixed, 99% CI) 1.03 [0.54, 1.98]
6.18 Nasal congestion 2 739 Odds Ratio (M-H, Fixed, 99% CI) 0.73 [0.39, 1.35]
6.19 Upper respiratory tract
infection
2 739 Odds Ratio (M-H, Fixed, 99% CI) 1.21 [0.54, 2.70]
7 Time to first pulmonary
exacerbation
2 739 Hazard Ratio (Fixed, 95% CI) 0.70 [0.57, 0.87]
8 Rate of exacerbations 2 739 Rate Ratio (Fixed, 95% CI) 0.70 [0.57, 0.87]
9 Weight (kg) (absolute change
from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 At 6 months 2 725 Mean Difference (IV, Fixed, 95% CI) 0.80 [0.42, 1.18]
10 BMI (absolute change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 At 28 days 2 739 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.07, 0.09]
10.2 At 6 months 2 725 Mean Difference (IV, Fixed, 95% CI) 0.29 [0.16, 0.43]
Comparison 7. Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life - Euro Quality
of Life Scale (EuroQol)
5-Dimension-3 Level
(EQ-5D-3L) Index Score
(absolute change from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 At 6 months 2 708 Mean Difference (IV, Fixed, 95% CI) 0.00 [-0.01, 0.02]
2 Quality of life - CFQ-R
respiratory domain (absolute
change from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 At 28 days 2 740 Mean Difference (IV, Fixed, 95% CI) 4.13 [1.94, 6.31]
2.2 At 6 months 2 720 Mean Difference (IV, Fixed, 95% CI) 2.18 [-0.11, 4.47]
3 Quality of life - EQ-5D-3L VAS
Score (absolute change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 At 6 months 2 710 Mean Difference (IV, Fixed, 95% CI) 2.30 [0.25, 4.36]
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4 FEV1 % predicted (relative
change from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 At 6 months 2 715 Mean Difference (IV, Fixed, 95% CI) 4.77 [2.93, 6.61]
5 FEV1 % predicted (absolute
change from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 At 28 days 2 740 Mean Difference (IV, Fixed, 95% CI) 2.42 [1.43, 3.40]
5.2 At 6 months 2 715 Mean Difference (IV, Fixed, 95% CI) 2.80 [1.75, 3.84]
6 Adverse events by end of study
(at 6 months)
2 Odds Ratio (M-H, Fixed, 99% CI) Subtotals only
6.1 Any adverse event 2 738 Odds Ratio (M-H, Fixed, 99% CI) 0.77 [0.30, 1.96]
6.2 Discontinuation due to an
adverse event
2 738 Odds Ratio (M-H, Fixed, 99% CI) 2.91 [0.85, 10.03]
6.3 At least 1 serious adverse
event
2 738 Odds Ratio (M-H, Fixed, 99% CI) 0.52 [0.33, 0.83]
6.4 Infective pulmonary
exacerbation
2 738 Odds Ratio (M-H, Fixed, 99% CI) 0.57 [0.39, 0.84]
6.5 Cough 2 738 Odds Ratio (M-H, Fixed, 99% CI) 0.58 [0.39, 0.88]
6.6 Headache 2 738 Odds Ratio (M-H, Fixed, 99% CI) 1.00 [0.59, 1.68]
6.7 Haemoptysis 2 738 Odds Ratio (M-H, Fixed, 99% CI) 1.00 [0.58, 1.74]
6.8 Diarrhoea 2 738 Odds Ratio (M-H, Fixed, 99% CI) 1.51 [0.80, 2.85]
6.9 Abnormal respiration 2 738 Odds Ratio (M-H, Fixed, 99% CI) 1.50 [0.71, 3.14]
6.10 Increased sputum 2 738 Odds Ratio (M-H, Fixed, 99% CI) 0.73 [0.44, 1.22]
6.11 Dyspnea 2 738 Odds Ratio (M-H, Fixed, 99% CI) 1.75 [0.93, 3.32]
6.12 Nasopharyngitis 2 738 Odds Ratio (M-H, Fixed, 99% CI) 1.23 [0.68, 2.21]
6.13 Oropharyngeal pain 2 738 Odds Ratio (M-H, Fixed, 99% CI) 0.78 [0.38, 1.63]
6.14 Abdominal pain 2 738 Odds Ratio (M-H, Fixed, 99% CI) 1.03 [0.53, 2.01]
6.15 Fatigue 2 738 Odds Ratio (M-H, Fixed, 99% CI) 1.19 [0.60, 2.35]
6.16 Nausea 2 738 Odds Ratio (M-H, Fixed, 99% CI) 1.74 [0.91, 3.34]
6.17 Pyrexia 2 738 Odds Ratio (M-H, Fixed, 99% CI) 0.97 [0.50, 1.87]
6.18 Nasal congestion 2 738 Odds Ratio (M-H, Fixed, 99% CI) 0.51 [0.26, 1.02]
6.19 Upper respiratory tract
infection
2 738 Odds Ratio (M-H, Fixed, 99% CI) 1.94 [0.93, 4.08]
7 Time to first pulmonary
exacerbation
2 740 Hazard Ratio (Fixed, 95% CI) 0.61 [0.49, 0.76]
8 Rate of exacerbations 2 740 Rate Ratio (Fixed, 95% CI) 0.61 [0.49, 0.76]
9 Weight (kg) (absolute change
from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 At 6 months 2 723 Mean Difference (IV, Fixed, 95% CI) 0.65 [0.27, 1.03]
10 BMI (absolute change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 At 28 days 2 740 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.06, 0.10]
10.2 At 6 months 2 723 Mean Difference (IV, Fixed, 95% CI) 0.25 [0.12, 0.39]
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Comparison 8. Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life - Euro Quality
of Life Scale (EuroQol)
5-Dimension-3 Level
(EQ-5D-3L) Index Score
(absolute change from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 At 6 months 2 1061 Mean Difference (IV, Fixed, 95% CI) 0.00 [-0.01, 0.01]
2 Quality of life - CFQ-R
respiratory domain (absolute
change from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 At 28 days 2 1108 Mean Difference (IV, Fixed, 95% CI) 3.70 [1.81, 5.58]
2.2 At 6 months 2 1076 Mean Difference (IV, Fixed, 95% CI) 2.62 [0.64, 4.59]
3 Quality of life - EQ-5D-3L VAS
Score (absolute change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 At 6 months 2 1060 Mean Difference (IV, Fixed, 95% CI) 2.28 [0.50, 4.06]
4 FEV1 % predicted (relative
change from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 At 6 months 2 1072 Mean Difference (IV, Fixed, 95% CI) 5.21 [3.61, 6.80]
5 FEV1 % predicted (absolute
change from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 At 28 days 2 1108 Mean Difference (IV, Fixed, 95% CI) 2.37 [1.52, 3.22]
5.2 At 6 months 2 1072 Mean Difference (IV, Fixed, 95% CI) 3.07 [2.17, 3.97]
6 Adverse events by end of study
(at 6 months)
2 Odds Ratio (M-H, Fixed, 99% CI) Subtotals only
6.1 Any adverse event 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 0.87 [0.38, 2.02]
6.2 Discontinuation due to an
adverse event
2 1108 Odds Ratio (M-H, Fixed, 99% CI) 2.65 [0.83, 8.45]
6.3 At least 1 serious adverse
event
2 1108 Odds Ratio (M-H, Fixed, 99% CI) 0.62 [0.42, 0.91]
6.4 Infective pulmonary
exacerbation
2 1108 Odds Ratio (M-H, Fixed, 99% CI) 0.62 [0.44, 0.86]
6.5 Cough 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 0.65 [0.46, 0.92]
6.6 Headache 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 1.00 [0.64, 1.57]
6.7 Haemoptysis 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 1.02 [0.63, 1.65]
6.8 Diarrhea 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 1.34 [0.76, 2.37]
6.9 Abnormal respiration 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 1.70 [0.89, 3.26]
6.10 Increased sputum 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 0.73 [0.47, 1.14]
6.11 Dyspnea 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 1.90 [1.08, 3.35]
6.12 Nasopharyngitis 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 0.87 [0.51, 1.50]
6.13 Oropharyngeal pain 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 1.14 [0.63, 2.06]
6.14 Abdominal pain 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 0.91 [0.51, 1.65]
6.15 Fatigue 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 1.11 [0.61, 2.03]
6.16 Nausea 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 1.38 [0.76, 2.51]
6.17 Pyrexia 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 1.00 [0.57, 1.76]
6.18 Nasal congestion 2 1108 Odds Ratio (M-H, Fixed, 99% CI) 0.62 [0.36, 1.07]
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6.19 Upper respiratory tract
infection
2 1108 Odds Ratio (M-H, Fixed, 99% CI) 1.57 [0.79, 3.11]
7 Weight (kg) (absolute change
from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 At 6 months 2 1081 Mean Difference (IV, Fixed, 95% CI) 0.72 [0.39, 1.05]
8 BMI (absolute change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 At 28 days 2 1108 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.05, 0.08]
8.2 At 6 months 2 1081 Mean Difference (IV, Fixed, 95% CI) 0.27 [0.16, 0.39]
Comparison 9. Lumacaftor (200 mg once daily) for 21 days plus ivacaftor (150 mg twice daily) for days 15 to 21
versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 % predicted (absolute
change from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 At 14 days (before
addition of ivacaftor)
1 41 Mean Difference (IV, Fixed, 95% CI) -1.80 [-4.39, 0.79]
1.2 At 21 days 1 41 Mean Difference (IV, Fixed, 95% CI) 2.80 [-1.39, 6.99]
2 Adverse events occurring in 10%
or more participants (from days
15 - 21)
1 Odds Ratio (M-H, Fixed, 99% CI) Subtotals only
2.1 Cough 1 41 Odds Ratio (M-H, Fixed, 99% CI) 1.06 [0.14, 8.09]
2.2 Pulmonary Exacerbation 1 41 Odds Ratio (M-H, Fixed, 99% CI) 2.22 [0.08, 58.11]
2.3 Oropharyngeal pain 1 41 Odds Ratio (M-H, Fixed, 99% CI) 0.5 [0.02, 13.07]
2.4 Nasal congestion 1 41 Odds Ratio (M-H, Fixed, 99% CI) 0.5 [0.02, 13.07]
2.5 Dizziness 1 41 Odds Ratio (M-H, Fixed, 99% CI) 5.81 [0.10, 341.36]
2.6 Prothrombin time
prolonged
1 41 Odds Ratio (M-H, Fixed, 99% CI) 5.81 [0.10, 341.36]
2.7 Upper respiratory tract
infection
1 41 Odds Ratio (M-H, Fixed, 99% CI) 5.81 [0.10, 341.36]
3 Sweat chloride concentration
(mmol/L) (change from
baseline)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 At 14 days (before
addition of ivacaftor)
1 34 Mean Difference (IV, Fixed, 95% CI) -3.10 [-8.58, 2.38]
3.2 At 21 days 1 33 Mean Difference (IV, Fixed, 95% CI) -5.0 [-11.61, 1.61]
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Comparison 10. Lumacaftor (200 mg once daily) for 21 days plus ivacaftor (250 mg twice daily) for days 15 to
21 versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 % predicted (absolute
change from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 At 14 days (before
addition of ivacaftor)
1 41 Mean Difference (IV, Fixed, 95% CI) -2.0 [-4.66, 0.66]
1.2 At 21 days 1 39 Mean Difference (IV, Fixed, 95% CI) 0.2 [-4.20, 4.60]
2 Adverse events occurring in 10%
or more participants (from days
15 - 21)
1 287 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.26, 3.33]
2.1 Cough 1 41 Odds Ratio (M-H, Fixed, 99% CI) 0.22 [0.01, 4.52]
2.2 Pulmonary Exacerbation 1 41 Odds Ratio (M-H, Fixed, 99% CI) 1.05 [0.03, 44.10]
2.3 Oropharyngeal pain 1 41 Odds Ratio (M-H, Fixed, 99% CI) 1.06 [0.07, 15.89]
2.4 Nasal congestion 1 41 Odds Ratio (M-H, Fixed, 99% CI) 1.68 [0.14, 20.50]
2.5 Dizziness 1 41 Odds Ratio (M-H, Fixed, 99% CI) 3.31 [0.05, 239.61]
2.6 Prothrombin time
prolonged
1 41 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
2.7 Upper respiratory tract
infection
1 41 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
3 Sweat chloride concentration
(mmol/L) (change from
baseline)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 At 14 days (before
addition of ivacaftor)
1 34 Mean Difference (IV, Fixed, 95% CI) -2.40 [-6.00, 3.20]
3.2 At 21 days 1 33 Mean Difference (IV, Fixed, 95% CI) -10.9 [-17.60, -4.20]
Comparison 11. Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life - CFQ-R
respiratory domain (absolute
change from baseline)
1 Mean Difference (Fixed, 95% CI) Subtotals only
1.1 up to and including week
24
1 204 Mean Difference (Fixed, 95% CI) 2.5 [-0.10, 5.10]
2 FEV1 % predicted (absolute
change from baseline)
1 Mean Difference (Fixed, 95% CI) Subtotals only
2.1 up to and including 24
weeks
1 204 Mean Difference (Fixed, 95% CI) 2.4 [0.40, 4.40]
3 LCI2.5 (absolute change from
baseline)
1 Mean Difference (Fixed, 95% CI) Subtotals only
3.1 up to and including 24
weeks
1 204 Mean Difference (Fixed, 95% CI) -1.1 [-1.40, -0.80]
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4 Treatment-emergent adverse
events with incidence > 10% in
any treatment group
1 Odds Ratio (M-H, Fixed, 99% CI) Totals not selected
4.1 Any adverse event 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.2 Any serious adverse event 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.3 Cough 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.4 Pulmonary exacerbation 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.5 Productive cough 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.6 Nasal congestion 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.7 Oropharyngeal pain 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.8 Pyrexia 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.9 Upper abdominal pain 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.10 Headache 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.11 Upper respiratory tract
infection
1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.12 Sputum increased 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.13 Abdominal pain 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.14 Nausea 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.15 Rhinorrhoea 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.16 Vomiting 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.17 Fatigue 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
4.18 Respiratory events 1 Odds Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
5 Sweat chloride concentration
(absolute change from baseline)
1 Mean Difference (Fixed, 95% CI) Subtotals only
5.1 up to and including 4
weeks
1 204 Mean Difference (Fixed, 95% CI) -20.8 [-23.40, -18.
20]
6 BMI (absolute change from
baseline)
1 Mean Difference (Fixed, 95% CI) Subtotals only
6.1 up to and including 24
weeks
1 204 Mean Difference (Fixed, 95% CI) 0.1 [-0.10, 0.30]
7 BMI for age z-score (absolute
change from baseline)
1 Mean Difference (Fixed, 95% CI) Subtotals only
7.1 up to and including 24
weeks
1 204 Mean Difference (Fixed, 95% CI) 0.0 [-0.10, 0.10]
Comparison 12. Lumacaftor (200 mg once daily monotherapy for 14 days) plus ivacaftor (150 mg or 250 mg
twice daily for days 15 to 21) for 21 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 % predicted (absolute
change from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 At 21 days 1 59 Mean Difference (IV, Fixed, 95% CI) 1.57 [-2.13, 5.27]
2 Adverse events occurring in 10%
or more participants (from days
15 - 21)
1 Odds Ratio (M-H, Fixed, 99% CI) Subtotals only
2.1 Cough 1 61 Odds Ratio (M-H, Fixed, 99% CI) 0.61 [0.09, 4.01]
2.2 Pulmonary exacerbation 1 61 Odds Ratio (M-H, Fixed, 99% CI) 1.62 [0.08, 34.55]
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2.3 Oropharyngeal pain 1 61 Odds Ratio (M-H, Fixed, 99% CI) 0.77 [0.07, 9.03]
2.4 Nasal congestion 1 61 Odds Ratio (M-H, Fixed, 99% CI) 1.06 [0.10, 11.04]
2.5 Dizziness 1 61 Odds Ratio (M-H, Fixed, 99% CI) 4.01 [0.08, 209.72]
2.6 Prothrombin time
prolonged
1 61 Odds Ratio (M-H, Fixed, 99% CI) 2.79 [0.05, 160.31]
2.7 Upper respiratory tract
infection
1 61 Odds Ratio (M-H, Fixed, 99% CI) 2.79 [0.05, 160.31]
3 Sweat chloride concentration
(mmol/L) (change from
baseline)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 At 21 days 1 50 Mean Difference (IV, Fixed, 95% CI) -7.95 [-13.81, -2.09]
Comparison 13. Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus either placebo or
ivacaftor (150 mg twice daily) alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CFQ-R respiratory domain
(absolute change from baseline)
1 Mean Difference (Fixed, 95% CI) Subtotals only
1.1 At 4 weeks 1 504 Mean Difference (Fixed, 95% CI) 5.1 [2.99, 7.21]
1.2 At 24 weeks 1 504 Mean Difference (Fixed, 95% CI) 5.1 [3.20, 7.00]
2 FEV1 % predicted (relative
change from baseline)
2 Mean Difference (Fixed, 95% CI) Subtotals only
2.1 At week 4 1 18 Mean Difference (Fixed, 95% CI) 3.72 [-7.77, 15.21]
2.2 At week 24 1 504 Mean Difference (Fixed, 95% CI) 6.80 [5.30, 8.30]
3 FEV1 % predicted (absolute
change from baseline)
2 Mean Difference (Fixed, 95% CI) Subtotals only
3.1 At week 4 2 522 Mean Difference (Fixed, 95% CI) 3.59 [2.40, 4.78]
3.2 At week 24 1 504 Mean Difference (Fixed, 95% CI) 4.0 [3.10, 4.90]
4 Most common adverse events
(occurring in at least 10% of
participants in either group)
2 Odds Ratio (M-H, Fixed, 99% CI) Subtotals only
4.1 Cough 2 527 Odds Ratio (M-H, Fixed, 99% CI) 0.70 [0.43, 1.15]
4.2 Pulmonary exacerbation 2 527 Odds Ratio (M-H, Fixed, 99% CI) 0.71 [0.44, 1.16]
4.3 Headache 2 527 Odds Ratio (M-H, Fixed, 99% CI) 1.26 [0.68, 2.35]
4.4 Nasal congestion or
nasopharyngitis
2 527 Odds Ratio (M-H, Fixed, 99% CI) 1.09 [0.59, 2.02]
4.5 Increased sputum 1 509 Odds Ratio (M-H, Fixed, 99% CI) 0.86 [0.46, 1.63]
4.6 Haemoptysis 2 527 Odds Ratio (M-H, Fixed, 99% CI) 0.74 [0.37, 1.49]
4.7 Pyrexia 2 527 Odds Ratio (M-H, Fixed, 99% CI) 0.89 [0.44, 1.79]
4.8 Oropharyngeal pain 1 509 Odds Ratio (M-H, Fixed, 99% CI) 0.76 [0.35, 1.63]
4.9 Fatigue 2 527 Odds Ratio (M-H, Fixed, 99% CI) 0.51 [0.23, 1.15]
4.10 Nausea 2 527 Odds Ratio (M-H, Fixed, 99% CI) 1.36 [0.60, 3.12]
5 Time to first pulmonary
exacerbation
1 Hazard Ratio (Fixed, 95% CI) Subtotals only
6 Sweat chloride change from
baseline
2 Mean Difference (Fixed, 95% CI) Subtotals only
6.1 At 4 weeks 2 522 Mean Difference (Fixed, 95% CI) -9.24 [-11.12, -7.35]
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6.2 At 24 weeks 1 504 Mean Difference (Fixed, 95% CI) -10.1 [-11.40, -8.80]
7 BMI change from baseline 1 Mean Difference (Fixed, 95% CI) Subtotals only
7.1 At 4 weeks 1 504 Mean Difference (Fixed, 95% CI) -0.03 [-0.13, 0.07]
7.2 At 24 weeks 1 504 Mean Difference (Fixed, 95% CI) 0.06 [-0.08, 0.20]
Analysis 1.1. Comparison 1 Lumacaftor versus placebo, Outcome 1 FEV&subStart;1&subEnd; % predicted
(absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 1 Lumacaftor versus placebo
Outcome: 1 FEV1 % predicted (absolute change from baseline)
Study or subgroup Lumacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 14 days
Boyle 2014 40 -0.2 (4.32615) 21 1.7 (4.174) 100.0 % -1.90 [ -4.13, 0.33 ]
Subtotal (95% CI) 40 21 100.0 % -1.90 [ -4.13, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.095)
-100 -50 0 50 100
Favours placebo Favours lumacaftor
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Analysis 1.2. Comparison 1 Lumacaftor versus placebo, Outcome 2 Adverse effects: 100 mg and 200 mg
lumacaftor groups (combined data) versus placebo.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 1 Lumacaftor versus placebo
Outcome: 2 Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo
Study or subgroup Lumacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Cough
Clancy 2012 17/36 7/17 100.0 % 1.28 [ 0.28, 5.92 ]
Subtotal (99% CI) 36 17 100.0 % 1.28 [ 0.28, 5.92 ]
Total events: 17 (Lumacaftor), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
2 Headache
Clancy 2012 7/36 3/17 100.0 % 1.13 [ 0.16, 8.04 ]
Subtotal (99% CI) 36 17 100.0 % 1.13 [ 0.16, 8.04 ]
Total events: 7 (Lumacaftor), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
3 Rales
Clancy 2012 6/36 1/17 100.0 % 3.20 [ 0.18, 57.82 ]
Subtotal (99% CI) 36 17 100.0 % 3.20 [ 0.18, 57.82 ]
Total events: 6 (Lumacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
4 Productive cough
Clancy 2012 10/36 3/17 100.0 % 1.79 [ 0.27, 11.98 ]
Subtotal (99% CI) 36 17 100.0 % 1.79 [ 0.27, 11.98 ]
Total events: 10 (Lumacaftor), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
5 Dyspnoea
Clancy 2012 6/36 1/17 100.0 % 3.20 [ 0.18, 57.82 ]
Subtotal (99% CI) 36 17 100.0 % 3.20 [ 0.18, 57.82 ]
Total events: 6 (Lumacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
6 Pulmonary exacerbation
Clancy 2012 6/36 2/17 100.0 % 1.50 [ 0.16, 14.31 ]
Subtotal (99% CI) 36 17 100.0 % 1.50 [ 0.16, 14.31 ]
0.001 0.01 0.1 1 10 100 1000
Favours lumacaftor Favours placebo
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(. . . Continued)
Study or subgroup Lumacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 6 (Lumacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
7 Fatigue
Clancy 2012 5/36 2/17 100.0 % 1.21 [ 0.12, 12.09 ]
Subtotal (99% CI) 36 17 100.0 % 1.21 [ 0.12, 12.09 ]
Total events: 5 (Lumacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
8 Fever
Clancy 2012 6/36 2/17 100.0 % 1.50 [ 0.16, 14.31 ]
Subtotal (99% CI) 36 17 100.0 % 1.50 [ 0.16, 14.31 ]
Total events: 6 (Lumacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
9 Nasal congestion
Clancy 2012 4/36 3/17 100.0 % 0.58 [ 0.07, 4.93 ]
Subtotal (99% CI) 36 17 100.0 % 0.58 [ 0.07, 4.93 ]
Total events: 4 (Lumacaftor), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
10 Wheezing
Clancy 2012 1/36 3/17 100.0 % 0.13 [ 0.01, 2.91 ]
Subtotal (99% CI) 36 17 100.0 % 0.13 [ 0.01, 2.91 ]
Total events: 1 (Lumacaftor), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.092)
11 Diarrhoea
Clancy 2012 2/36 3/17 100.0 % 0.27 [ 0.02, 3.31 ]
Subtotal (99% CI) 36 17 100.0 % 0.27 [ 0.02, 3.31 ]
Total events: 2 (Lumacaftor), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
12 Oropharyngeal pain
Clancy 2012 2/36 3/17 100.0 % 0.27 [ 0.02, 3.31 ]
Subtotal (99% CI) 36 17 100.0 % 0.27 [ 0.02, 3.31 ]
Total events: 2 (Lumacaftor), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
13 Upper respiratory tract infection
Clancy 2012 3/36 1/17 100.0 % 1.45 [ 0.07, 31.52 ]
0.001 0.01 0.1 1 10 100 1000
Favours lumacaftor Favours placebo
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(. . . Continued)
Study or subgroup Lumacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 36 17 100.0 % 1.45 [ 0.07, 31.52 ]
Total events: 3 (Lumacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
14 Sinus congestion
Clancy 2012 1/36 2/17 100.0 % 0.21 [ 0.01, 5.55 ]
Subtotal (99% CI) 36 17 100.0 % 0.21 [ 0.01, 5.55 ]
Total events: 1 (Lumacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
15 Respiration abnormal
Clancy 2012 4/36 0/17 100.0 % 4.85 [ 0.10, 243.04 ]
Subtotal (99% CI) 36 17 100.0 % 4.85 [ 0.10, 243.04 ]
Total events: 4 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
16 Haemoptysis
Clancy 2012 2/36 2/17 100.0 % 0.44 [ 0.03, 6.54 ]
Subtotal (99% CI) 36 17 100.0 % 0.44 [ 0.03, 6.54 ]
Total events: 2 (Lumacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
17 Constipation
Clancy 2012 2/36 0/17 100.0 % 2.54 [ 0.04, 147.25 ]
Subtotal (99% CI) 36 17 100.0 % 2.54 [ 0.04, 147.25 ]
Total events: 2 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
18 Abdominal pain
Clancy 2012 1/36 1/17 100.0 % 0.46 [ 0.01, 18.95 ]
Subtotal (99% CI) 36 17 100.0 % 0.46 [ 0.01, 18.95 ]
Total events: 1 (Lumacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
19 Myalgia
Clancy 2012 1/36 1/17 100.0 % 0.46 [ 0.01, 18.95 ]
Subtotal (99% CI) 36 17 100.0 % 0.46 [ 0.01, 18.95 ]
Total events: 1 (Lumacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
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(. . . Continued)
Study or subgroup Lumacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
20 Post-tussive vomiting
Clancy 2012 2/36 0/17 100.0 % 2.54 [ 0.04, 147.25 ]
Subtotal (99% CI) 36 17 100.0 % 2.54 [ 0.04, 147.25 ]
Total events: 2 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
21 Nausea
Clancy 2012 1/36 0/17 100.0 % 1.48 [ 0.02, 106.10 ]
Subtotal (99% CI) 36 17 100.0 % 1.48 [ 0.02, 106.10 ]
Total events: 1 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
22 Nasopharyngitis
Clancy 2012 3/36 0/17 100.0 % 3.66 [ 0.07, 193.30 ]
Subtotal (99% CI) 36 17 100.0 % 3.66 [ 0.07, 193.30 ]
Total events: 3 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
23 Dizziness
Clancy 2012 3/36 0/17 100.0 % 3.66 [ 0.07, 193.30 ]
Subtotal (99% CI) 36 17 100.0 % 3.66 [ 0.07, 193.30 ]
Total events: 3 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
24 Back pain
Clancy 2012 1/36 0/17 100.0 % 1.48 [ 0.02, 106.10 ]
Subtotal (99% CI) 36 17 100.0 % 1.48 [ 0.02, 106.10 ]
Total events: 1 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
25 Upper abdominal pain
Clancy 2012 3/36 1/17 100.0 % 1.45 [ 0.07, 31.52 ]
Subtotal (99% CI) 36 17 100.0 % 1.45 [ 0.07, 31.52 ]
Total events: 3 (Lumacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
26 Sputum abnormal
Clancy 2012 1/36 0/17 100.0 % 1.48 [ 0.02, 106.10 ]
Subtotal (99% CI) 36 17 100.0 % 1.48 [ 0.02, 106.10 ]
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(. . . Continued)
Study or subgroup Lumacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 1 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
27 Epistaxis
Clancy 2012 2/36 1/17 100.0 % 0.94 [ 0.04, 24.27 ]
Subtotal (99% CI) 36 17 100.0 % 0.94 [ 0.04, 24.27 ]
Total events: 2 (Lumacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
28 C-reactive protein increased
Clancy 2012 2/36 0/17 100.0 % 2.54 [ 0.04, 147.25 ]
Subtotal (99% CI) 36 17 100.0 % 2.54 [ 0.04, 147.25 ]
Total events: 2 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
29 Paranasal sinus hypersecretion
Clancy 2012 0/36 0/17 Not estimable
Subtotal (99% CI) 36 17 Not estimable
Total events: 0 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
30 Lung hyperinflation
Clancy 2012 2/36 0/17 100.0 % 2.54 [ 0.04, 147.25 ]
Subtotal (99% CI) 36 17 100.0 % 2.54 [ 0.04, 147.25 ]
Total events: 2 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
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Analysis 1.3. Comparison 1 Lumacaftor versus placebo, Outcome 3 Adverse effects: 200 mg lumacaftor
group versus placebo at 14 days.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 1 Lumacaftor versus placebo
Outcome: 3 Adverse effects: 200 mg lumacaftor group versus placebo at 14 days
Study or subgroup Lumacaftor group Placebo group Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Cough
Boyle 2014 6/41 1/21 100.0 % 3.43 [ 0.19, 60.73 ]
Subtotal (99% CI) 41 21 100.0 % 3.43 [ 0.19, 60.73 ]
Total events: 6 (Lumacaftor group), 1 (Placebo group)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 Pulmonary exacerbation
Boyle 2014 2/41 0/21 100.0 % 2.72 [ 0.05, 156.17 ]
Subtotal (99% CI) 41 21 100.0 % 2.72 [ 0.05, 156.17 ]
Total events: 2 (Lumacaftor group), 0 (Placebo group)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
3 Oropharyngeal pain
Boyle 2014 2/41 0/21 100.0 % 2.72 [ 0.05, 156.17 ]
Subtotal (99% CI) 41 21 100.0 % 2.72 [ 0.05, 156.17 ]
Total events: 2 (Lumacaftor group), 0 (Placebo group)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
4 Nasal congestion
Boyle 2014 0/41 0/21 Not estimable
Subtotal (99% CI) 41 21 Not estimable
Total events: 0 (Lumacaftor group), 0 (Placebo group)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Dizziness
Boyle 2014 0/41 0/21 Not estimable
Subtotal (99% CI) 41 21 Not estimable
Total events: 0 (Lumacaftor group), 0 (Placebo group)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Prothrombin time prolonged
Boyle 2014 1/41 0/21 100.0 % 1.59 [ 0.02, 113.01 ]
Subtotal (99% CI) 41 21 100.0 % 1.59 [ 0.02, 113.01 ]
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(. . . Continued)
Study or subgroup Lumacaftor group Placebo group Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 1 (Lumacaftor group), 0 (Placebo group)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
7 Upper respiratory tract infection
Boyle 2014 0/41 0/21 Not estimable
Subtotal (99% CI) 41 21 Not estimable
Total events: 0 (Lumacaftor group), 0 (Placebo group)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.4. Comparison 1 Lumacaftor versus placebo, Outcome 4 Adverse effects requiring study drug
discontinuation at day 28.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 1 Lumacaftor versus placebo
Outcome: 4 Adverse effects requiring study drug discontinuation at day 28
Study or subgroup Lumacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 25 mg lumacaftor
Clancy 2012 1/18 0/17 100.0 % 3.00 [ 0.11, 78.81 ]
Subtotal (95% CI) 18 17 100.0 % 3.00 [ 0.11, 78.81 ]
Total events: 1 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 50 mg lumacaftor
Clancy 2012 1/18 0/17 100.0 % 3.00 [ 0.11, 78.81 ]
Subtotal (95% CI) 18 17 100.0 % 3.00 [ 0.11, 78.81 ]
Total events: 1 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
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(. . . Continued)
Study or subgroup Lumacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
3 100 mg lumacaftor
Clancy 2012 1/17 0/17 100.0 % 3.18 [ 0.12, 83.76 ]
Subtotal (95% CI) 17 17 100.0 % 3.18 [ 0.12, 83.76 ]
Total events: 1 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
4 200 mg lumacaftor
Clancy 2012 1/19 0/17 100.0 % 2.84 [ 0.11, 74.42 ]
Subtotal (95% CI) 19 17 100.0 % 2.84 [ 0.11, 74.42 ]
Total events: 1 (Lumacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
0.01 0.1 1 10 100
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Analysis 1.5. Comparison 1 Lumacaftor versus placebo, Outcome 5 Change from baseline in sweat chloride
concentration after 28 days [mmol/L].
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 1 Lumacaftor versus placebo
Outcome: 5 Change from baseline in sweat chloride concentration after 28 days [mmol/L]
Study or subgroup Lumacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 100 mg lumacaftor
Clancy 2012 17 17 -6.13 (3.1225) 100.0 % -6.13 [ -12.25, -0.01 ]
Subtotal (95% CI) 17 17 100.0 % -6.13 [ -12.25, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
2 200 mg lumacaftor
Clancy 2012 19 17 -8.21 (3.1072) 100.0 % -8.21 [ -14.30, -2.12 ]
Subtotal (95% CI) 19 17 100.0 % -8.21 [ -14.30, -2.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0082)
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Analysis 1.6. Comparison 1 Lumacaftor versus placebo, Outcome 6 Sweat chloride concentration (mmol/L)
(change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 1 Lumacaftor versus placebo
Outcome: 6 Sweat chloride concentration (mmol/L) (change from baseline)
Study or subgroup Lumacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Fixed,95% CI IV,Fixed,95% CI
1 At 14 days
Boyle 2014 34 -4.45 (7.480383) 17 -1.7 (8.8462) 100.0 % -2.75 [ -7.65, 2.15 ]
Subtotal (95% CI) 34 17 100.0 % -2.75 [ -7.65, 2.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
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Analysis 2.1. Comparison 2 Cavosonstat (N91115) (200 mg twice daily) versus placebo, Outcome 1 CFQR
respiratory domain: absolute change from baseline.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 2 Cavosonstat (N91115) (200 mg twice daily) versus placebo
Outcome: 1 CFQR respiratory domain: absolute change from baseline
Study or subgroup Cavosonstat 200mg Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 28 days
Donaldson 2017 12 -0.8 (16.6) 12 -4.6 (20.9) 100.0 % 3.80 [ -11.30, 18.90 ]
Subtotal (95% CI) 12 12 100.0 % 3.80 [ -11.30, 18.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
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Analysis 2.2. Comparison 2 Cavosonstat (N91115) (200 mg twice daily) versus placebo, Outcome 2 CFQR
eating domain: absolute change from baseline.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 2 Cavosonstat (N91115) (200 mg twice daily) versus placebo
Outcome: 2 CFQR eating domain: absolute change from baseline
Study or subgroup Cavosonstat 200mg Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 28 days
Donaldson 2017 12 2.4 (7.8) 12 0 (4.7) 100.0 % 2.40 [ -2.75, 7.55 ]
Subtotal (95% CI) 12 12 100.0 % 2.40 [ -2.75, 7.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
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Analysis 2.3. Comparison 2 Cavosonstat (N91115) (200 mg twice daily) versus placebo, Outcome 3 Adverse
events occurring in > 10% of participants.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 2 Cavosonstat (N91115) (200 mg twice daily) versus placebo
Outcome: 3 Adverse events occurring in > 10% of participants
Study or subgroup Cavosonstat 200mg Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Cough
Donaldson 2017 6/14 5/12 100.0 % 1.05 [ 0.13, 8.17 ]
Subtotal (99% CI) 14 12 100.0 % 1.05 [ 0.13, 8.17 ]
Total events: 6 (Cavosonstat 200mg), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
2 Pulmonary exacerbation
Donaldson 2017 0/14 1/12 100.0 % 0.26 [ 0.00, 20.03 ]
Subtotal (99% CI) 14 12 100.0 % 0.26 [ 0.00, 20.03 ]
Total events: 0 (Cavosonstat 200mg), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
3 Chest discomfort
Donaldson 2017 2/14 0/12 100.0 % 5.00 [ 0.08, 308.20 ]
Subtotal (99% CI) 14 12 100.0 % 5.00 [ 0.08, 308.20 ]
Total events: 2 (Cavosonstat 200mg), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
4 Fatigue
Donaldson 2017 3/14 1/12 100.0 % 3.00 [ 0.13, 71.47 ]
Subtotal (99% CI) 14 12 100.0 % 3.00 [ 0.13, 71.47 ]
Total events: 3 (Cavosonstat 200mg), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
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Analysis 2.4. Comparison 2 Cavosonstat (N91115) (200 mg twice daily) versus placebo, Outcome 4 Sweat
chloride.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 2 Cavosonstat (N91115) (200 mg twice daily) versus placebo
Outcome: 4 Sweat chloride
Study or subgroup Cavosonstat 200mg Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 28 days
Donaldson 2017 12 -4.1 (5) 12 -0.8 (9) 100.0 % -3.30 [ -9.13, 2.53 ]
Subtotal (95% CI) 12 12 100.0 % -3.30 [ -9.13, 2.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
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Analysis 3.1. Comparison 3 N6022 versus placebo, Outcome 1 FEV&subStart;1&subEnd; % predicted
(relative change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 3 N6022 versus placebo
Outcome: 1 FEV1 % predicted (relative change from baseline)
Study or subgroup N6022 Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 5 mg/day N6022
Donaldson 2014 10 -0.5 (4.72) 19 1.5 (3.44) 100.0 % -2.00 [ -5.31, 1.31 ]
Subtotal (95% CI) 10 19 100.0 % -2.00 [ -5.31, 1.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
2 10 mg/day N6022
Donaldson 2014 9 -0.2 (3.99) 19 1.5 (3.44) 100.0 % -1.70 [ -4.73, 1.33 ]
Subtotal (95% CI) 9 19 100.0 % -1.70 [ -4.73, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
3 20 mg/day N6022
Donaldson 2014 9 -0.7 (4.08) 19 1.5 (3.44) 100.0 % -2.20 [ -5.28, 0.88 ]
Subtotal (95% CI) 9 19 100.0 % -2.20 [ -5.28, 0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
4 40 mg/day N6022
Donaldson 2014 19 0.5 (3.04) 19 1.5 (3.44) 100.0 % -1.00 [ -3.06, 1.06 ]
Subtotal (95% CI) 19 19 100.0 % -1.00 [ -3.06, 1.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
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Analysis 3.2. Comparison 3 N6022 versus placebo, Outcome 2 Treatment-emergent adverse events (mild).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 3 N6022 versus placebo
Outcome: 2 Treatment-emergent adverse events (mild)
Study or subgroup N6022 Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5 mg/day N6022
Donaldson 2014 4/10 11/19 100.0 % 0.48 [ 0.10, 2.30 ]
Subtotal (95% CI) 10 19 100.0 % 0.48 [ 0.10, 2.30 ]
Total events: 4 (N6022), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
2 10 mg/day N6022
Donaldson 2014 6/9 11/19 100.0 % 1.45 [ 0.28, 7.64 ]
Subtotal (95% CI) 9 19 100.0 % 1.45 [ 0.28, 7.64 ]
Total events: 6 (N6022), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
3 20 mg/day N6022
Donaldson 2014 4/9 11/19 100.0 % 0.58 [ 0.12, 2.88 ]
Subtotal (95% CI) 9 19 100.0 % 0.58 [ 0.12, 2.88 ]
Total events: 4 (N6022), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
4 40 mg/day N6022
Donaldson 2014 12/19 11/19 100.0 % 1.25 [ 0.34, 4.59 ]
Subtotal (95% CI) 19 19 100.0 % 1.25 [ 0.34, 4.59 ]
Total events: 12 (N6022), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
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Analysis 3.3. Comparison 3 N6022 versus placebo, Outcome 3 Treatment-emergent adverse events
(moderate).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 3 N6022 versus placebo
Outcome: 3 Treatment-emergent adverse events (moderate)
Study or subgroup N6022 Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5 mg/day N6022
Donaldson 2014 3/10 6/19 23.1 % 0.93 [ 0.18, 4.90 ]
Subtotal (95% CI) 10 19 23.1 % 0.93 [ 0.18, 4.90 ]
Total events: 3 (N6022), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
2 10 mg/day N6022
Donaldson 2014 3/9 6/19 20.5 % 1.08 [ 0.20, 5.87 ]
Subtotal (95% CI) 9 19 20.5 % 1.08 [ 0.20, 5.87 ]
Total events: 3 (N6022), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
3 20 mg/day N6022
Donaldson 2014 5/9 6/19 13.7 % 2.71 [ 0.53, 13.85 ]
Subtotal (95% CI) 9 19 13.7 % 2.71 [ 0.53, 13.85 ]
Total events: 5 (N6022), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
4 40 mg/day N6022
Donaldson 2014 2/19 6/19 42.8 % 0.25 [ 0.04, 1.48 ]
Subtotal (95% CI) 19 19 42.8 % 0.25 [ 0.04, 1.48 ]
Total events: 2 (N6022), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Total (95% CI) 47 76 100.0 % 0.92 [ 0.41, 2.04 ]
Total events: 13 (N6022), 24 (Placebo)
Heterogeneity: Chi2 = 3.77, df = 3 (P = 0.29); I2 =20%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Chi2 = 3.76, df = 3 (P = 0.29), I2 =20%
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Analysis 3.4. Comparison 3 N6022 versus placebo, Outcome 4 Treatment-emergent adverse events
(serious / severe).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 3 N6022 versus placebo
Outcome: 4 Treatment-emergent adverse events (serious / severe)
Study or subgroup N6022 Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5 mg/day N6022
Donaldson 2014 2/10 1/19 16.2 % 4.50 [ 0.35, 57.11 ]
Subtotal (95% CI) 10 19 16.2 % 4.50 [ 0.35, 57.11 ]
Total events: 2 (N6022), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
2 10 mg/day N6022
Donaldson 2014 0/9 1/19 27.9 % 0.65 [ 0.02, 17.51 ]
Subtotal (95% CI) 9 19 27.9 % 0.65 [ 0.02, 17.51 ]
Total events: 0 (N6022), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
3 20 mg/day N6022
Donaldson 2014 0/9 1/19 27.9 % 0.65 [ 0.02, 17.51 ]
Subtotal (95% CI) 9 19 27.9 % 0.65 [ 0.02, 17.51 ]
Total events: 0 (N6022), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
4 40 mg/day N6022
Donaldson 2014 1/19 1/19 27.9 % 1.00 [ 0.06, 17.25 ]
Subtotal (95% CI) 19 19 27.9 % 1.00 [ 0.06, 17.25 ]
Total events: 1 (N6022), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 47 76 100.0 % 1.37 [ 0.35, 5.41 ]
Total events: 3 (N6022), 4 (Placebo)
Heterogeneity: Chi2 = 1.28, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 1.28, df = 3 (P = 0.73), I2 =0.0%
0.01 0.1 1 10 100
Favours N6022 Favours placebo
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Analysis 4.1. Comparison 4 CPX versus placebo, Outcome 1 Adverse events occurring in more than 3% of
participants in all treatment groups (combined data) versus placebo.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 4 CPX versus placebo
Outcome: 1 Adverse events occurring in more than 3% of participants in all treatment groups (combined data) versus placebo
Study or subgroup CPX Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Abdominal pain
McCarty 2002 0/8 3/29 100.0 % 0.45 [ 0.01, 24.92 ]
Subtotal (99% CI) 8 29 100.0 % 0.45 [ 0.01, 24.92 ]
Total events: 0 (CPX), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
2 Asthenia
McCarty 2002 0/8 2/29 100.0 % 0.65 [ 0.01, 39.69 ]
Subtotal (99% CI) 8 29 100.0 % 0.65 [ 0.01, 39.69 ]
Total events: 0 (CPX), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
3 Headache
McCarty 2002 0/8 4/29 100.0 % 0.33 [ 0.01, 17.72 ]
Subtotal (99% CI) 8 29 100.0 % 0.33 [ 0.01, 17.72 ]
Total events: 0 (CPX), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
4 Pain
McCarty 2002 0/8 3/29 100.0 % 0.45 [ 0.01, 24.92 ]
Subtotal (99% CI) 8 29 100.0 % 0.45 [ 0.01, 24.92 ]
Total events: 0 (CPX), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
5 Diarrhoea
McCarty 2002 0/8 2/29 100.0 % 0.65 [ 0.01, 39.69 ]
Subtotal (99% CI) 8 29 100.0 % 0.65 [ 0.01, 39.69 ]
Total events: 0 (CPX), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
6 Dizziness
McCarty 2002 2/8 1/29 100.0 % 9.33 [ 0.32, 268.92 ]
Subtotal (99% CI) 8 29 100.0 % 9.33 [ 0.32, 268.92 ]
0.001 0.01 0.1 1 10 100 1000
Favours CPX Favours placebo
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(. . . Continued)
Study or subgroup CPX Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 2 (CPX), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.087)
7 Lung disease
McCarty 2002 0/8 3/29 100.0 % 0.45 [ 0.01, 24.92 ]
Subtotal (99% CI) 8 29 100.0 % 0.45 [ 0.01, 24.92 ]
Total events: 0 (CPX), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
8 Rhinitis
McCarty 2002 0/8 3/29 100.0 % 0.45 [ 0.01, 24.92 ]
Subtotal (99% CI) 8 29 100.0 % 0.45 [ 0.01, 24.92 ]
Total events: 0 (CPX), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
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Analysis 5.1. Comparison 5 4PBA versus placebo, Outcome 1 Adverse effects after 1 week.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 5 4PBA versus placebo
Outcome: 1 Adverse effects after 1 week
Study or subgroup 4PBA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Bad taste in mouth
Rubenstein 1998 1/9 2/9 100.0 % 0.44 [ 0.01, 13.44 ]
Subtotal (99% CI) 9 9 100.0 % 0.44 [ 0.01, 13.44 ]
Total events: 1 (4PBA), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
2 Diarrhoea
Rubenstein 1998 1/9 0/9 100.0 % 3.35 [ 0.04, 267.31 ]
Subtotal (99% CI) 9 9 100.0 % 3.35 [ 0.04, 267.31 ]
Total events: 1 (4PBA), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
0.002 0.1 1 10 500
Favours 4PBA Favours placebo
Analysis 5.2. Comparison 5 4PBA versus placebo, Outcome 2 Participants requiring study drug termination
or a reduced dosage.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 5 4PBA versus placebo
Outcome: 2 Participants requiring study drug termination or a reduced dosage
Study or subgroup 4PBA Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 30 g 4PBA
Zeitlin 2002 2/6 0/4 5.00 [ 0.18, 136.32 ]
0.001 0.01 0.1 1 10 100 1000
Favours 4PBA Favours placebo
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Analysis 6.1. Comparison 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 1 Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L)
Index Score (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 1 Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months
TRAFFIC 2015 175 0.0066 (0.1005) 179 0 (0.0989) 45.0 % 0.01 [ -0.01, 0.03 ]
TRANSPORT 2015 178 0.009 (0.091) 183 0.01 (0.091) 55.0 % 0.00 [ -0.02, 0.02 ]
Subtotal (95% CI) 353 362 100.0 % 0.00 [ -0.01, 0.02 ]
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
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Analysis 6.2. Comparison 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 2 Quality of life - CFQ-R respiratory domain (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 2 Quality of life - CFQ-R respiratory domain (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 28 days
TRAFFIC 2015 183 4 (15.18421) 184 3 (14.53356) 51.7 % 1.00 [ -2.04, 4.04 ]
TRANSPORT 2015 185 6.8 (15.26696) 187 1 (15.69811) 48.3 % 5.80 [ 2.65, 8.95 ]
Subtotal (95% CI) 368 371 100.0 % 3.32 [ 1.13, 5.51 ]
Heterogeneity: Chi2 = 4.62, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 2.97 (P = 0.0029)
2 At 6 months
TRAFFIC 2015 176 4.98 (15.6279) 184 1.1 (15.7486) 49.6 % 3.88 [ 0.64, 7.12 ]
TRANSPORT 2015 180 5.02 (15.6435) 185 2.81 (15.6825) 50.4 % 2.21 [ -1.00, 5.42 ]
Subtotal (95% CI) 356 369 100.0 % 3.04 [ 0.76, 5.32 ]
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.61 (P = 0.0091)
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Analysis 6.3. Comparison 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 3 Quality of life - EQ-5D-3L VAS Score (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 3 Quality of life - EQ-5D-3L VAS Score (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months
TRAFFIC 2015 173 3.5 (13.6791) 180 1.4 (13.8189) 51.9 % 2.10 [ -0.77, 4.97 ]
TRANSPORT 2015 177 5.7 (14.3685) 182 3.3 (14.4351) 48.1 % 2.40 [ -0.58, 5.38 ]
Subtotal (95% CI) 350 362 100.0 % 2.24 [ 0.18, 4.31 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.13 (P = 0.033)
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Analysis 6.4. Comparison 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 4 FEV&subStart;1&subEnd; % predicted (relative change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 4 FEV1 % predicted (relative change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months
TRAFFIC 2015 176 6.39 (12.1256) 180 -0.34 (12.2492) 52.5 % 6.73 [ 4.20, 9.26 ]
TRANSPORT 2015 181 4.42 (12.9289) 183 0 (12.9866) 47.5 % 4.42 [ 1.76, 7.08 ]
Subtotal (95% CI) 357 363 100.0 % 5.63 [ 3.80, 7.47 ]
Heterogeneity: Chi2 = 1.52, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 6.02 (P < 0.00001)
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Analysis 6.5. Comparison 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 5 FEV&subStart;1&subEnd; % predicted (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 5 FEV1 % predicted (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 28 days
TRAFFIC 2015 183 2.5 (7.592104) 184 0 (7.612819) 40.1 % 2.50 [ 0.94, 4.06 ]
TRANSPORT 2015 185 2.5 (6.245573) 187 0.3 (6.279242) 59.9 % 2.20 [ 0.93, 3.47 ]
Subtotal (95% CI) 368 371 100.0 % 2.32 [ 1.34, 3.31 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 4.62 (P < 0.00001)
2 At 6 months
TRAFFIC 2015 176 3.59 (6.9649) 180 -0.44 (7.0302) 51.4 % 4.03 [ 2.58, 5.48 ]
TRANSPORT 2015 181 2.46 (7.265) 183 -0.15 (7.2915) 48.6 % 2.61 [ 1.11, 4.11 ]
Subtotal (95% CI) 357 363 100.0 % 3.34 [ 2.30, 4.38 ]
Heterogeneity: Chi2 = 1.78, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 6.28 (P < 0.00001)
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Analysis 6.6. Comparison 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 6 Adverse events by end of study (at 6 months).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 6 Adverse events by end of study (at 6 months)
Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Any adverse event
TRAFFIC 2015 175/184 174/183 63.7 % 1.01 [ 0.29, 3.49 ]
TRANSPORT 2015 181/186 181/186 36.3 % 1.00 [ 0.19, 5.21 ]
Subtotal (99% CI) 370 369 100.0 % 1.00 [ 0.37, 2.71 ]
Total events: 356 (Lumacaftor-ivacaftor), 355 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
2 Discontinuation due to an adverse event
TRAFFIC 2015 8/184 4/183 66.5 % 2.03 [ 0.41, 10.08 ]
TRANSPORT 2015 6/186 2/186 33.5 % 3.07 [ 0.37, 25.56 ]
Subtotal (99% CI) 370 369 100.0 % 2.38 [ 0.67, 8.50 ]
Total events: 14 (Lumacaftor-ivacaftor), 6 (Placebo)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.079)
3 At least 1 serious adverse event
TRAFFIC 2015 33/184 49/183 49.4 % 0.60 [ 0.31, 1.15 ]
TRANSPORT 2015 51/186 57/186 50.6 % 0.85 [ 0.47, 1.54 ]
Subtotal (99% CI) 370 369 100.0 % 0.73 [ 0.47, 1.13 ]
Total events: 84 (Lumacaftor-ivacaftor), 106 (Placebo)
Heterogeneity: Chi2 = 1.09, df = 1 (P = 0.30); I2 =9%
Test for overall effect: Z = 1.87 (P = 0.061)
4 Infective pulmonary exacerbation
TRAFFIC 2015 65/184 87/183 51.0 % 0.60 [ 0.35, 1.05 ]
TRANSPORT 2015 80/186 95/186 49.0 % 0.72 [ 0.42, 1.24 ]
Subtotal (99% CI) 370 369 100.0 % 0.66 [ 0.45, 0.97 ]
Total events: 145 (Lumacaftor-ivacaftor), 182 (Placebo)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.77 (P = 0.0056)
5 Cough
TRAFFIC 2015 52/184 66/183 47.9 % 0.70 [ 0.39, 1.25 ]
TRANSPORT 2015 69/186 82/186 52.1 % 0.75 [ 0.43, 1.29 ]
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(. . . Continued)
Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 370 369 100.0 % 0.72 [ 0.49, 1.08 ]
Total events: 121 (Lumacaftor-ivacaftor), 148 (Placebo)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.036)
6 Headache
TRAFFIC 2015 28/184 25/183 43.4 % 1.13 [ 0.53, 2.44 ]
TRANSPORT 2015 30/186 33/186 56.6 % 0.89 [ 0.44, 1.82 ]
Subtotal (99% CI) 370 369 100.0 % 1.00 [ 0.59, 1.68 ]
Total events: 58 (Lumacaftor-ivacaftor), 58 (Placebo)
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
7 Haemoptysis
TRAFFIC 2015 22/184 24/183 49.3 % 0.90 [ 0.40, 2.03 ]
TRANSPORT 2015 30/186 26/186 50.7 % 1.18 [ 0.56, 2.50 ]
Subtotal (99% CI) 370 369 100.0 % 1.04 [ 0.60, 1.81 ]
Total events: 52 (Lumacaftor-ivacaftor), 50 (Placebo)
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
8 Diarrhoea
TRAFFIC 2015 16/184 13/183 42.6 % 1.25 [ 0.46, 3.39 ]
TRANSPORT 2015 20/186 18/186 57.4 % 1.12 [ 0.46, 2.72 ]
Subtotal (99% CI) 370 369 100.0 % 1.18 [ 0.61, 2.28 ]
Total events: 36 (Lumacaftor-ivacaftor), 31 (Placebo)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
9 Abnormal respiration
TRAFFIC 2015 26/184 9/183 39.2 % 3.18 [ 1.13, 8.96 ]
TRANSPORT 2015 14/186 13/186 60.8 % 1.08 [ 0.39, 3.03 ]
Subtotal (99% CI) 370 369 100.0 % 1.91 [ 0.94, 3.88 ]
Total events: 40 (Lumacaftor-ivacaftor), 22 (Placebo)
Heterogeneity: Chi2 = 3.62, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 2.34 (P = 0.019)
10 Increased sputum
TRAFFIC 2015 15/184 23/183 36.5 % 0.62 [ 0.25, 1.52 ]
TRANSPORT 2015 40/186 47/186 63.5 % 0.81 [ 0.43, 1.53 ]
Subtotal (99% CI) 370 369 100.0 % 0.74 [ 0.44, 1.24 ]
Total events: 55 (Lumacaftor-ivacaftor), 70 (Placebo)
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
11 Dyspnoea
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Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
TRAFFIC 2015 22/184 14/183 50.0 % 1.64 [ 0.65, 4.13 ]
TRANSPORT 2015 33/186 15/186 50.0 % 2.46 [ 1.05, 5.76 ]
Subtotal (99% CI) 370 369 100.0 % 2.05 [ 1.10, 3.83 ]
Total events: 55 (Lumacaftor-ivacaftor), 29 (Placebo)
Heterogeneity: Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.96 (P = 0.0031)
12 Nasopharyngitis
TRAFFIC 2015 9/184 20/183 50.8 % 0.42 [ 0.14, 1.22 ]
TRANSPORT 2015 14/186 20/186 49.2 % 0.68 [ 0.26, 1.73 ]
Subtotal (99% CI) 370 369 100.0 % 0.55 [ 0.27, 1.10 ]
Total events: 23 (Lumacaftor-ivacaftor), 40 (Placebo)
Heterogeneity: Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.026)
13 Oropharyngeal pain
TRAFFIC 2015 24/184 10/183 32.8 % 2.60 [ 0.95, 7.12 ]
TRANSPORT 2015 20/186 20/186 67.2 % 1.00 [ 0.42, 2.37 ]
Subtotal (99% CI) 370 369 100.0 % 1.52 [ 0.80, 2.89 ]
Total events: 44 (Lumacaftor-ivacaftor), 30 (Placebo)
Heterogeneity: Chi2 = 3.43, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.69 (P = 0.091)
14 Abdominal pain
TRAFFIC 2015 11/184 12/183 38.1 % 0.91 [ 0.30, 2.75 ]
TRANSPORT 2015 15/186 20/186 61.9 % 0.73 [ 0.29, 1.83 ]
Subtotal (99% CI) 370 369 100.0 % 0.80 [ 0.39, 1.62 ]
Total events: 26 (Lumacaftor-ivacaftor), 32 (Placebo)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
15 Fatigue
TRAFFIC 2015 17/184 19/183 65.0 % 0.88 [ 0.36, 2.17 ]
TRANSPORT 2015 13/186 10/186 35.0 % 1.32 [ 0.43, 4.05 ]
Subtotal (99% CI) 370 369 100.0 % 1.03 [ 0.51, 2.08 ]
Total events: 30 (Lumacaftor-ivacaftor), 29 (Placebo)
Heterogeneity: Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
16 Nausea
TRAFFIC 2015 9/184 11/183 40.9 % 0.80 [ 0.24, 2.64 ]
TRANSPORT 2015 20/186 17/186 59.1 % 1.20 [ 0.49, 2.93 ]
Subtotal (99% CI) 370 369 100.0 % 1.04 [ 0.51, 2.11 ]
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Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 29 (Lumacaftor-ivacaftor), 28 (Placebo)
Heterogeneity: Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
17 Pyrexia
TRAFFIC 2015 12/184 12/183 36.8 % 0.99 [ 0.34, 2.95 ]
TRANSPORT 2015 23/186 22/186 63.2 % 1.05 [ 0.46, 2.39 ]
Subtotal (99% CI) 370 369 100.0 % 1.03 [ 0.54, 1.98 ]
Total events: 35 (Lumacaftor-ivacaftor), 34 (Placebo)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
18 Nasal congestion
TRAFFIC 2015 9/184 25/183 59.0 % 0.33 [ 0.11, 0.92 ]
TRANSPORT 2015 24/186 19/186 41.0 % 1.30 [ 0.56, 3.02 ]
Subtotal (99% CI) 370 369 100.0 % 0.73 [ 0.39, 1.35 ]
Total events: 33 (Lumacaftor-ivacaftor), 44 (Placebo)
Heterogeneity: Chi2 = 7.17, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.33 (P = 0.18)
19 Upper respiratory tract infection
TRAFFIC 2015 16/184 10/183 48.9 % 1.65 [ 0.56, 4.83 ]
TRANSPORT 2015 8/186 10/186 51.1 % 0.79 [ 0.23, 2.77 ]
Subtotal (99% CI) 370 369 100.0 % 1.21 [ 0.54, 2.70 ]
Total events: 24 (Lumacaftor-ivacaftor), 20 (Placebo)
Heterogeneity: Chi2 = 1.31, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.61 (P = 0.54)
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Analysis 6.7. Comparison 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 7 Time to first pulmonary exacerbation.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 7 Time to first pulmonary exacerbation
Study or subgroup Lumacaftor-ivacaftor Placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
TRAFFIC 2015 183 184 -0.36817 (0.16) 46.8 % 0.69 [ 0.51, 0.95 ]
TRANSPORT 2015 185 187 -0.33408 (0.15) 53.2 % 0.72 [ 0.53, 0.96 ]
Total (95% CI) 368 371 100.0 % 0.70 [ 0.57, 0.87 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Not applicable
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Analysis 6.8. Comparison 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 8 Rate of exacerbations.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 8 Rate of exacerbations
Study or subgroup Lumacaftor-ivacaftor Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
TRAFFIC 2015 183 184 -0.3305 (0.168) 43.2 % 0.72 [ 0.52, 1.00 ]
TRANSPORT 2015 185 187 -0.3693 (0.1465) 56.8 % 0.69 [ 0.52, 0.92 ]
Total (95% CI) 368 371 100.0 % 0.70 [ 0.57, 0.87 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 3.19 (P = 0.0014)
Test for subgroup differences: Not applicable
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Analysis 6.9. Comparison 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 9 Weight (kg) (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 9 Weight (kg) (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months
TRAFFIC 2015 178 1.34 (2.735) 184 0.93 (2.7401) 45.9 % 0.41 [ -0.15, 0.97 ]
TRANSPORT 2015 180 1.57 (2.5223) 183 0.44 (2.5297) 54.1 % 1.13 [ 0.61, 1.65 ]
Subtotal (95% CI) 358 367 100.0 % 0.80 [ 0.42, 1.18 ]
Heterogeneity: Chi2 = 3.39, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 4.10 (P = 0.000041)
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Analysis 6.10. Comparison 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 10 BMI (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 6 Lumacaftor (600 mg once daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 10 BMI (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 28 days
TRAFFIC 2015 183 0.11 (0.621172) 184 0.08 (0.484452) 46.5 % 0.03 [ -0.08, 0.14 ]
TRANSPORT 2015 185 0.11 (0.485767) 187 0.12 (0.558155) 53.5 % -0.01 [ -0.12, 0.10 ]
Subtotal (95% CI) 368 371 100.0 % 0.01 [ -0.07, 0.09 ]
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
2 At 6 months
TRAFFIC 2015 178 0.35 (0.9339) 184 0.19 (0.9495) 47.1 % 0.16 [ -0.03, 0.35 ]
TRANSPORT 2015 180 0.48 (0.8855) 183 0.07 (0.8928) 52.9 % 0.41 [ 0.23, 0.59 ]
Subtotal (95% CI) 358 367 100.0 % 0.29 [ 0.16, 0.43 ]
Heterogeneity: Chi2 = 3.38, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 4.30 (P = 0.000017)
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Analysis 7.1. Comparison 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 1 Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L)
Index Score (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 1 Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months
TRAFFIC 2015 170 0.01 (0.0987) 179 0 (0.0989) 45.1 % 0.01 [ -0.01, 0.03 ]
TRANSPORT 2015 176 0.0108 (0.0906) 183 0.01 (0.091) 54.9 % 0.00 [ -0.02, 0.02 ]
Subtotal (95% CI) 346 362 100.0 % 0.00 [ -0.01, 0.02 ]
Heterogeneity: Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
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Analysis 7.2. Comparison 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 2 Quality of life - CFQ-R respiratory domain (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 2 Quality of life - CFQ-R respiratory domain (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 28 days
TRAFFIC 2015 182 5 (15.14266) 184 3 (14.53356) 51.7 % 2.00 [ -1.04, 5.04 ]
TRANSPORT 2015 187 7.4 (15.34926) 187 1 (15.69811) 48.3 % 6.40 [ 3.25, 9.55 ]
Subtotal (95% CI) 369 371 100.0 % 4.13 [ 1.94, 6.31 ]
Heterogeneity: Chi2 = 3.88, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 3.70 (P = 0.00022)
2 At 6 months
TRAFFIC 2015 172 2.6 (15.6329) 184 1.1 (15.7486) 49.3 % 1.50 [ -1.76, 4.76 ]
TRANSPORT 2015 179 5.66 (15.6402) 185 2.81 (15.6825) 50.7 % 2.85 [ -0.37, 6.07 ]
Subtotal (95% CI) 351 369 100.0 % 2.18 [ -0.11, 4.47 ]
Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.062)
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Analysis 7.3. Comparison 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 3 Quality of life - EQ-5D-3L VAS Score (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 3 Quality of life - EQ-5D-3L VAS Score (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months
TRAFFIC 2015 171 2.8 (13.3382) 180 1.4 (13.8189) 52.4 % 1.40 [ -1.44, 4.24 ]
TRANSPORT 2015 177 6.6 (14.3685) 182 3.3 (14.4351) 47.6 % 3.30 [ 0.32, 6.28 ]
Subtotal (95% CI) 348 362 100.0 % 2.30 [ 0.25, 4.36 ]
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 2.20 (P = 0.028)
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Analysis 7.4. Comparison 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 4 FEV&subStart;1&subEnd; % predicted (relative change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 4 FEV1 % predicted (relative change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months
TRAFFIC 2015 172 3.99 (12.105) 180 -0.34 (12.2492) 52.3 % 4.33 [ 1.79, 6.87 ]
TRANSPORT 2015 180 5.25 (12.8932) 183 0 (12.9866) 47.7 % 5.25 [ 2.59, 7.91 ]
Subtotal (95% CI) 352 363 100.0 % 4.77 [ 2.93, 6.61 ]
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 5.08 (P < 0.00001)
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Analysis 7.5. Comparison 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 5 FEV&subStart;1&subEnd; % predicted (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 5 FEV1 % predicted (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 28 days
TRAFFIC 2015 182 2.3 (7.571332) 184 0 (7.612819) 40.1 % 2.30 [ 0.74, 3.86 ]
TRANSPORT 2015 187 2.8 (6.279242) 187 0.3 (6.279242) 59.9 % 2.50 [ 1.23, 3.77 ]
Subtotal (95% CI) 369 371 100.0 % 2.42 [ 1.43, 3.40 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 4.81 (P < 0.00001)
2 At 6 months
TRAFFIC 2015 172 2.16 (6.9509) 180 -0.44 (7.0302) 51.2 % 2.60 [ 1.14, 4.06 ]
TRANSPORT 2015 180 2.85 (7.2449) 183 -0.15 (7.2915) 48.8 % 3.00 [ 1.50, 4.50 ]
Subtotal (95% CI) 352 363 100.0 % 2.80 [ 1.75, 3.84 ]
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 5.24 (P < 0.00001)
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Analysis 7.6. Comparison 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 6 Adverse events by end of study (at 6 months).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 6 Adverse events by end of study (at 6 months)
Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Any adverse event
TRAFFIC 2015 174/182 174/183 44.0 % 1.13 [ 0.31, 4.05 ]
TRANSPORT 2015 177/187 181/186 56.0 % 0.49 [ 0.12, 2.06 ]
Subtotal (99% CI) 369 369 100.0 % 0.77 [ 0.30, 1.96 ]
Total events: 351 (Lumacaftor-ivacaftor), 355 (Placebo)
Heterogeneity: Chi2 = 1.24, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 0.72 (P = 0.47)
2 Discontinuation due to an adverse event
TRAFFIC 2015 6/182 4/183 67.1 % 1.53 [ 0.28, 8.23 ]
TRANSPORT 2015 11/187 2/186 32.9 % 5.75 [ 0.78, 42.43 ]
Subtotal (99% CI) 369 369 100.0 % 2.91 [ 0.85, 10.03 ]
Total events: 17 (Lumacaftor-ivacaftor), 6 (Placebo)
Heterogeneity: Chi2 = 1.75, df = 1 (P = 0.19); I2 =43%
Test for overall effect: Z = 2.23 (P = 0.026)
3 At least 1 serious adverse event
TRAFFIC 2015 33/182 49/183 45.6 % 0.61 [ 0.31, 1.17 ]
TRANSPORT 2015 31/187 57/186 54.4 % 0.45 [ 0.23, 0.86 ]
Subtotal (99% CI) 369 369 100.0 % 0.52 [ 0.33, 0.83 ]
Total events: 64 (Lumacaftor-ivacaftor), 106 (Placebo)
Heterogeneity: Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 3.64 (P = 0.00027)
4 Infective pulmonary exacerbation
TRAFFIC 2015 67/182 87/183 46.9 % 0.64 [ 0.37, 1.11 ]
TRANSPORT 2015 65/187 95/186 53.1 % 0.51 [ 0.30, 0.88 ]
Subtotal (99% CI) 369 369 100.0 % 0.57 [ 0.39, 0.84 ]
Total events: 132 (Lumacaftor-ivacaftor), 182 (Placebo)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.71 (P = 0.00021)
5 Cough
TRAFFIC 2015 48/182 66/183 45.7 % 0.64 [ 0.35, 1.14 ]
TRANSPORT 2015 56/187 82/186 54.3 % 0.54 [ 0.31, 0.95 ]
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(. . . Continued)
Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 369 369 100.0 % 0.58 [ 0.39, 0.88 ]
Total events: 104 (Lumacaftor-ivacaftor), 148 (Placebo)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 3.41 (P = 0.00064)
6 Headache
TRAFFIC 2015 29/182 25/183 42.8 % 1.20 [ 0.56, 2.56 ]
TRANSPORT 2015 29/187 33/186 57.2 % 0.85 [ 0.42, 1.74 ]
Subtotal (99% CI) 369 369 100.0 % 1.00 [ 0.59, 1.68 ]
Total events: 58 (Lumacaftor-ivacaftor), 58 (Placebo)
Heterogeneity: Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
7 Haemoptysis
TRAFFIC 2015 30/182 24/183 46.2 % 1.31 [ 0.61, 2.81 ]
TRANSPORT 2015 20/187 26/186 53.8 % 0.74 [ 0.33, 1.67 ]
Subtotal (99% CI) 369 369 100.0 % 1.00 [ 0.58, 1.74 ]
Total events: 50 (Lumacaftor-ivacaftor), 50 (Placebo)
Heterogeneity: Chi2 = 1.74, df = 1 (P = 0.19); I2 =43%
Test for overall effect: Z = 0.00 (P = 1.0)
8 Diarrhoea
TRAFFIC 2015 24/182 13/183 41.3 % 1.99 [ 0.78, 5.04 ]
TRANSPORT 2015 21/187 18/186 58.7 % 1.18 [ 0.49, 2.83 ]
Subtotal (99% CI) 369 369 100.0 % 1.51 [ 0.80, 2.85 ]
Total events: 45 (Lumacaftor-ivacaftor), 31 (Placebo)
Heterogeneity: Chi2 = 1.10, df = 1 (P = 0.29); I2 =9%
Test for overall effect: Z = 1.68 (P = 0.092)
9 Abnormal respiration
TRAFFIC 2015 14/182 9/183 41.3 % 1.61 [ 0.52, 5.01 ]
TRANSPORT 2015 18/187 13/186 58.7 % 1.42 [ 0.53, 3.77 ]
Subtotal (99% CI) 369 369 100.0 % 1.50 [ 0.71, 3.14 ]
Total events: 32 (Lumacaftor-ivacaftor), 22 (Placebo)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
10 Increased sputum
TRAFFIC 2015 25/182 23/183 33.2 % 1.11 [ 0.50, 2.46 ]
TRANSPORT 2015 29/187 47/186 66.8 % 0.54 [ 0.28, 1.07 ]
Subtotal (99% CI) 369 369 100.0 % 0.73 [ 0.44, 1.22 ]
Total events: 54 (Lumacaftor-ivacaftor), 70 (Placebo)
Heterogeneity: Chi2 = 3.08, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 1.58 (P = 0.11)
11 Dyspnea
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(. . . Continued)
Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
TRAFFIC 2015 17/182 14/183 50.2 % 1.24 [ 0.47, 3.29 ]
TRANSPORT 2015 31/187 15/186 49.8 % 2.27 [ 0.96, 5.35 ]
Subtotal (99% CI) 369 369 100.0 % 1.75 [ 0.93, 3.32 ]
Total events: 48 (Lumacaftor-ivacaftor), 29 (Placebo)
Heterogeneity: Chi2 = 1.42, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 2.26 (P = 0.024)
12 Nasopharyngitis
TRAFFIC 2015 26/182 20/183 49.1 % 1.36 [ 0.60, 3.08 ]
TRANSPORT 2015 22/187 20/186 50.9 % 1.11 [ 0.48, 2.58 ]
Subtotal (99% CI) 369 369 100.0 % 1.23 [ 0.68, 2.21 ]
Total events: 48 (Lumacaftor-ivacaftor), 40 (Placebo)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
13 Oropharyngeal pain
TRAFFIC 2015 11/182 10/183 33.4 % 1.11 [ 0.35, 3.55 ]
TRANSPORT 2015 13/187 20/186 66.6 % 0.62 [ 0.24, 1.62 ]
Subtotal (99% CI) 369 369 100.0 % 0.78 [ 0.38, 1.63 ]
Total events: 24 (Lumacaftor-ivacaftor), 30 (Placebo)
Heterogeneity: Chi2 = 1.00, df = 1 (P = 0.32); I2 =0%
Test for overall effect: Z = 0.85 (P = 0.39)
14 Abdominal pain
TRAFFIC 2015 23/182 12/183 35.5 % 2.06 [ 0.79, 5.38 ]
TRANSPORT 2015 10/187 20/186 64.5 % 0.47 [ 0.17, 1.32 ]
Subtotal (99% CI) 369 369 100.0 % 1.03 [ 0.53, 2.01 ]
Total events: 33 (Lumacaftor-ivacaftor), 32 (Placebo)
Heterogeneity: Chi2 = 7.29, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 0.13 (P = 0.90)
15 Fatigue
TRAFFIC 2015 17/182 19/183 65.3 % 0.89 [ 0.36, 2.20 ]
TRANSPORT 2015 17/187 10/186 34.7 % 1.76 [ 0.61, 5.10 ]
Subtotal (99% CI) 369 369 100.0 % 1.19 [ 0.60, 2.35 ]
Total events: 34 (Lumacaftor-ivacaftor), 29 (Placebo)
Heterogeneity: Chi2 = 1.59, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.66 (P = 0.51)
16 Nausea
TRAFFIC 2015 14/182 11/183 41.7 % 1.30 [ 0.44, 3.82 ]
TRANSPORT 2015 32/187 17/186 58.3 % 2.05 [ 0.90, 4.68 ]
Subtotal (99% CI) 369 369 100.0 % 1.74 [ 0.91, 3.34 ]
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Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 46 (Lumacaftor-ivacaftor), 28 (Placebo)
Heterogeneity: Chi2 = 0.75, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.029)
17 Pyrexia
TRAFFIC 2015 17/182 12/183 35.0 % 1.47 [ 0.53, 4.04 ]
TRANSPORT 2015 16/187 22/186 65.0 % 0.70 [ 0.29, 1.70 ]
Subtotal (99% CI) 369 369 100.0 % 0.97 [ 0.50, 1.87 ]
Total events: 33 (Lumacaftor-ivacaftor), 34 (Placebo)
Heterogeneity: Chi2 = 2.02, df = 1 (P = 0.16); I2 =51%
Test for overall effect: Z = 0.13 (P = 0.90)
18 Nasal congestion
TRAFFIC 2015 11/182 25/183 56.9 % 0.41 [ 0.15, 1.08 ]
TRANSPORT 2015 13/187 19/186 43.1 % 0.66 [ 0.25, 1.73 ]
Subtotal (99% CI) 369 369 100.0 % 0.51 [ 0.26, 1.02 ]
Total events: 24 (Lumacaftor-ivacaftor), 44 (Placebo)
Heterogeneity: Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 2.51 (P = 0.012)
19 Upper respiratory tract infection
TRAFFIC 2015 17/182 10/183 50.2 % 1.78 [ 0.61, 5.17 ]
TRANSPORT 2015 20/187 10/186 49.8 % 2.11 [ 0.75, 5.94 ]
Subtotal (99% CI) 369 369 100.0 % 1.94 [ 0.93, 4.08 ]
Total events: 37 (Lumacaftor-ivacaftor), 20 (Placebo)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.31 (P = 0.021)
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Analysis 7.7. Comparison 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 7 Time to first pulmonary exacerbation.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 7 Time to first pulmonary exacerbation
Study or subgroup Lumacaftor-ivacaftor Placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
TRAFFIC 2015 182 184 -0.36962 (0.16) 50.0 % 0.69 [ 0.50, 0.95 ]
TRANSPORT 2015 187 187 -0.62923 (0.16) 50.0 % 0.53 [ 0.39, 0.73 ]
Total (95% CI) 369 371 100.0 % 0.61 [ 0.49, 0.76 ]
Heterogeneity: Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 4.41 (P = 0.000010)
Test for subgroup differences: Not applicable
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Analysis 7.8. Comparison 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 8 Rate of exacerbations.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 8 Rate of exacerbations
Study or subgroup Lumacaftor-ivacaftor Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
TRAFFIC 2015 182 184 -0.409 (0.1712) 44.5 % 0.66 [ 0.47, 0.93 ]
TRANSPORT 2015 187 187 -0.5693 (0.1532) 55.5 % 0.57 [ 0.42, 0.76 ]
Total (95% CI) 369 371 100.0 % 0.61 [ 0.49, 0.76 ]
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 4.36 (P = 0.000013)
Test for subgroup differences: Not applicable
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Analysis 7.9. Comparison 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 9 Weight (kg) (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 9 Weight (kg) (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months
TRAFFIC 2015 176 1.23 (2.7196) 184 0.93 (2.7401) 45.8 % 0.30 [ -0.26, 0.86 ]
TRANSPORT 2015 180 1.38 (2.5089) 183 0.44 (2.5297) 54.2 % 0.94 [ 0.42, 1.46 ]
Subtotal (95% CI) 356 367 100.0 % 0.65 [ 0.27, 1.03 ]
Heterogeneity: Chi2 = 2.68, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 3.32 (P = 0.00089)
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Analysis 7.10. Comparison 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 10 BMI (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 7 Lumacaftor (400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 10 BMI (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 28 days
TRAFFIC 2015 182 0.12 (0.550642) 184 0.08 (0.484452) 53.1 % 0.04 [ -0.07, 0.15 ]
TRANSPORT 2015 187 0.12 (0.558155) 187 0.12 (0.558155) 46.9 % 0.0 [ -0.11, 0.11 ]
Subtotal (95% CI) 369 371 100.0 % 0.02 [ -0.06, 0.10 ]
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
2 At 6 months
TRAFFIC 2015 176 0.32 (0.9419) 184 0.19 (0.9495) 46.7 % 0.13 [ -0.07, 0.33 ]
TRANSPORT 2015 180 0.43 (0.8855) 183 0.07 (0.8928) 53.3 % 0.36 [ 0.18, 0.54 ]
Subtotal (95% CI) 356 367 100.0 % 0.25 [ 0.12, 0.39 ]
Heterogeneity: Chi2 = 2.84, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 3.71 (P = 0.00021)
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Analysis 8.1. Comparison 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg
twice daily) versus placebo, Outcome 1 Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3
Level (EQ-5D-3L) Index Score (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 1 Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months
TRAFFIC 2015 345 0.008275 (0.099487) 179 0 (0.0989) 45.1 % 0.01 [ -0.01, 0.03 ]
TRANSPORT 2015 354 0.009895 (0.090677) 183 0.01 (0.091) 54.9 % 0.00 [ -0.02, 0.01 ]
Subtotal (95% CI) 699 362 100.0 % 0.00 [ -0.01, 0.01 ]
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
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Analysis 8.2. Comparison 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg
twice daily) versus placebo, Outcome 2 Quality of life - CFQ-R respiratory domain (absolute change from
baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 2 Quality of life - CFQ-R respiratory domain (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 28 days
TRAFFIC 2015 365 4.49863 (15.15094) 184 3 (14.53356) 52.3 % 1.50 [ -1.11, 4.11 ]
TRANSPORT 2015 372 7.101613 (15.29069) 187 1 (15.69811) 47.7 % 6.10 [ 3.37, 8.84 ]
Subtotal (95% CI) 737 371 100.0 % 3.70 [ 1.81, 5.58 ]
Heterogeneity: Chi2 = 5.69, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 3.83 (P = 0.00013)
2 At 6 months
TRAFFIC 2015 348 3.803678 (15.65326) 184 1.1 (15.7486) 49.5 % 2.70 [ -0.10, 5.51 ]
TRANSPORT 2015 359 5.339109 (15.62328) 185 2.81 (15.6825) 50.5 % 2.53 [ -0.25, 5.31 ]
Subtotal (95% CI) 707 369 100.0 % 2.62 [ 0.64, 4.59 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 2.60 (P = 0.0094)
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Analysis 8.3. Comparison 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg
twice daily) versus placebo, Outcome 3 Quality of life - EQ-5D-3L VAS Score (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 3 Quality of life - EQ-5D-3L VAS Score (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months
TRAFFIC 2015 344 3.152035 (13.49557) 180 1.4 (13.8189) 52.1 % 1.75 [ -0.72, 4.22 ]
TRANSPORT 2015 354 6.15 (14.35521) 182 3.3 (14.4351) 47.9 % 2.85 [ 0.27, 5.43 ]
Subtotal (95% CI) 698 362 100.0 % 2.28 [ 0.50, 4.06 ]
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.50 (P = 0.012)
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Analysis 8.4. Comparison 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg
twice daily) versus placebo, Outcome 4 FEV&subStart;1&subEnd; % predicted (relative change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 4 FEV1 % predicted (relative change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months
TRAFFIC 2015 348 5.203793 (12.15748) 180 -0.34 (12.2492) 52.4 % 5.54 [ 3.35, 7.74 ]
TRANSPORT 2015 361 4.83385 (12.89986) 183 0 (12.9866) 47.6 % 4.83 [ 2.53, 7.14 ]
Subtotal (95% CI) 709 363 100.0 % 5.21 [ 3.61, 6.80 ]
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 6.41 (P < 0.00001)
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Analysis 8.5. Comparison 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg
twice daily) versus placebo, Outcome 5 FEV&subStart;1&subEnd; % predicted (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 5 FEV1 % predicted (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 28 days
TRAFFIC 2015 365 2.400274 (7.571994) 184 0 (7.612819) 40.1 % 2.40 [ 1.05, 3.75 ]
TRANSPORT 2015 372 2.650806 (6.255879) 187 0.3 (6.279242) 59.9 % 2.35 [ 1.25, 3.45 ]
Subtotal (95% CI) 737 371 100.0 % 2.37 [ 1.52, 3.22 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 5.45 (P < 0.00001)
2 At 6 months
TRAFFIC 2015 348 2.883218 (6.984745) 180 -0.44 (7.0302) 51.2 % 3.32 [ 2.06, 4.59 ]
TRANSPORT 2015 361 2.65446 (7.247533) 183 -0.15 (7.2915) 48.8 % 2.80 [ 1.51, 4.10 ]
Subtotal (95% CI) 709 363 100.0 % 3.07 [ 2.17, 3.97 ]
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 6.66 (P < 0.00001)
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Analysis 8.6. Comparison 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg
twice daily) versus placebo, Outcome 6 Adverse events by end of study (at 6 months).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 6 Adverse events by end of study (at 6 months)
Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Any adverse event
TRAFFIC 2015 349/366 174/183 52.6 % 1.06 [ 0.36, 3.15 ]
TRANSPORT 2015 358/373 181/186 47.4 % 0.66 [ 0.17, 2.55 ]
Subtotal (99% CI) 739 369 100.0 % 0.87 [ 0.38, 2.02 ]
Total events: 707 (Lumacaftor-ivacaftor), 355 (Placebo)
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
2 Discontinuation due to an adverse event
TRAFFIC 2015 14/366 4/183 66.8 % 1.78 [ 0.41, 7.81 ]
TRANSPORT 2015 17/373 2/186 33.2 % 4.39 [ 0.63, 30.56 ]
Subtotal (99% CI) 739 369 100.0 % 2.65 [ 0.83, 8.45 ]
Total events: 31 (Lumacaftor-ivacaftor), 6 (Placebo)
Heterogeneity: Chi2 = 0.93, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.031)
3 At least 1 serious adverse event
TRAFFIC 2015 66/366 49/183 47.4 % 0.60 [ 0.35, 1.05 ]
TRANSPORT 2015 82/373 57/186 52.6 % 0.64 [ 0.38, 1.07 ]
Subtotal (99% CI) 739 369 100.0 % 0.62 [ 0.42, 0.91 ]
Total events: 148 (Lumacaftor-ivacaftor), 106 (Placebo)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 3.24 (P = 0.0012)
4 Infective pulmonary exacerbation
TRAFFIC 2015 132/366 87/183 48.9 % 0.62 [ 0.39, 1.00 ]
TRANSPORT 2015 145/373 95/186 51.1 % 0.61 [ 0.38, 0.97 ]
Subtotal (99% CI) 739 369 100.0 % 0.62 [ 0.44, 0.86 ]
Total events: 277 (Lumacaftor-ivacaftor), 182 (Placebo)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 3.76 (P = 0.00017)
5 Cough
TRAFFIC 2015 100/366 66/183 46.8 % 0.67 [ 0.40, 1.10 ]
TRANSPORT 2015 125/373 82/186 53.2 % 0.64 [ 0.40, 1.03 ]
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(. . . Continued)
Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 739 369 100.0 % 0.65 [ 0.46, 0.92 ]
Total events: 225 (Lumacaftor-ivacaftor), 148 (Placebo)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 3.21 (P = 0.0013)
6 Headache
TRAFFIC 2015 57/366 25/183 43.2 % 1.17 [ 0.60, 2.27 ]
TRANSPORT 2015 59/373 33/186 56.8 % 0.87 [ 0.47, 1.61 ]
Subtotal (99% CI) 739 369 100.0 % 1.00 [ 0.64, 1.57 ]
Total events: 116 (Lumacaftor-ivacaftor), 58 (Placebo)
Heterogeneity: Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
7 Haemoptysis
TRAFFIC 2015 52/366 24/183 47.7 % 1.10 [ 0.55, 2.17 ]
TRANSPORT 2015 50/373 26/186 52.3 % 0.95 [ 0.49, 1.86 ]
Subtotal (99% CI) 739 369 100.0 % 1.02 [ 0.63, 1.65 ]
Total events: 102 (Lumacaftor-ivacaftor), 50 (Placebo)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
8 Diarrhea
TRAFFIC 2015 40/366 13/183 41.9 % 1.60 [ 0.68, 3.78 ]
TRANSPORT 2015 41/373 18/186 58.1 % 1.15 [ 0.53, 2.48 ]
Subtotal (99% CI) 739 369 100.0 % 1.34 [ 0.76, 2.37 ]
Total events: 81 (Lumacaftor-ivacaftor), 31 (Placebo)
Heterogeneity: Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
9 Abnormal respiration
TRAFFIC 2015 40/366 9/183 40.3 % 2.37 [ 0.89, 6.32 ]
TRANSPORT 2015 32/373 13/186 59.7 % 1.25 [ 0.52, 3.01 ]
Subtotal (99% CI) 739 369 100.0 % 1.70 [ 0.89, 3.26 ]
Total events: 72 (Lumacaftor-ivacaftor), 22 (Placebo)
Heterogeneity: Chi2 = 1.58, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 2.11 (P = 0.035)
10 Increased sputum
TRAFFIC 2015 40/366 23/183 34.8 % 0.85 [ 0.42, 1.75 ]
TRANSPORT 2015 69/373 47/186 65.2 % 0.67 [ 0.39, 1.17 ]
Subtotal (99% CI) 739 369 100.0 % 0.73 [ 0.47, 1.14 ]
Total events: 109 (Lumacaftor-ivacaftor), 70 (Placebo)
Heterogeneity: Chi2 = 0.47, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.81 (P = 0.070)
11 Dyspnea
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Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
TRAFFIC 2015 39/366 14/183 50.1 % 1.44 [ 0.62, 3.33 ]
TRANSPORT 2015 64/373 15/186 49.9 % 2.36 [ 1.08, 5.14 ]
Subtotal (99% CI) 739 369 100.0 % 1.90 [ 1.08, 3.35 ]
Total events: 103 (Lumacaftor-ivacaftor), 29 (Placebo)
Heterogeneity: Chi2 = 1.24, df = 1 (P = 0.27); I2 =20%
Test for overall effect: Z = 2.91 (P = 0.0037)
12 Nasopharyngitis
TRAFFIC 2015 35/366 20/183 50.0 % 0.86 [ 0.40, 1.85 ]
TRANSPORT 2015 36/373 20/186 50.0 % 0.89 [ 0.42, 1.89 ]
Subtotal (99% CI) 739 369 100.0 % 0.87 [ 0.51, 1.50 ]
Total events: 71 (Lumacaftor-ivacaftor), 40 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
13 Oropharyngeal pain
TRAFFIC 2015 35/366 10/183 33.1 % 1.83 [ 0.70, 4.75 ]
TRANSPORT 2015 33/373 20/186 66.9 % 0.81 [ 0.37, 1.74 ]
Subtotal (99% CI) 739 369 100.0 % 1.14 [ 0.63, 2.06 ]
Total events: 68 (Lumacaftor-ivacaftor), 30 (Placebo)
Heterogeneity: Chi2 = 2.98, df = 1 (P = 0.08); I2 =66%
Test for overall effect: Z = 0.59 (P = 0.55)
14 Abdominal pain
TRAFFIC 2015 34/366 12/183 36.8 % 1.46 [ 0.59, 3.58 ]
TRANSPORT 2015 25/373 20/186 63.2 % 0.60 [ 0.27, 1.34 ]
Subtotal (99% CI) 739 369 100.0 % 0.91 [ 0.51, 1.65 ]
Total events: 59 (Lumacaftor-ivacaftor), 32 (Placebo)
Heterogeneity: Chi2 = 3.65, df = 1 (P = 0.06); I2 =73%
Test for overall effect: Z = 0.39 (P = 0.69)
15 Fatigue
TRAFFIC 2015 34/366 19/183 65.2 % 0.88 [ 0.41, 1.92 ]
TRANSPORT 2015 30/373 10/186 34.8 % 1.54 [ 0.58, 4.06 ]
Subtotal (99% CI) 739 369 100.0 % 1.11 [ 0.61, 2.03 ]
Total events: 64 (Lumacaftor-ivacaftor), 29 (Placebo)
Heterogeneity: Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.45 (P = 0.65)
16 Nausea
TRAFFIC 2015 23/366 11/183 41.3 % 1.05 [ 0.40, 2.78 ]
TRANSPORT 2015 52/373 17/186 58.7 % 1.61 [ 0.75, 3.44 ]
Subtotal (99% CI) 739 369 100.0 % 1.38 [ 0.76, 2.51 ]
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Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 75 (Lumacaftor-ivacaftor), 28 (Placebo)
Heterogeneity: Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
17 Pyrexia
TRAFFIC 2015 29/366 12/183 35.9 % 1.23 [ 0.49, 3.07 ]
TRANSPORT 2015 39/373 22/186 64.1 % 0.87 [ 0.42, 1.81 ]
Subtotal (99% CI) 739 369 100.0 % 1.00 [ 0.57, 1.76 ]
Total events: 68 (Lumacaftor-ivacaftor), 34 (Placebo)
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
18 Nasal congestion
TRAFFIC 2015 20/366 25/183 58.0 % 0.37 [ 0.16, 0.82 ]
TRANSPORT 2015 37/373 19/186 42.0 % 0.97 [ 0.45, 2.08 ]
Subtotal (99% CI) 739 369 100.0 % 0.62 [ 0.36, 1.07 ]
Total events: 57 (Lumacaftor-ivacaftor), 44 (Placebo)
Heterogeneity: Chi2 = 5.06, df = 1 (P = 0.02); I2 =80%
Test for overall effect: Z = 2.27 (P = 0.023)
19 Upper respiratory tract infection
TRAFFIC 2015 33/366 10/183 49.6 % 1.71 [ 0.66, 4.48 ]
TRANSPORT 2015 28/373 10/186 50.4 % 1.43 [ 0.54, 3.80 ]
Subtotal (99% CI) 739 369 100.0 % 1.57 [ 0.79, 3.11 ]
Total events: 61 (Lumacaftor-ivacaftor), 20 (Placebo)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.090)
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Analysis 8.7. Comparison 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg
twice daily) versus placebo, Outcome 7 Weight (kg) (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 7 Weight (kg) (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months
TRAFFIC 2015 354 1.285311 (2.724046) 184 0.93 (2.7401) 46.0 % 0.36 [ -0.13, 0.84 ]
TRANSPORT 2015 360 1.475 (2.513904) 183 0.44 (2.5297) 54.0 % 1.04 [ 0.59, 1.48 ]
Subtotal (95% CI) 714 367 100.0 % 0.72 [ 0.39, 1.05 ]
Heterogeneity: Chi2 = 4.04, df = 1 (P = 0.04); I2 =75%
Test for overall effect: Z = 4.29 (P = 0.000018)
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Analysis 8.8. Comparison 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg
twice daily) versus placebo, Outcome 8 BMI (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 8 Lumacaftor (600 mg once daily or 400 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 8 BMI (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 28 days
TRAFFIC 2015 365 0.114986 (0.586279) 184 0.08 (0.484452) 52.0 % 0.03 [ -0.06, 0.13 ]
TRANSPORT 2015 372 0.115027 (0.522728) 187 0.12 (0.558155) 48.0 % 0.00 [ -0.10, 0.09 ]
Subtotal (95% CI) 737 371 100.0 % 0.02 [ -0.05, 0.08 ]
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
2 At 6 months
TRAFFIC 2015 354 0.335085 (0.936677) 184 0.19 (0.9495) 46.9 % 0.15 [ -0.02, 0.31 ]
TRANSPORT 2015 360 0.455 (0.88462) 183 0.07 (0.8928) 53.1 % 0.39 [ 0.23, 0.54 ]
Subtotal (95% CI) 714 367 100.0 % 0.27 [ 0.16, 0.39 ]
Heterogeneity: Chi2 = 4.14, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 4.63 (P < 0.00001)
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Analysis 9.1. Comparison 9 Lumacaftor (200 mg once daily) for 21 days plus ivacaftor (150 mg twice daily)
for days 15 to 21 versus placebo, Outcome 1 FEV&subStart;1&subEnd; % predicted (absolute change from
baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 9 Lumacaftor (200 mg once daily) for 21 days plus ivacaftor (150 mg twice daily) for days 15 to 21 versus placebo
Outcome: 1 FEV1 % predicted (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 14 days (before addition of ivacaftor)
Boyle 2014 20 -0.1 (4.2734) 21 1.7 (4.174) 100.0 % -1.80 [ -4.39, 0.79 ]
Subtotal (95% CI) 20 21 100.0 % -1.80 [ -4.39, 0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
2 At 21 days
Boyle 2014 20 3.1 (6.6953) 21 0.3 (6.9891) 100.0 % 2.80 [ -1.39, 6.99 ]
Subtotal (95% CI) 20 21 100.0 % 2.80 [ -1.39, 6.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
-100 -50 0 50 100
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Analysis 9.2. Comparison 9 Lumacaftor (200 mg once daily) for 21 days plus ivacaftor (150 mg twice daily)
for days 15 to 21 versus placebo, Outcome 2 Adverse events occurring in 10% or more participants (from days
15 - 21).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 9 Lumacaftor (200 mg once daily) for 21 days plus ivacaftor (150 mg twice daily) for days 15 to 21 versus placebo
Outcome: 2 Adverse events occurring in 10% or more participants (from days 15 - 21)
Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Cough
Boyle 2014 4/20 4/21 100.0 % 1.06 [ 0.14, 8.09 ]
Subtotal (99% CI) 20 21 100.0 % 1.06 [ 0.14, 8.09 ]
Total events: 4 (Lumacaftor-ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
2 Pulmonary Exacerbation
Boyle 2014 2/20 1/21 100.0 % 2.22 [ 0.08, 58.11 ]
Subtotal (99% CI) 20 21 100.0 % 2.22 [ 0.08, 58.11 ]
Total events: 2 (Lumacaftor-ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
3 Oropharyngeal pain
Boyle 2014 1/20 2/21 100.0 % 0.50 [ 0.02, 13.07 ]
Subtotal (99% CI) 20 21 100.0 % 0.50 [ 0.02, 13.07 ]
Total events: 1 (Lumacaftor-ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
4 Nasal congestion
Boyle 2014 1/20 2/21 100.0 % 0.50 [ 0.02, 13.07 ]
Subtotal (99% CI) 20 21 100.0 % 0.50 [ 0.02, 13.07 ]
Total events: 1 (Lumacaftor-ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
5 Dizziness
Boyle 2014 2/20 0/21 100.0 % 5.81 [ 0.10, 341.36 ]
Subtotal (99% CI) 20 21 100.0 % 5.81 [ 0.10, 341.36 ]
Total events: 2 (Lumacaftor-ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
6 Prothrombin time prolonged
Boyle 2014 2/20 0/21 100.0 % 5.81 [ 0.10, 341.36 ]
0.001 0.01 0.1 1 10 100 1000
Favours lumacaftor-ivacaftor Favours placebo
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Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 20 21 100.0 % 5.81 [ 0.10, 341.36 ]
Total events: 2 (Lumacaftor-ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
7 Upper respiratory tract infection
Boyle 2014 2/20 0/21 100.0 % 5.81 [ 0.10, 341.36 ]
Subtotal (99% CI) 20 21 100.0 % 5.81 [ 0.10, 341.36 ]
Total events: 2 (Lumacaftor-ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
0.001 0.01 0.1 1 10 100 1000
Favours lumacaftor-ivacaftor Favours placebo
Analysis 9.3. Comparison 9 Lumacaftor (200 mg once daily) for 21 days plus ivacaftor (150 mg twice daily)
for days 15 to 21 versus placebo, Outcome 3 Sweat chloride concentration (mmol/L) (change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 9 Lumacaftor (200 mg once daily) for 21 days plus ivacaftor (150 mg twice daily) for days 15 to 21 versus placebo
Outcome: 3 Sweat chloride concentration (mmol/L) (change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 14 days (before addition of ivacaftor)
Boyle 2014 17 -4.8 (7.3908) 17 -1.7 (8.8462) 100.0 % -3.10 [ -8.58, 2.38 ]
Subtotal (95% CI) 17 17 100.0 % -3.10 [ -8.58, 2.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
2 At 21 days
Boyle 2014 17 -6.7 (9.5302) 16 -1.7 (9.8142) 100.0 % -5.00 [ -11.61, 1.61 ]
Subtotal (95% CI) 17 16 100.0 % -5.00 [ -11.61, 1.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
-100 -50 0 50 100
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Analysis 10.1. Comparison 10 Lumacaftor (200 mg once daily) for 21 days plus ivacaftor (250 mg twice
daily) for days 15 to 21 versus placebo, Outcome 1 FEV&subStart;1&subEnd; % predicted (absolute change
from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 10 Lumacaftor (200 mg once daily) for 21 days plus ivacaftor (250 mg twice daily) for days 15 to 21 versus placebo
Outcome: 1 FEV1 % predicted (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 14 days (before addition of ivacaftor)
Boyle 2014 20 -0.3 (4.487) 21 1.7 (4.174) 100.0 % -2.00 [ -4.66, 0.66 ]
Subtotal (95% CI) 20 21 100.0 % -2.00 [ -4.66, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
2 At 21 days
Boyle 2014 18 0.5 (6.9891) 21 0.3 (6.9891) 100.0 % 0.20 [ -4.20, 4.60 ]
Subtotal (95% CI) 18 21 100.0 % 0.20 [ -4.20, 4.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
-100 -50 0 50 100
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Analysis 10.2. Comparison 10 Lumacaftor (200 mg once daily) for 21 days plus ivacaftor (250 mg twice
daily) for days 15 to 21 versus placebo, Outcome 2 Adverse events occurring in 10% or more participants (from
days 15 - 21).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 10 Lumacaftor (200 mg once daily) for 21 days plus ivacaftor (250 mg twice daily) for days 15 to 21 versus placebo
Outcome: 2 Adverse events occurring in 10% or more participants (from days 15 - 21)
Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Cough
Boyle 2014 1/20 4/21 43.6 % 0.22 [ 0.01, 4.52 ]
Subtotal (99% CI) 20 21 43.6 % 0.22 [ 0.01, 4.52 ]
Total events: 1 (Lumacaftor-ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
2 Pulmonary Exacerbation
Boyle 2014 1/20 1/21 10.9 % 1.05 [ 0.03, 44.10 ]
Subtotal (99% CI) 20 21 10.9 % 1.05 [ 0.03, 44.10 ]
Total events: 1 (Lumacaftor-ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
3 Oropharyngeal pain
Boyle 2014 2/20 2/21 20.7 % 1.06 [ 0.07, 15.89 ]
Subtotal (99% CI) 20 21 20.7 % 1.06 [ 0.07, 15.89 ]
Total events: 2 (Lumacaftor-ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
4 Nasal congestion
Boyle 2014 3/20 2/21 19.5 % 1.68 [ 0.14, 20.50 ]
Subtotal (99% CI) 20 21 19.5 % 1.68 [ 0.14, 20.50 ]
Total events: 3 (Lumacaftor-ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
5 Dizziness
Boyle 2014 1/20 0/21 5.3 % 3.31 [ 0.05, 239.61 ]
Subtotal (99% CI) 20 21 5.3 % 3.31 [ 0.05, 239.61 ]
Total events: 1 (Lumacaftor-ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
6 Prothrombin time prolonged
Boyle 2014 0/20 0/21 Not estimable
0.001 0.01 0.1 1 10 100 1000
Favours lumacaftor-ivacaftor Favours placebo
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Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 20 21 Not estimable
Total events: 0 (Lumacaftor-ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Upper respiratory tract infection
Boyle 2014 0/20 0/21 Not estimable
Subtotal (99% CI) 20 21 Not estimable
Total events: 0 (Lumacaftor-ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (99% CI) 140 147 100.0 % 0.93 [ 0.26, 3.33 ]
Total events: 8 (Lumacaftor-ivacaftor), 9 (Placebo)
Heterogeneity: Chi2 = 2.46, df = 4 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 2.45, df = 4 (P = 0.65), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
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Analysis 10.3. Comparison 10 Lumacaftor (200 mg once daily) for 21 days plus ivacaftor (250 mg twice daily)
for days 15 to 21 versus placebo, Outcome 3 Sweat chloride concentration (mmol/L) (change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 10 Lumacaftor (200 mg once daily) for 21 days plus ivacaftor (250 mg twice daily) for days 15 to 21 versus placebo
Outcome: 3 Sweat chloride concentration (mmol/L) (change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 14 days (before addition of ivacaftor)
Boyle 2014 17 -4.1 (7.7798) 17 -1.7 (8.8462) 100.0 % -2.40 [ -8.00, 3.20 ]
Subtotal (95% CI) 17 17 100.0 % -2.40 [ -8.00, 3.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
2 At 21 days
Boyle 2014 17 -12.6 (9.8142) 16 -1.7 (9.8142) 100.0 % -10.90 [ -17.60, -4.20 ]
Subtotal (95% CI) 17 16 100.0 % -10.90 [ -17.60, -4.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.19 (P = 0.0014)
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Analysis 11.1. Comparison 11 Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 1 Quality of life - CFQ-R respiratory domain (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 11 Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 1 Quality of life - CFQ-R respiratory domain (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 up to and including week 24
Ratjen 2017 103 101 2.5 (1.3266) 100.0 % 2.50 [ -0.10, 5.10 ]
Subtotal (95% CI) 103 101 100.0 % 2.50 [ -0.10, 5.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.059)
-10 -5 0 5 10
Favours placebo Favours lumacaftor-ivacaftor
Analysis 11.2. Comparison 11 Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 2 FEV&subStart;1&subEnd; % predicted (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 11 Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 2 FEV1 % predicted (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 up to and including 24 weeks
Ratjen 2017 103 101 2.4 (1.0204) 100.0 % 2.40 [ 0.40, 4.40 ]
Subtotal (95% CI) 103 101 100.0 % 2.40 [ 0.40, 4.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
-4 -2 0 2 4
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Analysis 11.3. Comparison 11 Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 3 LCI&subStart;2.5&subEnd; (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 11 Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 3 LCI2.5 (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 up to and including 24 weeks
Ratjen 2017 103 101 -1.1 (0.1531) 100.0 % -1.10 [ -1.40, -0.80 ]
Subtotal (95% CI) 103 101 100.0 % -1.10 [ -1.40, -0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.18 (P < 0.00001)
-2 -1 0 1 2
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Analysis 11.4. Comparison 11 Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 4 Treatment-emergent adverse events with incidence > 10% in any treatment group.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 11 Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 4 Treatment-emergent adverse events with incidence > 10% in any treatment group
Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Any adverse event
Ratjen 2017 98/103 98/101 0.60 [ 0.09, 4.08 ]
2 Any serious adverse event
Ratjen 2017 13/103 11/101 1.18 [ 0.38, 3.63 ]
3 Cough
Ratjen 2017 46/103 47/101 0.93 [ 0.45, 1.91 ]
4 Pulmonary exacerbation
Ratjen 2017 20/103 18/101 1.11 [ 0.44, 2.81 ]
5 Productive cough
Ratjen 2017 18/103 6/101 3.35 [ 0.94, 11.98 ]
6 Nasal congestion
Ratjen 2017 17/103 8/101 2.30 [ 0.71, 7.40 ]
7 Oropharyngeal pain
Ratjen 2017 15/103 10/101 1.55 [ 0.51, 4.75 ]
8 Pyrexia
Ratjen 2017 15/103 20/101 0.69 [ 0.26, 1.81 ]
9 Upper abdominal pain
Ratjen 2017 13/103 7/101 1.94 [ 0.55, 6.88 ]
10 Headache
Ratjen 2017 13/103 9/101 1.48 [ 0.45, 4.81 ]
11 Upper respiratory tract infection
Ratjen 2017 13/103 10/101 1.31 [ 0.42, 4.15 ]
12 Sputum increased
Ratjen 2017 11/103 2/101 5.92 [ 0.79, 44.39 ]
13 Abdominal pain
Ratjen 2017 10/103 10/101 0.98 [ 0.29, 3.29 ]
14 Nausea
Ratjen 2017 10/103 9/101 1.10 [ 0.32, 3.81 ]
15 Rhinorrhoea
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Favours lumacaftor-ivacaftor Favours placebo
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Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Ratjen 2017 10/103 5/101 2.06 [ 0.48, 8.89 ]
16 Vomiting
Ratjen 2017 10/103 10/101 0.98 [ 0.29, 3.29 ]
17 Fatigue
Ratjen 2017 9/103 11/101 0.78 [ 0.23, 2.65 ]
18 Respiratory events
Ratjen 2017 19/103 13/101 1.53 [ 0.56, 4.19 ]
0.01 0.1 1 10 100
Favours lumacaftor-ivacaftor Favours placebo
Analysis 11.5. Comparison 11 Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 5 Sweat chloride concentration (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 11 Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 5 Sweat chloride concentration (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 up to and including 4 weeks
Ratjen 2017 103 101 -20.8 (1.3266) 100.0 % -20.80 [ -23.40, -18.20 ]
Subtotal (95% CI) 103 101 100.0 % -20.80 [ -23.40, -18.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 15.68 (P < 0.00001)
-100 -50 0 50 100
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Analysis 11.6. Comparison 11 Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 6 BMI (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 11 Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 6 BMI (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 up to and including 24 weeks
Ratjen 2017 103 101 0.1 (0.102) 100.0 % 0.10 [ -0.10, 0.30 ]
Subtotal (95% CI) 103 101 100.0 % 0.10 [ -0.10, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
-2 -1 0 1 2
Favours placebo Favours lumacaftor-ivacaftor
Analysis 11.7. Comparison 11 Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus
placebo, Outcome 7 BMI for age z-score (absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 11 Lumacaftor (200 mg twice daily) plus ivacaftor (250 mg twice daily) versus placebo
Outcome: 7 BMI for age z-score (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 up to and including 24 weeks
Ratjen 2017 103 101 0 (0.051) 100.0 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 103 101 100.0 % 0.0 [ -0.10, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
-1 -0.5 0 0.5 1
Favours placebo Favours lumacaftor-ivacaftor
170Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 12.1. Comparison 12 Lumacaftor (200 mg once daily monotherapy for 14 days) plus ivacaftor (150
mg or 250 mg twice daily for days 15 to 21) for 21 days, Outcome 1 FEV&subStart;1&subEnd; % predicted
(absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 12 Lumacaftor (200 mg once daily monotherapy for 14 days) plus ivacaftor (150 mg or 250 mg twice daily for days 15 to 21) for 21 days
Outcome: 1 FEV1 % predicted (absolute change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 21 days
Boyle 2014 38 1.868421 (6.869761) 21 0.3 (6.9891) 100.0 % 1.57 [ -2.13, 5.27 ]
Subtotal (95% CI) 38 21 100.0 % 1.57 [ -2.13, 5.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
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Analysis 12.2. Comparison 12 Lumacaftor (200 mg once daily monotherapy for 14 days) plus ivacaftor (150
mg or 250 mg twice daily for days 15 to 21) for 21 days, Outcome 2 Adverse events occurring in 10% or more
participants (from days 15 - 21).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 12 Lumacaftor (200 mg once daily monotherapy for 14 days) plus ivacaftor (150 mg or 250 mg twice daily for days 15 to 21) for 21 days
Outcome: 2 Adverse events occurring in 10% or more participants (from days 15 - 21)
Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Cough
Boyle 2014 5/40 4/21 100.0 % 0.61 [ 0.09, 4.01 ]
Subtotal (99% CI) 40 21 100.0 % 0.61 [ 0.09, 4.01 ]
Total events: 5 (Lumacaftor-ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 Pulmonary exacerbation
Boyle 2014 3/40 1/21 100.0 % 1.62 [ 0.08, 34.55 ]
Subtotal (99% CI) 40 21 100.0 % 1.62 [ 0.08, 34.55 ]
Total events: 3 (Lumacaftor-ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
3 Oropharyngeal pain
Boyle 2014 3/40 2/21 100.0 % 0.77 [ 0.07, 9.03 ]
Subtotal (99% CI) 40 21 100.0 % 0.77 [ 0.07, 9.03 ]
Total events: 3 (Lumacaftor-ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
4 Nasal congestion
Boyle 2014 4/40 2/21 100.0 % 1.06 [ 0.10, 11.04 ]
Subtotal (99% CI) 40 21 100.0 % 1.06 [ 0.10, 11.04 ]
Total events: 4 (Lumacaftor-ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
5 Dizziness
Boyle 2014 3/40 0/21 100.0 % 4.01 [ 0.08, 209.72 ]
Subtotal (99% CI) 40 21 100.0 % 4.01 [ 0.08, 209.72 ]
Total events: 3 (Lumacaftor-ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
6 Prothrombin time prolonged
Boyle 2014 2/40 0/21 100.0 % 2.79 [ 0.05, 160.31 ]
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Study or subgroup Lumacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 40 21 100.0 % 2.79 [ 0.05, 160.31 ]
Total events: 2 (Lumacaftor-ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
7 Upper respiratory tract infection
Boyle 2014 2/40 0/21 100.0 % 2.79 [ 0.05, 160.31 ]
Subtotal (99% CI) 40 21 100.0 % 2.79 [ 0.05, 160.31 ]
Total events: 2 (Lumacaftor-ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
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Analysis 12.3. Comparison 12 Lumacaftor (200 mg once daily monotherapy for 14 days) plus ivacaftor (150
mg or 250 mg twice daily for days 15 to 21) for 21 days, Outcome 3 Sweat chloride concentration (mmol/L)
(change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 12 Lumacaftor (200 mg once daily monotherapy for 14 days) plus ivacaftor (150 mg or 250 mg twice daily for days 15 to 21) for 21 days
Outcome: 3 Sweat chloride concentration (mmol/L) (change from baseline)
Study or subgroup Lumacaftor-ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 21 days
Boyle 2014 34 -9.65 (9.985105) 16 -1.7 (9.8142) 100.0 % -7.95 [ -13.81, -2.09 ]
Subtotal (95% CI) 34 16 100.0 % -7.95 [ -13.81, -2.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0079)
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Analysis 13.1. Comparison 13 Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus
either placebo or ivacaftor (150 mg twice daily) alone, Outcome 1 CFQ-R respiratory domain (absolute
change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 13 Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus either placebo or ivacaftor (150 mg twice daily) alone
Outcome: 1 CFQ-R respiratory domain (absolute change from baseline)
Study or subgroup Tezacaftor-ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 4 weeks
Taylor-Cousar 2017 248 256 5.1 (1.0771) 100.0 % 5.10 [ 2.99, 7.21 ]
Subtotal (95% CI) 248 256 100.0 % 5.10 [ 2.99, 7.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.73 (P < 0.00001)
2 At 24 weeks
Taylor-Cousar 2017 248 256 5.1 (0.9694) 100.0 % 5.10 [ 3.20, 7.00 ]
Subtotal (95% CI) 248 256 100.0 % 5.10 [ 3.20, 7.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.26 (P < 0.00001)
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Analysis 13.2. Comparison 13 Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus
either placebo or ivacaftor (150 mg twice daily) alone, Outcome 2 FEV&subStart;1&subEnd; % predicted
(relative change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 13 Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus either placebo or ivacaftor (150 mg twice daily) alone
Outcome: 2 FEV1 % predicted (relative change from baseline)
Study or subgroup Tezacaftor-ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At week 4
Donaldson 2018 14 4 3.72 (5.8624) 100.0 % 3.72 [ -7.77, 15.21 ]
Subtotal (95% CI) 14 4 100.0 % 3.72 [ -7.77, 15.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
2 At week 24
Taylor-Cousar 2017 248 256 6.8 (0.7653) 100.0 % 6.80 [ 5.30, 8.30 ]
Subtotal (95% CI) 248 256 100.0 % 6.80 [ 5.30, 8.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.89 (P < 0.00001)
-100 -50 0 50 100
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Analysis 13.3. Comparison 13 Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus
either placebo or ivacaftor (150 mg twice daily) alone, Outcome 3 FEV&subStart;1&subEnd; % predicted
(absolute change from baseline).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 13 Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus either placebo or ivacaftor (150 mg twice daily) alone
Outcome: 3 FEV1 % predicted (absolute change from baseline)
Study or subgroup Tezacaftor-ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At week 4
Donaldson 2018 14 4 3.2 (3.7246) 2.6 % 3.20 [ -4.10, 10.50 ]
Taylor-Cousar 2017 248 256 3.6 (0.6144) 97.4 % 3.60 [ 2.40, 4.80 ]
Subtotal (95% CI) 262 260 100.0 % 3.59 [ 2.40, 4.78 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 5.92 (P < 0.00001)
2 At week 24
Taylor-Cousar 2017 248 256 4 (0.4592) 100.0 % 4.00 [ 3.10, 4.90 ]
Subtotal (95% CI) 248 256 100.0 % 4.00 [ 3.10, 4.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.71 (P < 0.00001)
-4 -2 0 2 4
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Analysis 13.4. Comparison 13 Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus
either placebo or ivacaftor (150 mg twice daily) alone, Outcome 4 Most common adverse events (occurring in
at least 10% of participants in either group).
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 13 Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus either placebo or ivacaftor (150 mg twice daily) alone
Outcome: 4 Most common adverse events (occurring in at least 10% of participants in either group)
Study or subgroup Tezacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Cough
Donaldson 2018 2/14 0/4 1.0 % 1.80 [ 0.03, 124.22 ]
Taylor-Cousar 2017 66/251 88/258 99.0 % 0.69 [ 0.42, 1.14 ]
Subtotal (99% CI) 265 262 100.0 % 0.70 [ 0.43, 1.15 ]
Total events: 68 (Tezacaftor-ivacaftor), 88 (Placebo)
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.85 (P = 0.064)
2 Pulmonary exacerbation
Donaldson 2018 2/14 1/4 2.0 % 0.50 [ 0.01, 17.69 ]
Taylor-Cousar 2017 75/251 96/258 98.0 % 0.72 [ 0.44, 1.17 ]
Subtotal (99% CI) 265 262 100.0 % 0.71 [ 0.44, 1.16 ]
Total events: 77 (Tezacaftor-ivacaftor), 97 (Placebo)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.80 (P = 0.073)
3 Headache
Donaldson 2018 1/14 0/4 2.2 % 1.00 [ 0.01, 84.25 ]
Taylor-Cousar 2017 44/251 37/258 97.8 % 1.27 [ 0.68, 2.37 ]
Subtotal (99% CI) 265 262 100.0 % 1.26 [ 0.68, 2.35 ]
Total events: 45 (Tezacaftor-ivacaftor), 37 (Placebo)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
4 Nasal congestion or nasopharyngitis
Donaldson 2018 1/14 1/4 4.3 % 0.23 [ 0.00, 12.59 ]
Taylor-Cousar 2017 42/251 39/258 95.7 % 1.13 [ 0.60, 2.11 ]
Subtotal (99% CI) 265 262 100.0 % 1.09 [ 0.59, 2.02 ]
Total events: 43 (Tezacaftor-ivacaftor), 40 (Placebo)
Heterogeneity: Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 0.36 (P = 0.72)
5 Increased sputum
Taylor-Cousar 2017 36/251 42/258 100.0 % 0.86 [ 0.46, 1.63 ]
0.001 0.01 0.1 1 10 100 1000
Favours tezacaftor-ivacaftor Favours placebo
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(. . . Continued)
Study or subgroup Tezacaftor-ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 251 258 100.0 % 0.86 [ 0.46, 1.63 ]
Total events: 36 (Tezacaftor-ivacaftor), 42 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
6 Haemoptysis
Donaldson 2018 1/14 0/4 2.1 % 1.00 [ 0.01, 84.25 ]
Taylor-Cousar 2017 26/251 35/258 97.9 % 0.74 [ 0.36, 1.50 ]
Subtotal (99% CI) 265 262 100.0 % 0.74 [ 0.37, 1.49 ]
Total events: 27 (Tezacaftor-ivacaftor), 35 (Placebo)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
7 Pyrexia
Donaldson 2018 1/14 0/4 2.4 % 1.00 [ 0.01, 84.25 ]
Taylor-Cousar 2017 28/251 32/258 97.6 % 0.89 [ 0.44, 1.80 ]
Subtotal (99% CI) 265 262 100.0 % 0.89 [ 0.44, 1.79 ]
Total events: 29 (Tezacaftor-ivacaftor), 32 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
8 Oropharyngeal pain
Taylor-Cousar 2017 22/251 29/258 100.0 % 0.76 [ 0.35, 1.63 ]
Subtotal (99% CI) 251 258 100.0 % 0.76 [ 0.35, 1.63 ]
Total events: 22 (Tezacaftor-ivacaftor), 29 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
9 Fatigue
Donaldson 2018 1/14 0/4 2.3 % 1.00 [ 0.01, 84.25 ]
Taylor-Cousar 2017 16/251 31/258 97.7 % 0.50 [ 0.22, 1.14 ]
Subtotal (99% CI) 265 262 100.0 % 0.51 [ 0.23, 1.15 ]
Total events: 17 (Tezacaftor-ivacaftor), 31 (Placebo)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.14 (P = 0.033)
10 Nausea
Donaldson 2018 2/14 0/4 3.7 % 1.80 [ 0.03, 124.22 ]
Taylor-Cousar 2017 23/251 18/258 96.3 % 1.35 [ 0.58, 3.13 ]
Subtotal (99% CI) 265 262 100.0 % 1.36 [ 0.60, 3.12 ]
Total events: 25 (Tezacaftor-ivacaftor), 18 (Placebo)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
0.001 0.01 0.1 1 10 100 1000
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Analysis 13.5. Comparison 13 Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus
either placebo or ivacaftor (150 mg twice daily) alone, Outcome 5 Time to first pulmonary exacerbation.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 13 Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus either placebo or ivacaftor (150 mg twice daily) alone
Outcome: 5 Time to first pulmonary exacerbation
Study or subgroup Tezacaftor-ivacaftor Placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Taylor-Cousar 2017 248 258 -0.4463 (0.1685) 0.64 [ 0.46, 0.89 ]
0.01 0.1 1 10 100
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Analysis 13.6. Comparison 13 Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus
either placebo or ivacaftor (150 mg twice daily) alone, Outcome 6 Sweat chloride change from baseline.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 13 Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus either placebo or ivacaftor (150 mg twice daily) alone
Outcome: 6 Sweat chloride change from baseline
Study or subgroup Tezacaftor-ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 4 weeks
Donaldson 2018 14 4 -17.2 (7.4236) 1.7 % -17.20 [ -31.75, -2.65 ]
Taylor-Cousar 2017 248 256 -9.1 (0.9701) 98.3 % -9.10 [ -11.00, -7.20 ]
Subtotal (95% CI) 262 260 100.0 % -9.24 [ -11.12, -7.35 ]
Heterogeneity: Chi2 = 1.17, df = 1 (P = 0.28); I2 =15%
Test for overall effect: Z = 9.60 (P < 0.00001)
2 At 24 weeks
Taylor-Cousar 2017 248 256 -10.1 (0.6633) 100.0 % -10.10 [ -11.40, -8.80 ]
Subtotal (95% CI) 248 256 100.0 % -10.10 [ -11.40, -8.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 15.23 (P < 0.00001)
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Analysis 13.7. Comparison 13 Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus
either placebo or ivacaftor (150 mg twice daily) alone, Outcome 7 BMI change from baseline.
Review: Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Comparison: 13 Tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus either placebo or ivacaftor (150 mg twice daily) alone
Outcome: 7 BMI change from baseline
Study or subgroup Tezacaftor-ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 4 weeks
Taylor-Cousar 2017 248 256 -0.03 (0.0503) 100.0 % -0.03 [ -0.13, 0.07 ]
Subtotal (95% CI) 248 256 100.0 % -0.03 [ -0.13, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
2 At 24 weeks
Taylor-Cousar 2017 248 256 0.06 (0.0714) 100.0 % 0.06 [ -0.08, 0.20 ]
Subtotal (95% CI) 248 256 100.0 % 0.06 [ -0.08, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
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A D D I T I O N A L T A B L E S
Table 1. Classes of mutations affecting CFTR production, structure and function
Class Example mutation Impact on CFTR structure and function
I G542X Synthesis of CFTR is critically impaired, and no functional protein is produced. This is due to the
presence of a premature stop codon in the nucleotide sequence. Individuals have minimal CFTR
function
II F508del A full length of CFTR is produced, but this is structurally abnormal and destroyed by the cell before
it reaches the cell membrane. This is called a defect in the intracellular trafficking pathway. Small
amounts of CFTR do reach the cell membrane; however here, they display defective ion transport,
demonstrating that the phe508del mutation is more than just a processing defect. Individuals have
minimal CFTR function
III G551D CFTR is produced and embedded in the cell membrane, but the chloride channel does not respond
(’switch on’) to normal stimulation from the cell. This means there is no meaningful ion transport
across the protein. Individuals have minimal CFTR function
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Table 1. Classes of mutations affecting CFTR production, structure and function (Continued)
IV R347P CFTR is transported to the outer cell membrane, and responds to normal stimulation, but functions
at a low level because chloride ions do not cross the channel appropriately. Individuals have some
residual CFTR function
V A455E Normal CFTR is produced, but the amount of protein is reduced. Individuals have some residual
CFTR function
CFTR: cystic fibrosis transmembrane regulator
Table 2. Change from baseline CFQ-R domain scores at 28 days (Clancy 2012)
Lumacaftor Placebo
Domain 25 mg (n = 17) 50 mg (n = 17) 100 mg (n = 16) 200 mg (n =18) (n = 17)
Body -0.21 -1.63 2.61 0.06 -1.34
Digestion 2.28 -0.72 0.25 2.58 4.62
Eating -3.66 -7.27* 3.24 -2.58 2.11
Emotion -3.22 -1.36 3.49 -2.62 4.86
Health Perceptions -2.84 -6.97* -0.44 -1.9 5.03
Physical -5.97 -7.38* -3.46 -0.98 1.23
Respiratory -5.22 -6.32* -1.29 2.22 4.53
Role -5.94* -4.6 1.1 -6.53* 2.21
Social 0 -1.01 0.47 -2.64 -0.55
Treatment Burden 4.19 -5.96* 1.42 -0.68 2.46
Vitality -4.65 -7.23* -1.52 0.73 -2.18
Weight 5.41 2.18 8.83 -4.19 0.3
*statistically significant results versus placebo are highlighted by stars
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Table 3. Frequency of adverse effects occurring in more than one participant in any VX-809 treatment group (Clancy 2012)
Placebo
n (%)
Lumacaftor
n (%)
Total
n (%)
Adverse effect n
(%)
(n = 17) 25 mg (n = 18) 50 mg (n = 18) 100 mg (n = 17) 200 mg (n = 18) (n = 45)*
Cough 7 (41.2) 10 (55.6) 6 (33.3) 7 (41.2) 10 (52.6) 40 (88.9)
Headache 3 (17.6) 4 (22.2) 5 (27.8) 2 (11.8) 5 (26.3) 19 (42.2)
Rales 1 (5.9) 6 (33.3) 2 (11.1) 3 (17.6) 3 (15.8) 15 (33.3)
Productive
cough
3 (17.6) 2 (11.1) 0 (0.0) 4 (23.5) 6 (31.6) 15 (17.8)
Dyspnoea 1 (5.9) 5 (27.8) 3 (16.7) 2 (11.8) 4 (21.1) 15 (33.3)
Pulmonary exac-
erbation*
2 (11.8) 4 (22.2) 2 (11.1) 2 (11.8) 4 (21.1) 14 (31.1)
Fatigue 2 (11.8) 3 (16.7) 3 (16.7) 2 (11.8) 3 (15.8) 13 (28.9)
Fever 2 (11.8) 2 (11.1) 1 (5.6) 1 (5.9) 5 (26.3) 11 (24.4)
Nasal congestion 3 (17.6) 2 (11.1) 1 (5.6) 2 (11.8) 2 (10.5) 10 (22.2)
Wheezing 3 (17.6) 1 (5.6) 4 (22.2) 1 (5.9) 0 (0.0) 9 (20.0)
Diarrhoea 3 (17.6) 3 (16.7) 1 (5.6) 2 (11.8) 0 (0.0) 9 (20)
Oropharyngeal
pain
3 (17.6) 0 (0.0) 3 (16.7) 0 (0.0) 2 (10.5) 8 (17.8)
Upper res-
piratory tract in-
fection
1 (5.9) 2 (11.1) 1 (5.6 3 (17.6) 0 (0.0) 7 (15.6)
Sinus congestion 2 (11.8) 1 (5.6) 2 (11.1) 0 (0.0) 1 (5.3) 6 (13.3)
Respiration ab-
normal
0 (0.0) 1 (5.6) 1 (5.6) 0 (0.0) 4 (21.1) 6 (13.3)
Haemoptysis 2 (11.8) 1 (5.6) 1 (5.6) 0 (0.0) 2 (10.5) 6 (13.3)
Constipation 0 (0.0) 2 (11.1) 2 (11.1) 1 (5.9) 1 (5.3) 6 (13.3)
Abdominal pain 1 (5.9) 3 (16.7) 1 (5.6) 0 (0.0) 1 (5.3) 6 (13.3)
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Table 3. Frequency of adverse effects occurring in more than one participant in any VX-809 treatment group (Clancy 2012)
(Continued)
Myalgia 1 (5.9) 0 (0.0) 3 (16.7) 0 (0.0) 1 (5.3) 5 (11.1)
Post-tussive
vomiting
0 (0.0) 0 (0.0) 2 (11.1) 1 (5.9) 1 (5.3) 4 (8.9)
Nausea 0 (0.0) 3 (16.7) 0 (0.0) 0 (0.0) 1 (5.3) 4 (8.9)
Nasopharyngitis 0 (0.0) 1 (5.6) 0 (0.0) 1 (5.9) 2 (10.5) 4 (8.9)
Dizziness 0 (0.0) 1 (5.6) 0 (0.0) 2 (11.8) 1 (5.3) 4 (8.9)
Back pain 0 (0.0) 2 (11.1) 1 (5.6) 0 (0.0) 1 (5.3) 4 (8.9)
Abdominal pain
upper
1 (5.9) 0 (0.0) 0 (0.0) 1 (5.9) 2 (10.5) 4 (8.9)
Sputum abnor-
mal
0 (0.0) 2 (11.1) 0 (0.0) 0 (0.0) 1 (5.3) 3 (6.7)
Epistaxis 1 (5.9) 0 (0.0) 0 (0.0) 0 (0.0) 2 (10.5) 3 (6.7)
C-reactive pro-
tein increased
0 (0.0) 1 (5.6) 0 (0.0) 2 (11.8) 0 (0.0) 3 (6.7)
Paranasal sinus
hypersecretion
0 (0.0) 2 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.4)
Lung hyperinfla-
tion
0 (0.0) 0 (0.0) 0 (0.0) 2 (11.8) 0 (0.0) 2 (4.4)
* Unclear why the total number of participants in the study is shown to be 45. The author has been contacted for clarification.
Table 4. Frequency of occurrence of adverse effects occurring in more than 3% of participants in any CPX treatment group
in McCarty 2002
Placebo CPX
Adverse ef-
fects, n
(n = 8) 1 mg (n = 4) 3 mg (n = 4) 10mg (n = 4) 30mg (n = 4) 100 mg (n =
5)
300 mg (n =
4)
1000mg (n =
4)
Abdominal
pain
0 0 0 0 0 1 1 1
Asthenia 0 0 0 0 0 0 1 1
Headache 0 0 0 2 1 0 1 0
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Table 4. Frequency of occurrence of adverse effects occurring in more than 3% of participants in any CPX treatment group
in McCarty 2002 (Continued)
Pain 0 0 0 1 0 0 2 0
Diarrhoea 0 0 0 0 0 1 1 0
Dizziness 2 0 0 1 0 0 0 0
Lung
Disease
0 0 0 1 0 0 0 2
Rhinitis 0 2 0 1 0 0 0 2
CPX: 8-cyclopentyl-1, 3-dipropylxanthine
Table 5. Adverse events (non-serious) reported in Donaldson 2014 (N6022 versus placebo)
Placebo N6022 Total
Adverse events, n (n = 19) 5 mg (n = 10) 10 mg (n = 9) 20 mg (n = 9) 40 mg (n = 19) (n = 66)
Lymphadenopa-
thy
1 0 0 0 0 1
Chest tightness 1 2 0 0 2 5
Atrioventricular
block second de-
gree
0 0 1 0 0 1
Nodal rhythm 0 0 0 1 0 1
Supraventricular
extrasystoles
0 0 0 1 0 1
Supraventricular
tachycardia
0 0 1 0 0 1
Ventricular
extrasystoles
1 0 0 0 0 1
Ventricular
tachycardia
0 0 0 1 0 1
Diarrhoea 2 0 1 0 0 3
Nausea 1 1 0 0 1 3
Vomiting 0 0 0 0 2 2
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Table 5. Adverse events (non-serious) reported in Donaldson 2014 (N6022 versus placebo) (Continued)
Flatulence 0 0 1 0 0 1
Parosmia 0 0 0 2 0 2
Night sweats 0 0 2 0 0 2
Fatigue 1 1 0 0 2 4
Pyrexia 0 1 0 0 2 3
Infective
pulmonary exac-
erbations of CF
1 1 0 0 1 3
Upper res-
piratory tract in-
fection
1 0 0 0 0 1
Headache 1 1 1 2 1 6
Cough 7 3 1 3 2 16
Increased
bronchial secre-
tion
3 2 2 2 1 10
Nasal congestion 1 3 0 0 1 5
Rales 0 3 0 1 0 4
Total
participants with
at
least one adverse
event, n (%)
18 (95%) 9 (90%) 9 (100%) 9 (100%) 15 (79%) 60 (91%)
CF: cystic fibrosis
Table 6. Adverse events with an incidence of ≥ 0.20 events per patient-year in Konstan 2017
Event Lumacaftor
400 mg twice daily/iva-
caftor 250 twice daily
(n = 340)
Placebo transitioned to
lumacaftor
400mg twice daily/iva-
caftor 250 mg twice
daily (n = 176)
Lumacaftor 600
mgonce daily/ivacaftor
250 mg twice daily (n =
335)
Placebo transitioned to
lumacaftor
600 mg once daily/ iva-
caftor 250 mg twice
daily (n = 178)
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Table 6. Adverse events with an incidence of ≥ 0.20 events per patient-year in Konstan 2017 (Continued)
Total exposure in pa-
tient-years
570 290 570 300
Infective pulmonary ex-
acerbation
0.980 1.035 1.157 1.080
Cough 0.510 0.573 0.627 0.609
Haemoptysis 0.266 0.200 0.235 0.239
Increased sputum 0.208 0.207 0.224 0.175
Nasopharyngitis 0.194 0.169 Not reported Not reported
Headache 0.140 0.107 0.129 0.101
Dyspnoea 0.124 0.166 0.117 0.128
Pyrexia 0.114 0.152 0.148 0.148
Upper respiratory tract
infection
0.129 0.131 Not reported Not reported
Diarrhoea 0.093 0.145 0.111 0.101
Abnormal respiration 0.077 0.128 0.088 0.145
Nausea 0.072 0.104 Not reported Not reported
Fatigue 0.084 0.090 Not reported Not reported
Abdominal pain 0.087 0.066 0.087 0.084
Oropharyngeal pain Not reported Not reported 0.101 0.081
Nasal congestion Not reported Not reported 0.104 0.091
Rhinitis Not reported Not reported 0.064 0.030
Any adverse event: n (%) 333 (97.9) 176 (100) 331 (98.8) 177 (99.4)
Any serious adverse
event: n (%)
143 (42.1) 89 (50.6) 156 (46.6) 77 (43.3)
Any treatment emergent
respiratory event: n (%)
99 (29) 67 (38) 102 (30) 67 (38)
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Table 7. Secondary efficacy outcomes reported in Konstan 2017
Outcome Lumacaftor
400 mg twice daily/iva-
caftor 250 mg twice
daily (n = 340)
Placebo transitioned to
lumacaftor
400mg twice daily/iva-
caftor 250 mg twice
daily (n = 176)
Lumacaftor 600
mgonce daily/ivacaftor
250 mg twice daily (n =
335)
Placebo transitioned to
lumacaftor 600
mgonce daily/ivacaftor
250 mg twice daily (n =
178)
FEV1 (% predicted):
1
Week 72
0.5 (95% CI -0.4 to 1.5)
P = 0.2806
1.5 (95% CI 0.2, 2.9)
P = 0.0254
1.2 (95% CI 0.3 to 2.2)
P = 0.0127
1.9 (95% CI 0.6 to 3.2)
P = 0.0037
FEV1 (% predicted):1
Week 96
0.5 (95% CI -0.7 to 1.6)
P = 0.4231
0.8 (95% CI -0.8, 2.3)
P = 0.3495
0.0 (95% CI -1.1 to 1.1)
P = 0.9682
1.6 (95% CI -0.1 to 3.2)
P = 0.0632
FEV1 (% predicted):
2
Week 72
0.9 (95% CI 0.0 to 1.9)
P = 0.0500
1.9 (95% CI 0.6 to 3.2)
P = 0.0040
1.7 (95% CI 0.8 to 2.7)
P = 0.0003
2.2 (95% CI 1.0 to 3.5)
P = 0.0005
FEV1 (% predicted):
2
Week 96
1.1 (95% CI 0.0 to 2.2)
P = 0.0535
1.1 (95% CI -0.5 to 2.6)
P = 0.1696
0.7 (95% CI -0.4 to 1.8)
P = 0.1966
2.0 (95% CI 0.4 to 3.6)
P = 0.0149
FEV1 (% predicted):1
Relative change
Week 72
1.4 (95% CI -0.3 to 3.2)
P = 0.1074
2.6 (95% CI 0.2 to 5.0)
P = 0.0332
2.4 (95% CI 0.6 to 4.1)
P = 0.0080
3.8 (95% CI 1.4 to 6.1)
P = 0.0017
FEV1 (% predicted):1
Relative change
Week 96
1.2 (95% CI -0·8 to 3·3)
P = 0·2372
1·1 (95%CI -1·7 to 3·9)
P = 0·4415
0.1 (95% CI -1.9 to 2.1)
P = 0.9297
3.6 (95% CI 0.6 to 6.6)
P = 0.0172
BMI
Week 72
0.69 (95% CI 0.56 to 0.
81)
P < 0.0001
0.62 (95% CI 0.45 to 0.
79)
P < 0.0001
0.72 (95% CI 0.60 to 0.
84)
P < 0.0001
0.52 (95% CI 0.36 to 0.
69)
P < 0.0001
BMI
Week 96
0.96 (95% CI 0.81 to 1.
11)
P < 0.0001
0.76 (95% CI 0.56 to 0.
97)
P < 0.0001
0.81 (95% CI 0.66 to 0.
95)
P < 0.0001
0.55 (95% CI 0.34 to 0.
76)
P < 0.0001
CFQ-R respiratory do-
main
Week 72
5.7 (95% CI 3.8 to 7.5)
P < 0.0001
3.3 (95% CI 0.7 to 5.9)
P = 0.0124
3.2 (95% CI 1.4 to 5.1)
P = 0.0007
3.3 (95% CI 0.7 to 5.8)
P = 0.0116
CFQ-R respiratory do-
main
Week 96
3.5 (95% CI 1.3 to 5.8)
P = 0·0018
0.5 (95% CI -2.7 to 3.6)
P = 0·7665
1.1 (95% CI -1.1 to 3.2)
P = 0.3339
2.0 (95% CI -1.1 to 5.1)
P = 0.2033
Pulmonary
exacerbations:
events per patient year
0.65 (95% CI 0.56 to 0.
75)
0.69 (95% CI 0·56 to 0.
85)
0.80 (95% CI 0.70 to 0.
92)
0.76 (95% CI 0.62 to 0.
93)
Pulmonary
exacerbations:
events requiring hospi-
tal admission per patient
0.24 (95% CI 0.19 to 0.
29)
0.30 (95% CI 0.22 to 0.
40)
0.31 (95% CI 0.25 to 0.
38)
0.35 (95% CI 0.26 to 0.
47)
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Table 7. Secondary efficacy outcomes reported in Konstan 2017 (Continued)
year
Pulmonary
exacerbations:
events requiring IV an-
tibiotics per patient year
0.32 (95% CI 0.26 to 0.
38)
0.37 (95% CI 0.29 to 0.
49)
0.38 (95% CI 0.32 to 0.
46)
0.42 (95% CI 0.33 to 0.
54)
BMI: body mass index
CFQ-R: cystic fibrosis questionnaire-revised
CI: confidence interval
FEV1: forced expiratory volume at one second
IV: intravenous
Unless otherwise stated, all outcomes reported are the mean (95%CI) absolute change from baseline. P values correspond to the within-
group change compared to baseline.
1. Calculated using Wang-Hankinson equations.
2. Calculated using Global Lungs Initiative equations.
Table 8. Acute changes in FEV1 (% predicted) following study drug administration in Ratjen 2017
Lumacaftor plus ivacaftor
mean (SD)
Placebo
mean (SD)
Day 1, ≤ 2 hours post dose n = 91
-5.5 (8.2)
n = 97
-0.1 (5.1)
Day 1, 4 to 6 hours post dose n = 92
-7.7 (7.3)
n = 96
-1.4 (7.1)
Day 1, 24 hours post dose n = 38
-4.1 (10.1)
n = 44
-1.7 (6.8)
Day 15, ≤ 2 hours post dose n = 88
-1.4 (7.0)
n = 87
0.9 (5.5)
Day 15, 4 to 6 hours post dose n = 86
-1.3 (6.4)
n = 87
0.1 (5.2)
Week 16, ≤ 2 hours post dose n = 33
1.7 (4.8)
n = 42
0.8 (5.8)
Week 16, 4 to 6 hours post dose n = 33
0.5 (7.4)
n = 42
0.6 (7.1)
Week 24, ≤ 2 hours post dose n = 25
0.3 (4.1)
n = 23
0.0 (3.4)
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Table 8. Acute changes in FEV1 (% predicted) following study drug administration in Ratjen 2017 (Continued)
Week 24, 4 to 6 hours post dose n = 24
-2.8 (4.0)
n = 24
0.1 (4.3)
SD: standard deviation
A P P E N D I C E S
Appendix 1. Electronic search strategies
Database/resource Date searched Seach strategy
US National Institutes of Health database
(clinicaltrials.gov/)
25 January 2018 Cystic fibrosis AND (VX OR corrector)
WHO ICTRP
(www.who.int/ictrp/en/)
25 January 2018 Cystic fibrosis AND (VX OR corrector)
European Medicines Agency
(www.clinicaltrialsregister.eu/)
25 January 2018 Cystic fibrosis AND (VX OR corrector)
C O N T R I B U T I O N S O F A U T H O R S
Roles and responsibilities
TASK WHO WILL UNDERTAKE THE TASK?
Protocol stage: draft the protocol IS, SP with comments from all
Review stage: select which trials to include (2 + 1 arbiter) IS, SP (+ KWS)
Review stage: extract data from trials (2 people) IS, SP
Review stage: enter data into RevMan SP, SJN
Review stage: carry out the analysis SP, SJN
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(Continued)
Review stage: interpret the analysis IS, SP, SJN
Review stage: draft the final review IS, SP with comments from all
Update stage: update the review SP
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Lung clearance index (LCI) was added as an outcome due to the increasing use of this outcome as a measure of lung function in the
younger population.
We have added a statement to the Methods section that 99% confidence intervals will be used to analyse separate adverse events. This
is the most appropriate statistical approach for considering adverse events individually.
Originally, we intended to combine all studies included in the review using a random-effects approach to meta-analysis. However, due
to the substantial differences in the designs and interventions employed within the studies, we considered it more appropriate to make
separate comparisons within the review, and where small numbers of studies of a similar design and intervention were pooled in meta-
analysis, a fixed-effect approach was appropriate.
In line with current Cochrane guidance, we have included summary of findings tables for all comparisons.
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